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Abstract
There are many factors which contribute to the clinical outcome of antiretroviral
therapy, including inter- and intra-individual variability in pharmacokinetics and
drug-drug interactions. Drug transporters and metabolism enzymes are known to
influence pharmacokinetics of many xenobiotics and hence the role of drug
transporters, both efflux and influx, on intracellular accumulation in different in vitro
models was explored. Further, the impact of polymorphisms in SLCOtransporters on
the pharmacokinetics of the protease inhibitor (PI) lopinavir was observed.
Using the CEM and MDCKII cell line models darunavir, a PI, was a substrate of
ABCB1, whilst rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI),
wasnot a substrate of ABCB1, but intracellular accumulation was influenced by the
presence of human serum albumin (HSA).
To assess antiretrovirals as potential substrates for SLCO transporters, these
transporters werefirst isolated and cloned, followed by subcloning into an expression
vector for use in the X. /aevis model. Using this model, PIs were identified as
substrates for SLCO1A2, 1B1 and 1B3; whereas, of the NNRTIs, only rilpivirine
wasa substrate in the absence of HSA.
Single nucleotide polymorphisms (SNPs) in SLCO transporters were determined in
the Liverpool therapeutic drug monitoring (TDM) cohort to observe associations
with plasma concentration. Of the SNPs tested, SLCO1B1 521T>C wassignificantly
associated with an increase in plasma concentrations of lopinavir. Other factors such
as weight and co-administered PI were also significantly associated with lopinavir
plasma concentrations.
To determine whether knockdown ofindividual transporters would impact on the
cellular transport of SLCO1A2, SLCOIB1, SLCO1B3 and SLCO3A1 against basal
levels of expression of various other transporters, SLCOs were knocked-down using
siRNA; however, due to the low levels of expression of SLCOs in cell lines, the
results were inconclusive.
Antiretrovirals have been characterised for efflux transporters, particularly ABCB1,
but with the recent identification of SLCOs, many xenobiotics have yet to be
characterised for these transporters. This thesis has found PIs to be substrates for
SLCOs and has implicated a role for these transporters in the variability of plasma
concentrations seen in a HIV+ population.
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General Introduction
1. Introduction
1.1 HIV epidemiology
The human immunodeficiency virus (HIV) was first characterised over twenty years ago
(Barre-Sinoussi ef al. 1983) and is a major epidemic in the world today. HIV is a complex
retrovirus, part of the family Retroviridae and the lentivirus genus, with two distinct strains,
HIV-1 and HIV-2 (Clavel et al. 1986). HIV-1 has a high transmission rate and high
virulence and is an epidemic around the world. HIV-2 is localised to West Africa and has a
lower transmission rate and lower virulence than HIV-1 (Berry ef al. 1998). HIV is
transmitted by contact with body fluids from infected to uninfected individuals.
Transmission occurs by sexual contact, contaminated blood or equipment (Jaffe ef al.
1983), from mother to child during pregnancy (Sprecher er al. 1986) and breast feeding
(Thiry ef al. 1985). It can remain asymptomatic for many years, making infection
managementdifficult.
In 2007, UNAIDSreported an estimate of 33 million people world-wide living with HIV,
with around 2.7 million people being newly infected with the virus. It is affecting both
developed and developing countries, but 22 million people infected with HIV live in Sub-
Saharan Africa (www.unaids.org). HIV infections progress to acquired immunodeficiency
syndrome (AIDS)andleadsto an increased risk of opportunistic infections and subsequent
mortality. With the increasing treatments available for people infected with HIV, we are
now dealing with a chronic disease in the West, with people living longer, having fewer
Opportunistic infections and the time taken for progression to AIDS being increased (Lee et
al. 2001; Wongef al. 2004).
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1.2 Structure and genome of HIV
HIV-1 is a spherical virus containing two copies of single stranded, positive sense RNA
enclosed in a conical capsid composed of 2000 copies of the capsid protein, p24. The RNA
is bound in a complex with the nucleocapsid proteins, p7 and essential enzymes for viral
replication and development, reverse transcriptase (RT) and integrase (IN). This core
structure is surrounded by a matrix consisting of viral protein, p17 and a viral envelope
containing phospholipids obtained during viral budding from the host cell and viral
glycoproteins, transmembrane envelope protein (gp41, TM) and surface envelope protein
(gp120, SU) (Freed 2001). The structure ofthe virus is illustrated in Fig. 1.
The HIV genome encodes 9 genes, of which 3 are structural and 6 are regulatory (also
called “accessory” or “auxillery”) proteins (Fig. 2). The 3 structural genes are polymerase
(Pol), group-specific antigen (Gag) and envelop glycoproteins (Env) and the 6 regulatory
genesare viral infectivity factor (Vif), viral protein R (Vpr), viral protein U (Vpu), negative
factor (Nef), trans-activator of transcription (Zar) and regulator of virion (Rev). Cleavage of
Pol produces protease (PR), RT and IN, whereas Gag produces matrix proteins (MA),
capsid proteins (CA), nucleocapsid proteins (NC) and p6 andis performed byviral PR. Env
is processed by host cellular machinery in the Golgi apparatus and in the endoplastic
reticulum to produce gp120 and gp41. The regulatory genes are important as they increase
the infectivity of the virus and co-ordinate the progression of the virus life cycle, the
assembly and release of the virus, but they are not required for virus replication (Freed
2001; Seelamgari et al. 2004).
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Fig. 1. Diagrammatic representation ofthe structure of a HIV-1 virion (modified from
Robinson, 2002).
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1.3 The HIVlife cycle
HIV-1 targets circulating CD4+ T cells and macrophages for replication. The virion
enters the host cell by utilising glycoprotein gp120, found on the viral envelope as
gp41/gp120 trimers, to bind co-receptors CCR5 or CXCR4 on the cell membrane.
Following co-receptor binding, gp120 dissociates from gp41, changing the conformation
of gp41 to allow fusion of the viral envelope with the cell membrane (Wain-Hobson
1996; Berger et al. 1999; Seelamgari et al. 2004). This releases the viral core into the
host cell cytoplasm where uncoating of the viral core and dissociation of the MA
proteins occurs. Meanwhile, reverse transcription of single stranded viral RNAto linear,
double stranded viral DNA is achieved by using HIV-1 RT (Freed 2001). Following
transcription, the viral DNA forms pre-integration complexes (PICs), which are
imported into the nucleus. Nuclear transport enables HIV-1 to infect non-dividing cells,
a characteristic of the lentivirus genus. Viral integrase primarily processes the viral DNA
and the host DNAto allow integration of viral DNA into the host genome (Gallay efal.
1997) and also facilitates nuclear import of pro-viral DNA (Hearps and Jans 2006).
HIV-1 is transcribed using host transcription factors and viral Tat protein. The Tat
protein recruits transcription factors to the transcription activation responsive element
region (TAR) to form the Tat/TAR complex, which is essential for HIV-1 transcription.
The newly transcribed HIV-1 mRNAis spliced by host cellular splicing machinery and
produces Tat, Rev and Nef proteins. When the amount of Rev produced reaches a
threshold, HIV-1 mRNA production shifts from being multiply spliced to singly spliced
and unspliced transcripts. Rev binds to the rev response element found in the singly
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spliced and unspliced mRNA and exports the transcripts into the cytoplasm for
translation of viral proteins (Nielsen ef al. 2005).
Singly spliced transcripts produce Env, Vif, Vpr and Vpu proteins, whereas unspliced
transcripts produce Gag and Gag-Pol proteins and contain the viral genome. Theviral
genome is packaged and undergoes virus budding, regulated by Vpu and Vif. Vpu
mediates the release of the virus at the cell membrane and the release of Env from the
endoplasmic reticulum and allows further processing of Env into gp41 and gp120 (Freed
2001; Seelamgari ef al. 2004). Vif mediates the processing of Gag by PR and also
prevents APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-
like 3G) from deaminating its DNA:RNA hybrids and interfering with Pol (Sheehyetal.
2002). Vprarrests the cell cycle prior to cell division and Nef downregulates host CD4.
Gagis cleaved by PR to produce CA, MA and NCparticles, which are assembledin the
cell membrane. Following budding, the virus undergoes maturation where Gag-Polis
cleaved by PR and produces IN, RT and PR. After maturation, the virus is ready to
infect (Freed 2001).
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1.4 Viral tropism
There are two tropic strains of HIV-1, CCRS (R5) and CXCR4 (X4), depending on
which co-receptor they utilise for cell entry; some viruses are dual tropic (R5X4), which
can utilise either co-receptor (Berger et al. 1999). Other human receptors have been
shownto be utilised to a lesser extent by HIV, but R5 and X4 receptor usageis byall
strains of HIV (Bergeret al. 1999). The majority of primary infections are by R5 tropic
strains with the more virulent X4 tropic strains appearing later in disease progression
(Philpott 2003). Individuals who are homozygousfor the CCR5 A32 genotype express a
non-functional, truncated version of CCRS and are immune from R35tropic strains
(Samson ef al. 1996). The discovery of the effect of the CCR5 A32 genotype on
susceptibility of viral infection with no detriments to health supported the development
of CCRSantagonists (Este and Telenti 2007).
1.5 Antiretroviral therapy
There are several classes of drugs used to treat HIV-1, each targeting a different part of
the virus life cycle (illustrated in Fig. 3). CCRS antagonists prevent the virus binding to
the CCRSco-receptors and inhibit entry of the virus into the host cell (Dorr et al. 2005),
whereasfusion inhibitors inhibit viral gp41 to prevent fusion of the viral envelope with
the host cell membrane (Wild ef al. 1994; Liu et al. 2005). Due to tropism in HIV,
CCRS inhibitors are not effective against X4 tropic viruses (Dorr et al. 2005) and
tropism profiling is recommended prior to commencing CCR5 inhibitors. Non-
nucleoside reverse transcriptase inhibitors (NNRTIs) act by inhibiting reverse
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transcriptase, whilst nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs,
NtRTI) mimic endogenous DNAbasesand terminate reverse transcription by binding to
the active site of RT (Nielsen et al. 2005). Integrase inhibitors prevent the integration of
the viral DNA to host DNA andthe specific mechanism of action of raltegravir is by
strand transfer inhibition (Summa ef al. 2008). Protease inhibitors (PIs) with the
exception of tipranavir (Poveda 2008) are peptidomimetic compounds, which block
HIV-1 protease cleavage of Gag and Gag-Pol, disrupting viral assembly (Nielsen e7al.
2005). The antiretrovirals that are approved andare currently in use in the UKarelisted
in Table 1. The molecular structures of antiretrovirals which are commonly used in
antiretroviral therapy or used in subsequentchaptersareillustrated in Fig. 4.
Highly active antiretroviral therapy (HAART) is the standard for administering
antiretrovirals, as it has demonstrated good virologic and immunologic response (Autran
et al. 1997; Chen et al. 2007). However, recent studies have found that patients with
HIV suppression to <50 copies/ml for at least 6 months can be treated with a simplified
regimen (for example monotherapy consisting of boosted lopinavir) and experience no
viral rebound (Pulido ef a/. 2008; Bierman ef al. 2009). All PIs, except nelfinavir, are
boosted with low dose ritonavir to increase their half life and bioavailability (Gazzard
2008). This boosting effect was first demonstrated using saquinavir (Merry ef al. 1997)
and was shownto also be effective for boosting of other PIs, such as lopinavir (Kempfef
al. 1997; von Hentig 2007). For first line therapy in the UK, efavirenz is administered
with an optimised background of two NRTIs and for second line therapy, boosted
lopinavir, boosted fosamprenavir, boosted atazanavir or boosted saquinavir with two
NRTIs is recommended. Nevirapine is used with two NRTIs for patients with
10
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neuropsychological problems or for female patients who wish to become pregnant
(Gazzard 2008). For heavily experienced patients with poor virologic response to
therapy, boosted darunavir, etravirine, raltegravir or maraviroc with two NRTIs may be
used (Gazzard 2008).
Apart from the regimens within HAART,clinicians are also faced with the dilemmas of
prescribing concomitant drugs used to treat opportunistic infections which occur in some
HIV patients, such as hepatitis (Gazzard 2008), tuberculosis (Moreno ef al. 2006) and
malaria (Skinner-Adamsef al. 2008). These drugs may haveinteractions with the drugs
used in HAART as many share, induce and/or repress transporters and metabolism
enzymesin their absorption and elimination pathways. Rifampicin, an anti-tuberculosis
drug, is an example of an inducer of CYP3A4 and increases the metabolism of Pls
boosted with ritonavir, resulting in a loss of virologic response and increased risk of
emergence ofviral mutation (Morenoet al. 2006). Similarly, the administration of some
drugs which require clearance by CYP3A4(e.g. some antihistamines, sedatives) with
boosted lopinavir has been contraindicated by the U.S. Food and Drugs Administration
(FDA) due to competitive inhibition by ritonavir and lopinavir (Qazi et al. 2002).
New drugs are also being developed against other viral targets. One example is
bevirimat, which is a maturation inhibitor, and acts by binding viral Gag protein to
prevent cleavage by protease, thus disrupting the production of viral CA and other
structural proteins. Bevirimat is currently in clinical trials to establish its long term
efficacy and tolerability (Martin et al. 2008). New drugs against existing drug targets
such as rilpivirne (NNRTI) and apricitabine (NRTI) are also in development to
overcomevirusesresistant to current classes of antiretrovirals (De Clercq 2008).
11
Table 1. List of antiretrovirals licensed for use in the UK.
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 Reverse transcriptase inhibitors
  
Non- Protease Entry/Fusion Intergrase
Nucleoside/Nucleotide . inhibitors inhibitors inhibitorsnucleoside
Zidovudine Efavirenz Ritonavir Enfuvirtide Raltegravir
(ZDV) (EFV) (RTV) (T-20) (RAL)
Lamivudine Nevirapine Saquinavir Maraviroc
(3TC) (NVP) (SQV) (MVC)
Didanosine Etravirine Lopinavir
(ddI) (ETR) (LPV)
Stavudine Indinavir
(d4T) (DV)
Abacavir Amprenavir
(ABC) (APV)
Tenofovir Fosamprenavir
(TFV) (FPV)
Emtricitabine Nelfinavir
(FTC) (NFV)
Atazanavir
(ATZ)
Tipranavir
(TPV)
Darunavir
(DRV)     
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1.6 Therapeutic failure
Failure of therapy can be defined by virologic, immunologic or clinical failure.
Virologic failure is defined during treatment as consistent elevations of more than 50
copies/ml of HIV RNA (Hammeret al. 2008). Immunologic failure is when CD4 cell
counts fall to below 350 cells/ul after 48 weeks of treatment (Gazzard 2008). Clinical
failure is a reoccurrence of an opportunistic infection after more than 3 months of
therapy (WHO 2007). In patients who are treatment experienced, reaching maximum
suppression but not to undetectable levels with clinical and immunological stability is
generally acceptable for not changing therapy. Decisions to change regimensare usually
based on viral load response (Kalkut 2005).
1.6.1 Viral Resistance
Infected individuals often have a large numberof quasispecies, whichall differ by a few
nucleotides. HIV has a rapid mutation rate dueto its use of RNAasits hereditary genetic
material, a lack of proof-reading mechanismsin the virus replication pathway and a high
genetic recombination rate, which allows it to evade the host immune system and
acquire resistance to antiretrovirals (Coffin 1995; Freed 2001).
Viral resistance may occur whenthe therapeutic concentration of a drug inside host cells
is not achieved or maintained. This may be due to pharmacological factors such as active
transport of a drug outof cells by drug transporters, which causes low concentrations of
the drug at the site of action (Jones ef al. 2001), or poor patient adherence to drug
regimens leading to lowered concentrations of drugs in plasma (hence less inside the
15
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cells) (Groscheler al. 1997). If therapeutic concentrations are not maintained, then viral
replication may not be suppressed. This creates a selection pressure for drug resistant
viruses to dominate the HIV-1 population in the host and render the drug regimen
ineffective (Coffin 1995; Wang ef al. 2000). Another barrier to effective therapy is the
existence of anatomical sanctuary sites such as in the central nervous system and the
genital tract, and also in cellular sanctuary sites such as CD4 cells and macrophages,
where low levels of HIV-1 replication occur and therapeutic drug concentrations are
difficult to maintain (Hoetelmans 1998; Geeraert ef al. 2008).
The difficulty in the eradication of HIV-1 is the viral reservoirs. These reservoirs contain
fit, wildtype viruses as well as drug-resistant quasi-species. Viral persistence is mainly
caused by infected latent memory CD4+ cells, which have HIV-1 DNA integrated
within the host genome, but do not undergo replication or HIV-1 gene expression until
re-activation of the hostcell, and are not affected by HAARTinits latent state (Siliciano
et al. 2003; Geeraert et al. 2008).
Certain antiretroviral regimens have been reserved for patients harbouring HIV-1 with
mutations, for example darunavir andetravirine for their potency against HIV-1 strains
resistant to first line Pls and NNRTIsrespectively. Antiretrovirals in new classes have
also been used for experienced patients, for example maraviroc, enfuvirtide and
raltegravir because they do not confercross class resistance and are effective against PI
and NNRTIresistant strains (Gazzard 2008). Increasing the doses of the drugs has also
been used to treat resistant viruses, but this can also lead to increased risk of drug
toxicity and adverse reactions.
16
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1.6.2 Adverse reactions
Adverse effects are common for antiretroviral drugs and are the main reason for
discontinuation of a drug regimen and for lack of adherence in patients (Chesney 2000;
Applebaum er al. 2009). The antiretrovirals are generally well tolerated, but there are a
number of adverse effects. These effects vary from mild symptoms such as headaches
and fatigue to moderate symptoms such as vomiting and diarrhoea to severe orfatal
symptomssuch as abacavir hypersensitivity (Staszewskief al. 1998; Calmyer al. 2007)
and lipodystrophy for regimens containing boosted PIs (Carr ef al. 1998; Calmy et al.
2007; Caron et al. 2009).
Efavirenz has been associated with neurological related adverse effects (Arendt ef al.
2007); however, the extent of the adverse reactions varies amongst patients, with a
greater number of adverse events and more severe neurotoxicity reported in Black-
African patients (Stohr ef al. 2008). Efavirenz is also not recommended for women who
wish to become pregnant as it has been linked to increased incidence of birth defects
(Saitoh ef al. 2005).
Nevirapine is often used as an alternative for efavirenz, especially for patients with a
history of neuropsychological disorders (Gazzard 2008); however, patients receiving
nevirapine also have a higherrisk of idiosyncratic hepatotoxicity compared to patients
receiving efavirenz or commonly used boosted PI regimens (Sulkowski ef al. 2000;
Rivero et al. 2007).
Newantiretroviral drugs are now designed to have better tolerance, better efficacy and
fewer incidents of adverse reactions. Research on the pharmacokinetic boosting
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compound, GS 9350, which has no metabolic toxicity, adverse effects or antiviral
activity, is ongoing by Gilead. This has the potential to replace ritonavir, which often
causespoortolerancein PI containing regimens (Gilead Sciences 2009).
1.7.‘ Drug absorption anddistribution
There are many factors which can affect the pharmacokinetics of a drug and determine
its efficacy. The bioavailability of an orally administered drug is subject to absorption in
the gut and first pass metabolism, which influences the drug concentration in systemic
blood circulation and subsequent distribution (Riviere and Papich 2009). The
distribution of drug in different tissues is determined by tissue permability, blood flow,
perfusionrate, pH and protein binding (Riviere and Papich 2009). Mostcells are able to
metabolise xenobiotics, but the liver has a major role in the metabolism of a drug.
Following metabolism, the drug is excreted via the bile canaliculus or by renal clearance
(Riviere and Papich 2009). Renal clearance is affected by glomerular filtration,
secretion from the peritubular capillaries to the nephron and reabsorption from the
nephronbackto the peritubular capillaries (Riviere and Papich 2009).
Intracellular drug concentrations have an impact on the ability of a drug to suppress HIV
and may therefore influence the development of resistance and disease progression
(Chandler et al. 2007). The physiochemical properties of a drug and the overall
metabolism and transport of a drug are the main pharmacological factors which can
affect intracellular drug concentrations. Intracellular drug accumulation at the site of
action, such as CD4 cells and macrophages, affects viral replication. This is different to
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intracellular concentrations in organs such asthe liver, intestines and kidneys, which
influences drug disposition from a whole body perspective. Drug metabolism and
transport act in concert to remove toxic endogenous and foreign compoundsand this is
reflected by their co-ordinated regulation through similar nuclear receptor pathways.
1.7.1 Protein binding
The majority of antiretrovirals are taken orally and are absorbedinto the systemic blood
circulation via epithelial intestinal cells. There are many plasma serum proteins in
systemic blood, including albumin, acid glycoproteins, globulin and lipoproteins. Protein
binding of xenobiotics can lower concentrations of unbound (active) drug in systemic
blood circulation and in organs (Boffito et al. 2003). This can also reduce the
accumulation of drugs at their site of action and hence lowertheir activity (Bilello et al.
1996). Antiretrovirals have been shown to bind to plasma proteins with PIs showing
generally higher affinities for al-acid-glycoprotein (AAG) (Bilello e¢ al. 1996) and
NNRTIs for human serum albumin (HSA) (Boffito et al. 2003). HSA is the most
abundant plasmaprotein with efavirenz more than 99% bound and nevirapine more than
60% bound to HSA (Boffito et al. 2003). AAG was found to reduce the intracellular
concentrations and hence,antiviral activity of saquinavir, ritonavir and indinavir in vitro
(Jones et al. 2001). When bound to plasma proteins, drugs cannot penetrate cell
membranes bypassive diffusion, but can be transported by active efflux (Boffito er al.
2003).
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1.7.1. Drug metabolism
Drug metabolism is an enzymatic process involving the biochemical modification of
drugs into their metabolites. Some drugs require metabolism to become bio-activated,
whereasothers are inactivated after metabolism. Metabolism is classified into two types
of reactions, phase I and phase II, and the primary objective is to metabolise the
compounds into metabolites which are easier to excrete by drug transport or passive
permeation (Beers 2006). Phase I may involve oxidation, reduction, hydrolysis,
cyclisation or decyclisation and is performed by a range of enzymes including
cytochome P450s (CYPs), alcohol dehydrogenase and esterases (Batt et al.1994; Beers
2006). Phase II are conjugative reactions such as glucuronidation, glutathione
conjugation and sulphation, usually on the metabolites of phase I reactions and are
performed by enzymes such as UDP-glucuronosyltransferases (UGTs), glutathione S-
transferases (GSTs) and sulfotransferases (Batt et al.1994; Danielson 2002; Beers 2006).
CYPs are membrane bound haemoproteins found in mitochondria or the endoplasmic
reticulum ofcells and perform oxidative reactions (Danielson 2002). These are the main
enzymes which are responsible for metabolism of xenobiotic compounds and are
expressed in varioustissues, but are highly expressed in hepatocytes and enterocytes,i.e.
the main sites for drug metabolism (Guengerich ef al. 1986; Kolars et al. 1992). Of the
CYP family the main subfamilies of pharmacological interest are CYP1, CYP2, CYP3
and CYP4 (Ferraro and Buono 2005).
Similar to other xenobiotics, antiretrovirals are substrates for metabolic enzymes. For
example, the PIs are extensively metabolised by CYP3A4 enzyme(Paland Mitra 2006).
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PIs are commonly co-administered with ritonavir, which is a potent inhibitor of
CYP3A4. Inhibition of CYP3A4 increases the half life of the PIs in the body and is
required to maintain the therapeutic concentrations of these compounds (Gazzard 2008).
Other enzymes important in the metabolism of antiretrovirals include CYP2B6, which
metabolises efavirenz (Ward et al. 2003) and nevirapine (Erickson ef al. 1999);
UGTIA1, which metabolises raltegravir (Kassahun et al. 2007); and CYP2C9,
CYP2C18 and CYP2C19, which metabolise etravirine (Seminari ef al. 2008). The
metabolites of the compounds then move out of cells by active transport or passive
permeation and are excreted.
1.7.2 Drug transport
Drugtransporter proteins modulate the distribution and movementof various drugs and
their metabolites by influencing absorption or excretion. Drug transporters impact on the
bioavailability and also intracellular drug concentrations of compounds which are
substrates (Hoggard and Owen 2003). Drug transporters are broadly classified into two
groups, the ATP-binding cassette (ABC) family of efflux transporters and the solute
carrier (SLC) family of influx transporters.
The ABCfamily of transporters are involved in the efflux of endogenous and exogenous
compounds and require ATP for active transport. There are currently 48 ABCproteins
identified, which are divided into 7 subfamilies (Toyodaet al. 2008).
ABCBI (P-glycoprotein, P-gp) is an extensively researched transporter protein, and was
identified due to its ability to cause multi-drug resistance in cancer cells (Juliano and
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Ling 1976). It was subsequently found to have broad substrate specificity, transporting
various endogenous compounds such as bilirubin, lipids and steroids, and also
xenobiotics including anti-cancer, antibiotics and PIs (Janneh ef al. 2007; Sharom 2008).
ABCBI hasa widetissue distribution from the brain to the liver and the genital tract. It
is a 170kDaprotein located in cell membranes and is encoded by ABCB/ (also knownas
multidrug resistance protein 1, MDR1).
ABCBI expressed in the intestine and liver can affect the bioavailability of substrate
drugs by efflux into the gut lumen andbile respectively. ABCB1 at the blood-brain and
blood-testes barrier has been shownto reduce drug penetration into these sites (Cordon-
Cardo et al. 1989), which mayallow reservoirs for viral replication to establish (see
section 1.6.1). At the cellular level, ABCB1 expression has been demonstrated in
lymphocyte subsets including natural killer cells, CD8 and CD4+ cells (Ford ef al.
2003). Here, drug efflux may serve to decrease drug concentrationsat sites vital for the
control of HIV replication. ABCB1 shares some substrate specificity with CYP3A4 and
many PIs have been found to be substrates of ABCB1 and CYP3A4, suggesting a
synergistic effect between metabolism and transport to remove the compound from the
body. ABCBI1 also shares substrate specificity with the ABCC proteins (multidrug
resistance proteins, MRP), which arealso efflux transporters (Toyodaet al. 2008).
To date, the ABCC subfamily consists of 12 proteins (ABCC1-12), including the cystic
fibrosis transmembrane conductance regulator (CFTR, ABCC7) and sulfonylurea
receptors (SURI, ABCC8 and SUR2, ABCC9). They vary in tissue distribution but
often share substrate specificity between themselves and with other members of the
ABC family (Toyoda et al. 2008). ABCC1 (multidrug resistance associated protein 1,
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MRP1) has been shown to be expressed ubiquitously, whereas ABCC2 (multidrug
resistance associated protein 2, MRP2) is predominantly expressed in liver and kidney
cells (Bleasby ef al. 2006). Of the ABCCs, ABCC1, ABCC2 and ABCG2(breast cancer
resistance protein 1, BCRP1) are more robustly characterised and some Pls are
substrates (Huismanefal. 2002; Janneh et al. 2005; Weisset al. 2007).
Currently, there are 359 influx transporters identified in humansand they are classified
under the SLC family of transporters. The SLC subfamilies are described in Table 2.
Currently 48 subfamilies have been identified, with the main subfamilies transporting
xenobiotics being organic anion transporting polypeptides (OATP; SLC21, SLCO),
organic anion and cation transporters (OAT, OCT, OCTN; SLC22), and proton
oligopetide co-transporter (PEPT; SLC11) (Koepsell et al. 2007; Nigam et al. 2007;
Hagenbuch and Gui 2008; Sala-Rabanaler a/. 2008). They vary in tissue distribution and
substrate specificity.
Many xenobiotics are substrates of the SLC/SLCOs,including statins, anticancer and
antibiotic drugs. SLC22 proteins are mostly expressed in the brain, kidneys and the
gastrointestinal tract, and are important in the transport of xenobiotic compounds
(Koepsell et al. 2007; Nigam et al. 2007). SLC15 proteins are expressed in the
gastrointestinal tract, at the blood-brain barrier and in glands (Bleasby ef al. 2006).
Antibiotics and antivirals are substrates for this subfamily of proteins and their ability to
transport compoundsis pH dependent (Sala-Rabanalet al. 2008). The SLCOs subfamily
has 12 members with varied tissue expression and is listed in Table 3. They are of
particular pharmacological interest as they have been identified as transporters of
various xenobiotics such as statins (Kopplow ef al. 2005), anticancer agents (Abe et al.
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1999), antibiotics (Tamaiet al. 2000) and antiretrovirals (Su ef al. 2004). Saquinavir is
a substrate of SLCO1A2 (SLC21A3) (Su etal. 2004). Aside from the potential ability to
manipulate these transporters to enhance drug delivery, sometransporters have also been
exploited as drug targets, such as glucose transporters (SLC5), neurotransmitter
transporters (SLC6), intestinal bile acid transporters (SLC10) and cation-Cl
cotransporters (SLC12). Dapagliflozin, an inhibitor of SLCSA2 (SGLT2), wasrecently
developed andis currently undergoing PhaseIIb trials to prevent reabsorption of glucose
for the treatment of diabetes mellitus (Komoroskiet al. 2009). SLC6 and SLC12 have
been identified as targets for the treatment of neurological and psychiatric diseases, with
many commercially available anti-depressants being potent inhibitors of SLC6
transporters (Gether ef al. 2006; Kahle et al. 2008). SLC10 inhibitors have been
developed for cholesterol lowering therapy (Geyeref al. 2006).
Research into the SLC/SLCOfamily is rapidly increasing, with more transporters being
identified and roles for the better characterised proteins becoming clearer; however,the
role of many influx transporters on intracellular drug accumulation and the affect on
plasma concentrationsof antiretrovirals has not yet been characterised.
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Table 2. List of currently approved solute carrier transport families by the HUGO
nomenclature committee (modified from an original review by Hedigeref al. 2002).
 HUGO Solute carrier families Numberof
nomenclature members
SLC 1 High-affinity glutamine and neutral amino 7
acid family
SLC2 Facultative GLUTtransporter family 14
SLC3 Heavy subunits of the heteromeric amino acid 2
transporter family
SLC4 Bicarbonate transporter family 10
SLC5 Sodium glucose cotransporter family 12
SLC6 Sodium- and chloride-dependent 19
neurotransmitter transporter family
SLC7 Cationic aminoacid transporter/glycoprotein 14
associated amino acid transporter family
SLC8 Na‘/Ca?* exchangerfamily 3
SLC9 Na”H* exchanger family 11
SLC10 Sodium bile salt cotransporter family 7
SLCII Proton coupled metal ion transporter family Z
SLC12 Electroneutral cation-Cl cotransporter family 9
SLC13 Human Na’-sulphate/carboxylate 5
cotransporter family
SLC14 Urea transport family 2
SLC15 Proton oligopeptide cotransporter family 5
SLC16 Monocarboxylate transporter family 14
SLC17 Vesicular glutamate transporter family 8
SLC18 Vesicular aminetransporter family 3
SLC19 Folate/thiamine transporter family 3
SLC20 Type-III Na’-phosphate costransporter family 2
SLC21/SLCO Organic anion transporting family 10
SLC22 Organic cation/anion/zwitterions transporter 22
family
SLC23 Na’-dependentascorbic acid transporter 4
family
SLC24 Na’‘/(Ca?* -K*) exchangerfamily 6
SLC25 Mitochondrial carrier family 43
SLC26 Multifunctional anion exchanger family 11
SLC27 Fatty acid transport protein family 6
SLC28 Na’® -coupled nucleoside transport family 3
SLC29 Facultative nucleoside transporter family 4
SLC30 Zinc efflux family 10
SLC31 Coppertransporter family 2
SLC32 Vesicular inhibitory amino acid transporter 1
family
SLC34 Type-II Na’ -phosphate cotransporter family 3
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 HUGO Solute carrier families Numberof
nomenclature members
SLC35 Nucleoside-sugar transporter family 23
SLC36 Proton-coupled amino acid transporter family 4
SLC37 Sugar-phosphate/phosphate exchanger family 4
SLC38 System A and N, sodium-coupled neutral 11
amino acid transporter family
SLC39 Metalion transporter family 14
SLC40 Basolateral iron transporter family 1
SLC41 MgtE-like magnesium transporter family 3
SLC42 Rh ammonium transporter family 3
SLC43 Nat -independent, system-L-like amino acid 3
transporter family
SLC44 Choline-like transporter 5
SLC45 Putative sugar transporter 4
SLC46 Hemecarrier transporter 3
SLC47 Multidrug and toxin extrusion 2
SLC48 Hemetransporter 1
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Fig. 3. Distribution and cellular localization of drug transporters in polarizedtissues.
Intestinal epithelia (A), renal epithelia (B), hepatocytes (C), blood-brain barrier (D),
blood-CSFbarrier (E) are shown. Thesetissues are composedof polarized epithelial or
endothelial cells with a tight junction structure to limit passive diffusion. Selective
expression ofparticular transporter moleculeson the apical or basolateral side determine
the net transport of compoundsacross these monolayers. ABC transporters are indicated
by closed circles (modified from Ito et al. 2005).
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1.8 Regulation of expression of drug metabolism and transport
The discovery of xenobiotic activated nuclear hormone receptors (NRs) has greatly
increased understanding of the regulation of expression of drug metabolism enzymes
and transporter proteins. Apart from xenobiotics, NRs can be activated by numerous
endogenous compoundssuchas vitamins, non steroidal hormones and bile salts (Lew er
al. 2004; Pascussi ef al. 2008). The activation of NRs triggers a cascade of up- and
down-regulation of proteins involved in metabolism and transport to eliminate toxic
compounds from the body (Kakizaki et al. 2008). When bound to ligands,
conformational changes in the nuclear receptors occur and they bind directly to DNA
and recruit co-regulators to up-regulate or repress nearby genes. The ability of the NRs
to bind DNAclassifies them as transcription factors. The NR family is divided by amino
acid sequence homology, into 7 subfamilies. Within the NR subfamily 1, the pregame X
receptor (PXR, NR/J2), the constitutive androstane receptor (CAR, NRJJ3) and the
farnesoid X receptor (FXR, NR/H4) have beenrelatively well characterised and are of
pharmacological interest as they are important receptors involved in the regulation of
metabolism and transport of xenobiotic compounds (Eloranta et al. 2005; Urquhart ef al.
2007).
The general pathway of activation for NRs within subfamily 1, with the exception of
PXR whichstarts in the nucleus, starts in the cytoplasm asillustrated in Fig. 4. CAR is
constitutively active in the absence of a ligand, which is unusual for NRs. CAR is
located in the cytoplasm, whereit is bound to molecular chaperones and uponactivation,
disassociates from the chaperonesandtranslocates to the nucleus. NRs can be activated
by forming a ligand with a wide variety of endogenous and xenobiotic compounds,
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which enter through the cell membrane by passive diffusion or active transport. In the
nucleus, histone deacetylase complexes dissociate from the CAR, allowing recruitment
of histone acetylases to open up the nucleosomestructure to allow access to the DNA
and target genes. The ligand-NR forms either a homodimer or a heterodimer with
retinoid X receptor (RXR). PXRis located in the nucleus and in the absenceofa ligand,
is bound to co-repressors. When activated, PXR forms a heterodimer with RXR. The
heterodimer complexes bind response elements in promoter and enhancer sections of
DNAandupregulate adjacent genes (Urquhartef al. 2007).
PXR and CARhavebeenreported to up-regulate the expression of CYP2B6, CYP3A4,
ABCB1, ABCC2 and UGTIA1. FXRhas been shown to regulate SLCO1B3 and also
CYP3A4 and ABCC2 (Lim and Huang 2008). PXR has also been reported to regulate
SLCO1A2 (Meyer zu Schwabedissen et al. 2008). Rifampicin and St. John’s Wort are
examples of xenobiotic activators of PXR and have been shownto induce expression of
proteins regulated by PXR, whereas phenobarbital and somestatins activate CAR
(Kobayashi er al. 2005; Lim and Huang 2008). Bile salts are the main activators of FXR
(Lim and Huang 2008).
The nuclear receptors share ligands and can auto-regulate as well as regulate eachother,
as there is a complex cross-talk between their pathways (Lew efal. 2004; Pascussief al.
2008). The interplay between metabolism, transporters and their regulators, the nuclear
receptors, may cause complex drug-drug interactions (Seden ef al. 2009, Zhanget al.
2006) and alter the pharmacokinetic and pharmacodynamic profiles of drugs, hence
treatment with antiretrovirals should be preceded with caution if a patient has been
prescribed other drugs or is consuming herbal remedies.
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Fig.4. A diagrammatic representation of nuclear receptor activation. Ligands enter the
cell by passive diffusion or active transport. a. In the cytoplasm, ligands can bind to
CAR,causing a conformational change and dissociation from its chaperone (Hsp, heat
shock protein). CARis translocated to the nucleus whereit can form a heterodimer with
RXR.b. Passive diffusion ofligands into the nucleus allows binding of ligands by PXR.
PXR forms a heterodimer with RXR.
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1.9 The influence of pharmacogenetics on antiretroviral therapy
Pharmacogeneticsis the study of the effects of genetic polymorphismson drug response.
The main areas of pharmacogenetics include drug metabolism and transporter genes,
which have been studied to observe their impact on drug concentrations, and also genes
that influence drugsafety.
The strongest association in pharmacogenetics related to antiretrovirals is the HLA-
B*5701 genotype and abacavir hypersensitivity (Mallal e¢ a/. 2002). This has led to
testing of patients for the HLA-B*5701 genotype prior to commencing a regimen
containing abacavir and has subsequently lowered the incidence of abacavir
hypersensitivity (Mallal et al. 2008).
In metabolism, numeroussingle nucleotide polymorphisms (SNP) and haplotypes have
been identified in CYP2B6. G516T (rs3745274) and T1459C (rs3211371) were
originally described by Langefal. (2001) who saw anassociation between the presence
of these SNPs and reduced hepatic expression and activity of CYP2B6. The association
between G516T and protein expression and activity was not significant in that study due
to the small sample size. However, a study by Haas ef al. (2005) found significantly
higher plasma efavirenz concentrations in homozygotes for the TT genotype, but no
change in immunologic or virologic response. T983C (rs28399499) has been more
recently described and studies have shown an association between this SNP and
increased neurotoxicity in patients administered efavirenz (Wyen ef al. 2008). The
frequency of this genotype is as high as 7.5% among Black-African ethnicities but the
allele has not been found in Caucasian populations (Mehlotra ef al. 2007).
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Several ABCBI genotypes have been documented and 3 SNPs were noted to be in
linkage disequilibrium and may have an effect on protein expression: C1236T
(rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642) (Chinn and Kroetz
2007). Of these SNPs, G2677T and C3435T have been more extensively studied, but
associations between reduced protein expression and these SNPsindividually, as well as
these SNPs in conjunction, has yielded conflicting results (Hoffmeyer ef al. 2000; Kim
et al. 2001; Sakaedaet al. 2003). Associations between increased plasma concentrations
and better immunologic response of nelfinavir — an ABCB1 substrate — with ABCB/
C3435T have also been documented (Fellay et al. 2002). However, the associations
remain controversial, with some research groups finding no change in drug plasma
concentrations of saquinavir, also a ABCB1 substrate (la Porte ef al. 2007). The unusual
aspect of this genotypeis thatit is a silent mutation, one that does not lead to a change in
the amino acid sequence. It has been theorised that this SNP may be in linkage
disequilibrium with a functional mutation, or that the silent mutation alters the splicing
or the frequency of the splice site of the ABCB/ gene, thereby altering the amount of
functional ABCB1 present on the cell membrane (Kimchi-Sarfaty ef al. 2007). An
additional complication is the inhibitory effect of ritonavir, and since manyPIs are co-
administered with ritonavir, the effects of SNPs in ABCB1 may be masked.
In peripheral blood mononuclear cells (PBMCs) from healthy volunteers, CXCR4 has
been shown to correlate with ABCB] mRNAexpression and co-localise with ABCB1 in
the cell membrane (Owenef al. 2004; Chandler et al. 2007). This study also found that
the ABCBI C3435T genotype influences the expression of ABCB1 as well as CXCR4,
with CC homozygotes expressing more ABCBI! than CT heterozygotes and TT
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homozygotes. The correlation between CXCR4 expression with ABCB1 expression was
also observed in a study involving PBMCsfrom HIV positive patients (Chandlerer al.
2007). This positive correlation suggests that ABCB1 and CXCR4are regulated by an
overlapping pathway; although, the specific links between the regulations of the two
genes have yet to be identified. The implication of this association is that X4 tropic
strains may also have increased protection against antiretrovirals with the increased P-gp
leading to increased efflux of drug out of the lymphocytes and thereby lowering the
intracellular drug concentration below therapeutic levels.
Recently, an association between unboosted atazanavir and the NRIJ2 C63396T
(ts2472677) SNP was found (Siccardi et al. 2008). TT homozygotes had significantly
lower atazanavir trough plasma concentrations than CC homozygotes or CT
heterozygotes. This suggests that polymorphisms in NRJJ2 mayalter its ability to
regulate target genes, including ones which mayalter atazanavir concentrations suchas
metabolising enzymes andtransporters. In this study, atazanavir was not administered
with ritonavir, which maybe the reason for a clearer association than studies examining
SNPswith individuals on boosted PI regimens.
For any given drug regimen,there is a large inter-patient variability. Studying genotype
and haplotype associations of genes responsible for metabolism, transport, toxicity and
the regulators of these genes maylead to better predictors of therapeutic outcome and
aid the goal of personalised medicine. In broad terms there are twodistinct approaches
of identifying novel associations. Firstly, whole genome association studies can be
conducted, but there are problemsassociated with the rigorous corrections that need to
be applied for multiple comparisons. Secondly, and relevantto this thesis, basic science
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can be applied to characterise the mechanismsinvolvedin drug disposition and thereby
identify novel candidate genes for pharmacogenetic association studies.
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1.10 Aims of thesis
The aims of this thesis are to determine the factors that can influence cellular drug
accumulation. This includes the characterisation of antiretrovirals (PIs and NNRTIs) as
potential substrates for drug efflux by using existing models, such as CEM (cultured
lymphocytes) and MDCKII(caninekidneycells) cells. Whilst these cells are established
models to evaluate substrate affinity for ABC transporters, there are limitations to drug
selected (CEM)and transfected (MDCKII) models. The drug selected cells over-express
ABCtransporters and mayalsoselect for and over-express other known and unidentified
transporters, whereas transfected cells contain the target genes and other endogenous
transporters. Therefore, a new in vitro model, the X. /aevis oocyte expression system
was developed.
SLCOtransporters were chosen for evaluating influx of antiretrovirals because they
were well characterised at the molecular level and have been shown to modulate plasma
concentration of various xenobiotics. In addition, lopinavir has been known to have
drug-drug interactions with statins in patients, which may be attributed to drug
transporters. For evaluation of SLCOtransporters using the X. laevis oocytes, clones of
the individual transporters were first established. The DNA sequencesofthe clones were
verified and sub-cloned into the pBluescriptII-KSM vector, which contains X. laevis B-
globin 3’ and 5’ untranslated regionsflanking the multiple cloningsite to allow efficient
translation of human SLCO genes. SLCO cRNAwasgenerated from the cloned cDNA
by in vitro transcription for use in the X. /aevis oocyte model.
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The X. laevis oocyte model contains few endogenous transporters. Oocytes were
injected with SLCO transporters and uptake experiments were conducted to assess
antiretrovirals as potential substrates of SLCO influx transporters.
Following the results generated from the X. laevis oocyte model, the effect of genetic
polymorphisms in SLCOtransporters on the pharmacokinetics of antiretrovirals was
explored. Polymorphisms in SLCOtransporters have beenassociated with differences in
plasma concentrations of statins and hence are likely to influence plasma concentrations
of antiretrovirals. Patient plasma samples from the Liverpool TDMregistry were used
for examining pharmacogeneticassociations due to the availability of a large cohort size,
lopinavir plasma concentrations and some population demographicdata.
Finally, the effect of SLCO transporter knockdown was observed by using siRNA in
human cell lines. The impact of SLCO transporter knockdown was observed by
analysing the uptake of a paradigm substrate, estrone-3-sulphate. Cell lines representing
liver, intestinal and kidney tissues were used as the distribution of SLCO transporters is
tissue specific.
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Chapter 2
Evaluating the transport of darunavir and
rilpivirine by ABCB1: the impact of protein
binding
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2.1 Introduction
Darunavir (DRV, TMC114) is a protease inhibitor (PI), which was given FDA
approval during 2006.It has potentantiretroviral activity against HIV strainsthat are
resistant to other Pls in vitro and has low cytotoxicity ex vivo (De Meyeret al. 2005)
with similar effects also observed in patient trials (Arasteh et al. 2005; Lefebvre and
Schiffer 2008). The chemical structure of DRV is derived from amprenavir, yet DRV
has a higheraffinity for HIV protease than amprenavir and other PIs (King et al.
2004). This tighter protease binding gives DRV higherantiviral activity and confers
a higher genetic barrier to resistance, i.e. viruses are required to harbour multiple
mutations at the protease bindingsites in order to develop resistance to DRV (King
et al., 2004, De Meyeret al. 2005).
The antiretroviral activity and cytotoxicity of DRV was assessed by De Meyeret al.
(2005) in a study testing DRV against drugresistant viruses with different mutations.
DRV wasfound to be non-cytotoxic at 100uM, which was the highest concentration
and gavea selectivity index of >20 000 (De Meyeret al. 2005).
Rilpivirine is an experimental NNRTI currently in Phase III clinical trials and is a
diarylpyrimidine (DAPY) molecule. DAPY molecules are similar to pyrimidine
nucleotides used in DNAreplication. Rilpivirine has also been demonstrated to have
potent antiviral effects against viruses with mutations against the existing NNRTIs,
efavirenz (EFV) and nevirapine (NVP) in vitro (Mordantetal. 2007) andis effective
in reducingviral load in treatment naive patients (Goebel er al. 2006).
DRVis a substrate of CYP3A4 and the plasma concentration of DRV is boosted
when co-administered with ritonavir (Rittweger and Arasteh 2007). Intracellular drug
concentrations of other PIs can be influenced by drug transporters, with ABCB1
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being the most extensively researched transporter. The impact of drug transporters on
the intracellular accumulation of DRV andrilpivirine has not yet been assessed. PIs
and amprenavir — from whichthestructure of DRV is derived — have been shownto
be substrates of ABCB1 whilst NNRTIs have been shown not to be substrates
(Jannehef al. 2005, Strémeret al. 2004). Therefore, we can hypothesise that DRV is
also a likely substrate, whereas rilpivirine is unlikely to be a substrate. In addition,
protein binding also influences drug plasma concentrations and subsequently,
intracellular drug concentrationsof antiretrovirals. PIs and NNRTIs have been shown
to bind with high affinity to serum proteins a1-acid-glycoprotein (AAG)(Jonesefal.
2001) and human serum albumin (HSA)respectively (Boehringer-Ingelheim 1999;
Bristol-Myers-Squibb 2008). Protein binding is an important factor for intracellular
accumulation and with increasing concentrations of AAG,the antiviral activity of PIs
decrease (Zhangef al. 1999). When boundto protein, antiretrovirals cannot penetrate
cellular membranes and cellular accumulation is dependent on active transport
(Boffito et al. 2003).
The aim of this chapter was to first characterise transport of DRV andrilpivirine by
ABCB1 using different in vitro models; secondly, to determine whether intracellular
concentrations of DRV at its site of action are modifiable by known inhibitors of
efflux and influx; and thirdly, to observe whether protein binding alters the
intracellular concentrationsofrilpivirine.
4]
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2.2 Methods
2.2.1 Materials
['“C] DRV (specific activity, 0.21mCi/mmol) and (°H] rilpivirine (specific activity
20mCi/mmol) was provided by Tibotec (Mechelen, Belgium). ['4C] EFV (specific
activity, 12.7uCi/umol) was provided by Bristol-Myers-Squibb and PH] NVP
(specific activity, 1.6Ci/mmol) was purchased from Moravek Chemicals (California,
USA). Foetal calf serum (FCS) was purchased from Biosera (East Sussex, UK).
Tariquidar was a gift from Xenova Group Plc. (Berkshire, UK), GF120918 was
obtained from GlaxoSmithKline (Greenford, UK), MK571 and montelukast were
gifts from Merck Frosst (Quebec, Canada). Ultima Gold scintillation fluid was
purchased from Perkin Elmer (Boston, USA). Primary UIC2 (IgG2A) antibody was
purchased from Immunotech (Marseilles, France), primary QCRL (IgG1) antibody
was purchased from Calbiochem (Nottingham, UK), ABCB1 isotype control
(IgG2A), ABCB1 secondary PE conjugated antibody, ABCC1 isotype control (IgG1)
and ABCC1 FITC conjugated secondary antibodies were purchased from Serotec Ltd
(Oxford, UK). CellFIX was obtained from Becton Dickinson (Oxford, UK) andall
other reagents were purchased from Sigma-Aldrich (Poole, UK). PBMC were
isolated from blood buffy coats obtained from the regional blood transfusion centre
(Liverpool, UK). CEM (parental), CEMvpiioo (ABCB1 over-expressing) and
CEMeg1000 (ABCC1 over-expressing) cells were gifts from Dr. R. Davey, University
of Queensland, Australia.
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2.2.2 Cell culture
CEMcells are human T-lymphoblastoid cells, from which CEMypzi00 and CEMe1000
cells are derived. CEMyptioo cells were selected for ABCB1 over-expression by
stepwise selection with vinblastine to a final concentration of 100ng/ml, whilst
CEMe1000 cells were selected for ABCC1 over-expression by stepwise selection with
epirubicin up to 1000ng/ml, as described by Davey ef al. (1996). Cell lines were
cultured in RPMI 1640 medium with 10% FCS and incubated at 37.5°C in the
presence of 5% CO. CEMypi and CEMg000 were treated routinely with 100ng/mlof
vinblastine and 1000ng/ml of epirubicin respectively to maintain their phenotype.
Cells were passaged 1:6 every 3-4 days and passagedat least twice in the absence of
selecting compoundprior to use in experiments.
The MDCKIIcell lines are canine kidney derived cells, from which, the MDCKI-
ABCBI cell was generated by transfection with the plasmid containing the ABCB1
gene (Horio ef al. 1989). The cell lines were cultured with DMEM supplemented
with 10% FCS and incubated at 37.5°C with 5% CO). MDCKII-ABCBI1 was
routinely treated with the antibiotic G418 to select for cells containing the ABCB1
plasmid, whichalso confers resistance to G418.
2.2.3 Verification of ABCB1 and ABCCI1expression by flow cytometry
CEM, CEMyszioo, CEMe1000, MDCKII and MDCKII-ABCBI cells were counted
using the NucleoCounter (Chemometec) following the manufacturer’s protocol. Each
cell line was resuspended in CellFIX (1:10, 2x 10° cells/ml, 30 mins) andtransferred
to a 96 well round bottomedplate (100ul, in quadruplicate).
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To determine ABCB1 expression, fixed cells were centrifuged (2000rpm, 7 mins),
the supernatant was discarded and the cell pellets resuspended in primary mouse
anti-human UIC2 antibody or primary mouse anti-human IgG2a isotype control
antibodies (2.5ug/ml, room temperature, Ihr). The cells were centrifuged (2000rpm,
7 mins) and washed with Hank’s balanced salt solution (HBSS, 2001) twice and
resuspended in secondary goat anti-mouse r-phycoerythrin (PE) conjugated antibody
(2.5ug/ml, room temperature, lhr). The cells were washed twice with HBSS (200u1)
before fixing in CellFIX (300u1) and transferral into 5mlplastic test tubes.
For ABCC1, fixed cells were centrifuged (2000rpm, 7 mins), the supernatant was
removed and the cells were permeabilised with HBSS (200p1) containing saponin
(0.lug/ml, 4°C, 30 mins). The cells were centrifuged (2000rpm, 7 mins) and
resuspended in primary mouse anti-human QCRL1 antibody or primary mouse anti-
human IgG1 isotype control antibody (2.5ug/ml in HBSS with saponin, room
temperature, 1 hr). The cells were washed twice with HBSS containing saponin
(2001) before resuspension in secondary goat anti-mouse fluorescein isothiocyanate
(FITC) conjugated antibody (2.5ug/ml in HBSS with saponin, room temperature, |
hr). The cells were washed twice with HBSS (200u1) and fixed with CellFIX (300u1)
before transferral into 5mlplastic test tubes.
Cells were analysed using the Coulter epics XL-MCLflow cytometer. Thetarget cell
population was electronically gated using their forward and side scatter
characteristics and fluorescence measured in FL1 and FL2 for ABCC1 (FITC) and
ABCBI (PE) respectively. Arbitrary fluorescence units were calculated by
subtraction of the median fluorescence of isotype control incubated cells with that of
those incubated with a specific antibody.
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2.2.4 Determining the toxicity of darunavir andrilpivirine
Thecellular toxicity of DRV wasassessed using the MTT(thiazolyl blue tetrazolium
bromide) cytotoxicity method (Mosmann ef al., 1983). CEM, CEMvgi CEMe1o00
cells were counted using the NucleoCounter and cells were resuspended in RPMI
1640 media containing 10% FCS, 1x10° cells/ml. DRV wasserially diluted in RPMI
1640 media containing 10% FCS to give a range of concentrations (100-0.2uM).
Drug dilutions (5Opl) were addedtosterile 96-well plates, which were followed by
the addition of CEM, CEMyp, or CEMejo00 cells (50ul). The plates were then
incubated (3 days, 37.5°C, 5% COz). The assays were terminated by adding MTT
(20ul, Smg/ml dissolved in HBSS) to each well. The plates were returned to the
incubator (37.5°C, 5% CO», 2hrs). Lysis solution (50% v/v dimethylformide in
water, 20% w/v lauryl sulphate, 100u1) was added to each well and plates were
incubated overnight (37.5°C, 5% CQO). Plates were analysed using the Genios
XFLUOR4fluorescence plate reader (560nmd). The cellular toxicity of rilpivirine
was performed as above in CEM and CEMyp;cells
2.2.5 Characterising cellular accumulation of darunavir in CEM celllines
CEM, CEMyatioo and CEMg9090 cells were counted using NucleoCounter. Thecells
were centrifuged (2000rpm, 5 min) and resuspended with RPMI 1640 medium
containing 10% FCS (5x10° cells/ml). Aliquots of cell suspension (500pl) were
incubated (37.5°C, 5% CO>, 20 mins) with RPMI 1640 (5001) containing serum and
(‘4C]-DRV (1M; 0.026uCi/ml). After incubation, the samples were centrifuged
(9000rpm, 1 min, 4°C) and the supernatant (1001) wastransferred from each sample
to scintillation vials. The remaining supernatant was discarded andthe cell pellet was
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washed with Iml of HBSS (9000rpm, 1 min, 4°C). Cell pellets were solubilised with
tap water and transferred to scintillation vials. Scintillation fluid (4ml) was added to
each vial and the samples were counted.
Following a correction for volume, a comparable value called the cellular
accumulation ratio (CAR) wascalculated using the following formula:
CAR = Intracellular associated radioactivity
Extracellular associated radioactivity
The volume of a CEM cell was taken as 1pl (Joneset al. 2001).
To assess the effects of ABCB1 transport on DRV, the CAR in CEM and CEMypatioo
wascalculated in the presence or absence of tariquidar (XR9576; ABCB1 inhibitor;
0-1.M concentrations) and in the presence of 10% FCS.
For evaluating ABCC1 transport of DRV, the CAR in CEM, CEMyar and CEMg1000
was calculated in the presence or absence of MK571 (MRP inhibitor, 0-100H4M
concentrations) and in the presence of 10% FCS.
2.2.6 Characterising transcellular transport of darunavir in MDCKIIcell lines
The interactions between ABCB1 and DRV were assessed using the MDCKII and
MDCKII-ABCBI cell lines and tariquidar was used to confirm the role of ABCB1.
Firstly, transwell plate inserts (3um pore size, 24 mm diameter, Costar) were
incubated with DMEM supplemented with 10% FCS MDCKII (30mins, 37°C, 5%
CO2). MDCKII-CTL and MDCKII-ABCB1 cells (1.5x10°) were suspended in
DMEMcontaining 10% FCS and seeded onto inserts in transwell plates (2ml) and
media (2ml) was added to the bottom chamber. The cells were then cultured with
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fresh DMEM supplemented with 10% FCS in the apical (top) and basolateral
(bottom) chambers each day (3 days, 37°C, 5% COz). Confluence was measured by
transepithelial resistance (above 150Q was accepted). The media wasaspirated and,
in one half of the plate, DMEM containing DRV alone (2ml, 0.063Ci /ml) was
added to the basolateral chamber, with DMEMalone (2ml) in the apical chamber. On
the other half of the plate, DMEM (2ml) was addedto the basolateral chamber and
['4C] DRV in DMEM (2ml) was added to the apical chamber. The process was
repeated in another plate, where DMEMcontaining ('4C] DRVand tariquidar (1M)
was added to the chambers.
2.2.7. Characterising cellular accumulation of darunavir in PBMCs
PBMCs were isolated from healthy volunteer blood by gradient density
centrifugation, using lymphoprep (15ml) and were centrifuged (2000rpm, 30 min).
PBMCswereextracted from the solution and washed with HBSS (50ml, 2000rpm, 5
min). The cells were resuspended and cultured overnight in RPMI 1640 media
containing 15% FCSin the presence of phytohaemagglutinin (10ug/ml).
Similar procedures as described for cell lines (see above, section 2.6) were used
except 1x10’ cells/ml were used and tissue solubilising solution (50u1, Optisolve:
glacial acetic acid: hydrogen peroxide in a 5:5:2.5 ratio) was used with water (1001)
to solubilise the cell pellets. CAR values were calculated as described using the
average volume of a PBMCas0.4pl (Janneh ef al. 2005). To ascertain the effects of
transport proteins present in PBMC on DRV CAR,a range of inhibitors were co-
incubated withthe cells and ['4C] DRV (Table 1).
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Table 1. Inhibitors used to characterise drug transporters.
 
Inhibitor Action Referencfes
1 uM tariquidar Inhibitor of ABCB1, alsoknown to inhibit BCRP Mistry et al. 2001
50 uM MK571 Inhibitor of ABCC1, ABCC2,ABCC3, ABCC4, ABCC7, and
influx
Su et al. 2004,
Leier et al. 2000,
Klokouzaset al. 2003
Ray et al. 2006,
Chenet al. 2003
Letschert et al. 2006
 
100 uM GF120918 Inhibitor of ABCB1 and BCRP
Trauneckeref al. 1999,
Su et al. 2004
50 uM
dipyridamole
Inhibitor of ABCB1 and
ABCC1
Utoguchi. et al. 2000,
Curtin et al. 1999
50 uM frusemide Inhibitor of ABCC1 and
Klokouzaset al. 2003
 
ABCC2 Bakosef al. 2000
100 uM estrone-3-| Inhibits BCRP and influx Su et al., 2004
sulphate transporters
50 uM montelukast
Inhibitor of influx transporters
SLCO1B3, SLCO1B1 and
SLCO2B1
Letschert et al. 2006
50 uM verapamil Non-specific inhibitor of efflux
Pereira et al. 1994
Klokouzaset al. 2003
 
50 uM probenecid Inhibitor of ABCC1, MRP3 andinflux transporters   Lucia et al. 2005
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2.2.8 Inhibition of transport by darunavir
CEM and CEMyprcells were counted using the NucleoCounter and then cells were
resuspended in RPMI 1640 media containing 10% FCS (1x10°cells/ml). Vinblastine
wasserially diluted in RPMI 1640 media containing 10% FCSto give a range of
concentrations (2000-10ng/ml). In one set of dilutions, tariquidar (final
concentration, 1uM) was added. In another set of dilutions, DRV (final
concentration, 25uM) was added. Dilutions without DRV or tariquidar were used as
controls. Each of these drug dilutions (50pl) were added to sterile 96-well plates,
which were followed by the addition of CEM or CEMyprcells (S0pl). The plates
were incubated (3 days, 37.5°C, 5% COz). The assays were terminated by adding
MTT (20u1, Smg/ml dissolved in HBSS) to each well and the plates were returned to
the incubator (37.5°C, 5% CO2hrs). Lysis solution (1001) was added to each well
and plates were incubated overnight (37.5°C, 5% CO). The plates were analysed
using the Genios XFLUOR4fluorescence plate reader (560nm A).
2.2.9 Characterising cellular accumulation of rilpivirine in CEM cell lines
Rilpivirine transport was assessed using the same methods as for DRV, exceptcells
were incubated in serum free media containing [°H]rilpivirine (140nM; 0.47pCi/ml).
The CARofrilpivirine was also calculated in the same way as for DRV.
2.2.10 Assessing the impact of protein binding on NNRTItransport
PBMCswereisolated from healthy volunteers and counted as described previously.
PH] NVP (1nM; 0.045pCi/ml), ['4C] EFV (1M; 0.23pCi/ml) and [PH]rilpivirine
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(1uM; 0.32uCi/ml) were incubated with 5 x 10° cells (37°C, 20mins) in RPMI 1640
media in the absence or presence of protein (10% FCS or 0-60mg/ml HSA).
Washing,scintillation counting and analysis of CAR was performed as described for
DRV.
2.2.11 Statistical analysis
To analyse the DRV accumulation in eachcell line and PBMC,StatsDirect 2.4.5 was
used. The Shapiro-Wilk test was used to test for normality of the data. The CEM,
CEMyp_ and CEMg000 cells in the presence or absence of MK571 ortariquidar data
were log transformed andtested for differences using the paired t-test. The paired t-
test was also used to assess the PBMC data for differences in accumulation between
each inhibitor with the control (no inhibitors).
The toxicity data were tested for normality by Shaprio-Wilk and statistical
significance was tested using the paired t-test. The DRV inhibition of transport data
were analysed using the GraphPad Prism 3.0 software. Log transformation and non-
linear regression analysis was used to obtain ECs) concentrations and the pairedt-test
was usedto test for statistical significance.
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2.3. Results
2.3.1 ABCB1 and ABCC1expressionin cell lines
Using flow cytometry to quantify relative amounts of protein (median fluorescence —
isotype control, relative fluorescence units (RFU)), higher ABCB1 expression was
detected in CEMyp, (6.75RFU) than in CEM (0.04RFU, n=2) and CEMgyio00 cells
(0.05RFU, n = 2, Fig. 1a). Similarly, more ABCC1 was expressed by CEMe1000
(18.31RFU) than CEM (2.52RFU, n=2) and CEMvpy (1.81RFU, n = 2) cells (Fig.
1b). MDCKII-ABCBI1 expressed more ABCB1 (54.16RFU) than in MDCKII
parental cells (-0.025RFU,Fig. Ic).
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Fig. 1 Relative expression of a) ABCB1 in CEM, CEMyp. and CEMe1000 cells
(n=2), b) ABCC1 in CEM, CEMypt and CEMgy090 cells (n=2) and c) ABCB1
in MDCKIIparental and MDCKII-ABCBI cells (n=2).
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2.3.2 Toxicity of darunavir and rilpivirine
There was no evidence of reducedcell viability in the CEM, CEMvpr and CEMe1000
cells when cultured in concentrations up to 50uM of DRV (CEM cell viability,
126%, CEMyprcell viability, 117%, Fig. 2a).
CEM cells had a lower ECs9 in the presence of rilpivirine than CEMypr (3.0 +
0.64uM compared to 6.2 + 3.3.M), but this wasnotstatistically significant (Fig. 2b).
 
a) 150-
i —=— E1000
S ——CEM
£O SSa5 754£8
a 50-
5 25- 15 10 05 00 05 10 15
log concentration of DRV (uM)
Ss — 150- —— CEM
—— VBL
= oO oO 1
Via
ble
cel
ls
(%
of
con
tro
l)
o 2
  0 T T I-1 0 1 2 3
log concentrationof rilpivirine (uM)
Fig. 2 Toxicity of a) DRV in CEM, CEMyp_ and CEMej000 cells (n=4) and b)
rilpivirine in CEM and CEMyprcells (n=4)
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2.3.3. Cellular accumulation of darunavir in CEM cell lines
The concentrations of darunavir (14M) and rilpivirine (140nM) used to assess drug
transport were determined by no or low cytotoxicity and drug solubility. The
incubation time during cell uptake assays was 20 minutes as this was previously
shownto be sufficient for the antiretrovirals (Janneh ef al. 2005, Janneh et al. 2007).
The CAR of DRV wassignificantly higher in CEM cells (mean + s.d, 5.6 + 0.7) than
in CEMyprcells (1.4 + 0.6, p<0.001, n=7).
In CEMypr cells, the CAR wassignificantly increased in the presence of tariquidar
in a concentration dependant manner(Fig. 3a), with significant increases of CAR at
10nM (1.5 + 0.2, p<0.05), 20nM tariquidar (2.9 + 0.5, p<0.01, n=4), 30nM tariquidar
(4.6 + 0.8, p<0.001, n=4) and higher concentrations of tariquidar (100nM, 300nM,
1000nM) showingtrends towards further increase (4.8, 5.2, 5.2, n=3).
The CAR of DRV was lower in CEMg1000 cells (3.6 + 0.5) compared to CEM cells
(5.1 + 1.0, p<0.05, n=6); however, MK571 did not reverse the difference in
accumulation significantly (Fig. 3b). In this experiment, there was consistency in the
differential accumulation in CEMyp, (0.9 + 0.06) compared with CEM (5.6 + 1.0,
p<0.001, n=6) and the accumulation in CEMypzrwasincreased by tariquidar (300nM,
5.8 + 0.4 p<0.001, n=6); however, MK571 also significantly increased the mean
CAR in CEMypycells (5uM, 1.1 + 0.1, p<0.001, 10nM 1.7 + 0.2, p<0.001, n=6).
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Fig. 3 The effect of a) tariquidar on [C'*] DRV CAR in CEM and CEMypzcell lines
and b) MK571 on [C'*] DRV CAR in CEM; CEMypr and CEMe1000 cell
lines. *** p<0.001 (n=7), compared to CEM control. * p<0.05 (n=4), **
p<0.01 (n=4), *** p<0.001 (n=7) compared to CEMypi control. * p<0.05
compared to CEM control (n=6), *** p<0.001 compared to CEM control
(n=6), *** p<0.001 (n=6) compared to CEMyzicontrol
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2.3.4 Transcellular transport of darunavir across MDCKII and MDCKII-
ABCBIcells
Transport of ['*C] DRV from the basolateral (BL) chamber to the apical (AP)
chamber wasobserved in the MDCKII-ABCB1 transwell experiments (Fig. 4a). The
transcelluar transport was reversed with the addition of tariquidar (Fig. 4b) and
minimaltransport was observed from the AP to the BL chamber(Fig. 4a and 4b).
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Fig. 4 The transport of [c'*] DRV through a MDCKII-ABCB1 monolayera)in the
absence and b) in the presence of tariquidar (n=3).
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2.3.5 Cellular accumulation of darunavir in PBMCs
In PBMC,the only inhibitors to lead to a significant change in DRV CAR were
dipyridamole (6.9 + 1.3, p < 0.01, n=8) and montelukast (5.7 + 1.0, p < 0.01, n=8)
compared to baseline CAR (6.2 + 1.1, n = 8, Fig. 5a). The mean CAR of DRV was
not significantly altered by tariquidar (6.6 + 1.7, n=8), verapamil (6.5 + 0.8, n=8),
probenecid (6.3 + 1.2, n=8), MK571 (6.4 + 1.4, n=8), GF120918 (6.6 + 1.0, n=4),
frusemide (6.1 + 1.0, n=8) or estrone-3-sulphate (6.0 + 1.0, n=8).
Dipyridamole increased CARin 7 out of 8 samples by a mean CAR change (11.8% +
9.4, Fig. 5b), whilst montelukast decreased mean CAR in all 8 samples (-7.5% +
5.44, Fig. 5c).
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2.3.6 Inhibition of ABCB1 transport by darunavir
A lower vinblastine ECs) was observed in CEM than in CEMypy cells (0.02 +
0.01ng/ml, compared to 35.3 + 9.8ng/ml, p<0.001, Fig. 6a). CEM cells cultured in
the presence of vinblastine with tariquidar (0.017 + 0.002ng/ml, Fig. 6b) or DRV
(0.004 + 0.004ng/ml Fig. 6c) had no changein cell viability. Culturing CEMyprcells
in the presence of vinblastine and tariquidar reduced the ECso of the cells (0.45 +
0.08ng/ml, p<0.001, Fig. 6d). When CEMyprcells are cultured in the presence of
vinblastine and DRV, the ECso was reduced (3.50 + 1.22ng/ml) compared to
CEMyprcells cultured only in vinblastine (35.3 + 9.8ng/ml, p<0.001 Fig. 6e).
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Fig. 6 Toxicity of vinblastine in a) CEM (—*—) and CEMyp. (——)cells alone
(n=4), b) in CEM cells in the presence and absence of tariquidar ( ——)
(n=4), c) CEMcells in the presence and absence of DRV (——) (n=4), d)
CEMvyprcells in the presence of tariquidar (—-— ) (n=4) and e) in CEMypi
cells in the presence ofDRV ( —s— ) (n=4).
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2.3.7 Cellular accumulation of rilpivirine in CEM celllines
No significant differences were observed between CEM, CEMypi and CEMe1000
cells and the addition of tariquidar and MK571 had no observable difference in
intracellular accumulation ofrilpivirine (Fig. 7a and 7b).
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Fig. 7 The effect of a) tariquidar on [H?] rilpivirine CAR in CEM and CEMyp;cell
lines (n=4) and b) MKS571 on [H°] rilpivirine CAR in CEM; CEMyp. and
CEMe1000cell lines (n=4).
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2.3.8 Impact of protein binding on the transport the of NNRTIs
The CAR of NVP wastheleast affected by protein, with the highest concentration,
60mg/ml HSA (CAR = 1.5) and 10% FCS(1.8) comparable to protein free control
(1.9, n=3, Fig. 8a). EFV showeda trend towards a decrease in cellular accumulation
with increasing HSA concentration (20mg/ml, CAR = 10.3, 40mg/ml, 7.3, 10% FCS,
96.3), with the lowest amountofcellular accumulation observed with 60mg/ml HSA
(4.9) compared to protein free control (303.2, n=3, Fig. 8b.). Rilpivirine also showed
a trend towards decreased cellular accumulation with increasing HSA concentrations
(20mg/ml, CAR = 9.1, 40mg/ml, 3.7, 10% FCS, 150.6), with the lowest amount of
cellular accumulation observed with 60mg/ml HSA (4.5) compared to protein free
control (481.5, n=3, Fig. 8c.).
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Fig. 8 The CARofa) [H] NVP b)['*C] EFV andc) [°H]rilpivirine in the absence
or presence of 10% FCSorin varying concentrations of HSA (n=3).
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2.4 Discussion
Drugtransport mayalter intracellular drug concentrations, which ultimately affects a
drug’s ability to suppress HIV replication. The transport of DRV andrilpivirine and
the impact of protein binding onrilpivirine were investigated.
CEM, CEMyzg, and CEMgijo00 cells were analysed to assess relative ABCB1 and
ABCC1 expression. CEMyp, and CEMej000 expressed comparably high levels of
ABCB1 and ABCC1 relative to CEM parental cells.
The CEM, CEMygy and CEMg000 cell lines are CD4+ T cell leukaemia cell lines
previously used for assessing the intracellular accumulation of xenobiotics (Davey ef
al. 1996). Since the site of action for antiretrovirals are within CD4+ cells, cultured
lymphocytes provide a useful model to assess intracellular accumulation of
antiretrovirals. CEMyp_ and CEMg1000 expressrelatively high levels of ABCB1 and
ABCC1, but these phenotypes were drug-selected and other transporters which were
not investigated may also be up- or down-regulated. For example, a study by Janneh
et al. (2008) showedthatof the panel ofinflux transporters tested, PBMCsonly had
detectable mRNA expression of SLCO3A1. Whilst detectable levels of SLCO3A1
were observed in CEM, CEMypy and CEMg000 cells, SLCO4A1 was detected in
CEM, CEMypi and CEMe000 cells and SLCO1A2 mRNA wasdetected only in
CEMvs. cells.
The toxicity of DRV was assessed in CEM, CEMypr and CEMi000 cells, but the
highest concentration used (50uM,dictated by solubility) was not toxic in thesecells,
which wasconsistent with the lack of toxicity observed by De Meyeret al. (2005) in
a different cell line.
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A significantly lower cellular accumulation of [C'*] DRV was observed in CEMypt
cells compared to parental CEM cells, suggesting DRV to be an ABCB1 substrate.
This was further supported as the CAR in CEMyp, increased with increasing
concentrations of the ABCB1 inhibitor tariquidar and at 30nM, the difference in
CAR between CEM and CEMypr was abrogated. An increase in transport of DRV
between MDCKII-ABCB1 basolateral compared to apical chambers in the transwell
system wasalso observed, and this increase was reversed with the addition of 1uM
tariquidar. Furthermore, no transport was observed from the apical to the basolateral
chamber, whichis consistent with other studies which found ABCB1 to be expressed
on the basolateral membrane (Horio ef al. 1989). Both of these uptake models
suggest that DRV is a substrate of ABCB1. The CEM uptake modelis an established
method of assessing transport by ABCB1 and ABCC1 and has been used to
demonstrate SQV and LPVassubstrates of ABCB1 and ABCC1 (Jannehet al. 2005;
Janneh et al. 2007). The MDCKII uptake model, developed by transfecting ABC
transporter genes (Horio ef al. 1989; Bakos et al. 1998), is also an established model
for assessing transport. Using this model, SQV has been shown to be a substrate of
ABCC]and ABCC2(Williamsef a/. 2002) and LPV was confirmed to be a substrate
of ABCB1 and ABCC2 (Agarwalet al. 2007).
A difference in CAR of DRV between CEM and CEMe009 cells was observed, but
this was not reversed by the addition of the inhibitor MK571. This does not confirm
nor refute DRV as a substrate of ABCC1 and further evidence will be needed to
validate DRV as substrate of ABCC1. DRV CAR in CEMypy cells also had small
increases in the presence of MK571 at any concentration, which suggests that
MK571 doesnot have good specificity for ABCC1.
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PBMCsare a mixed population of subsets (primarily CD4+ and CD8+ cells) and
during culture, they were incubated with phytohaemogluttin, which activates the
cells (Martin-Romero ef al. 2000). In PBMC,the only change in CAR observed was
in the presence of dipyridamole or montelukast. Montelukast significantly lowered
CAR of DRV in all of the PBMC samples, which indicates that DRV may be a
substrate of influx. This also suggests that influx does have an impact(albeit small)
on DRV cellular accumulation ex vivo. The ABCBI1 inhibitors tariquidar and
verapamil did not appear to alter CAR in PBMC samples. This may be due to lower
levels of ABCB1 in PBMC compared to CEMypz_, which suggests that ABCB1 may
not be a major regulator of intracellular accumulation in PBMC. MK571, the ABCC
inhibitor also did not alter cellular accumulation of DRV in PBMC.Dipyridamole is
a known inhibitor of multiple transporters (including ABCB1 and ABCC1) and
increased 7 out of 8 PBMCsamples. This suggests that the inhibition of both ABCB1
and ABCC1 maybe required to increase drug accumulation in PBMCsand provides
further evidence that DRV maybe a substrate of ABCC1 as well as ABCB1 orthat
dipyridamole inhibits other efflux transporters. In contrast, LPV accumulation in
PBMCs increased with the addition of tariquidar (9% increase), MK571 (45%
increase), dipyridamole (37% increase) and frusemide (27% increase) (Jannehetal.
2007), suggesting a stronger affinity for LPV than DRV by the ABCB1 and ABCC1
transporters. In a separate study by Janneh ef al. (2005), SQV accumulation in
PBMCsalso increased with the addition of tarquidar (14% increase), MK571 (39%
increase), dipyridamole (45% increase) and frusemide (82% increase), suggesting
that there are differences in the transporters involved in intracellular accumulation of
different PIs.
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CEMypicells were more resistant to vinblastine toxicity due to over-expression of
ABCB1 onthese cells; whereas, CEM cells express much lower levels of ABCB1
and have reducedcell viability when cultured with vinblastine. Tariquidar was used
as a positive control against CEMypr cells as it inhibits ABCB1 and it reduced
CEMypst cell viability in the presence of vinblastine. CEMysr cell viability was
reduced when DRV wasincluded in vinblastine cultures, indicating that DRV is also
a competitive inhibitor of ABCB1. CEM cells were cultured with vinblastine and
tariquidar or DRV to act as a negative control and to confirm that changesin cell
viability are attributable to ABCB1. Neither tariquidar nor DRV altered cell viability
of CEM cells cultured with vinblastine.
Rilpivirine is more cytotoxic than DRVandis toxic between 3-64.M when incubated
for three days in CEM cells. The concentrations of rilpivirine used to assess
intracellular accumulation in PBMCs, CEM, CEMypr and CEMe1000 cells were up to
1uM. This would not be likely to affect the data as the cells were incubated with
rilpivirine for 20 mins as opposed to 3 days, which was used to assess toxicity.
Rilpivirine does not appear to be a substrate for ABCB1 or ABCC1 using the CEM
uptake model. This suggests that these efflux transporters may not be relevant in
determiningrilpivirine cellular accumulation.
EFV and NVP have been shownto be primarily bound to HSA in vivo, with over
99% (Bristol-Myers-Squibb 2008) and 60% (Boehringer-Ingelheim 1999) bound
respectively. Concentrations of HSA were chosen to be above (60mg/ml), below
(20mg/ml) and within (40mg/ml) the in vivo concentration range (30-50g/l). 10%
FCS was included as it was used to evaluate DRV andrilpivirine transport. Serum
free media was used in these experiments as a protein free control. The effect of
protein binding of EFV, NVPandrilpivirine to HSA in vitro was investigated. The
67
Evaluating the transport of darunavir andrilpivirine
order of affinity for protein binding with 10% FCS and HSAisrilpivirine > EFV >
NVP. This suggests that rilpivirine is highly bound to albumin. Cellular
accumulation experiments to assess ABCB1 function on rilpivirine were performed
with the inclusion of 10% FCS in the incubation medium, hence the 10% FCS
condition was included to observe the effect of FCS on the cellular accumulation of
rilpivirine. Rilpivirine binding to FCS was higher than that of EFV, yet rilpivirine
showed higher binding to HSA compared to EFV. This suggests that rilpivirine may
have less affinity for other composite proteins in serum compared to EFV. These
results are similar to other studies which found higher protein binding by EFV
(Almondef al. 2005) than by NVP (Almondetal. 2005).
In conclusion, this study suggests that DRV is a substrate of ABCB1in vitro, but that
the effect of ABCB1 on DRVtransport is not as marked in PBMC comparedto the
cell line models. It is possible that ABCB1 may not be the main transporter altering
cellular concentrations of DRV ex vivo. However, inhibition of both ABCB1 and
ABCC1 appears to have some impact on cellular accumulation of DRV ex vivo
compared to inhibition of ABCB1 or ABCC1 separately. Whilst ABCB1 alone does
not appear to have a strong influence on the intracellular accumulation of DRV,the
effect may be observedin othertissues such asthe gut, liver and brain where ABCB1
has a more prominent role. For example, DRV may not be very effective against
viral reservoirs due to the abundance of ABCB1 at the blood-brain barrier (Choo ef
al. 2000). These findings also support the use of a PI-booster in conjunction with
DRV to improve the bioavailability of DRV by lowering the rate of clearance of
DRV by ABCBI (Rittweger and Arasteh 2007). Inhibition of influx transporters also
appears to have a modest effect on DRV accumulation in PBMCs, but the effects of
individual influx transporters still remain to be elucidated. The impact of individual
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transporters is difficult to identify as the use of inhibitors may inhibit unknown, in
addition to target transporters. DRV is an inhibitor of ABCB1 efflux, whichis likely
to be competitive inhibition as it is also a substrate of ABCB1. The interactions
between DRV and ABCC1 remain unclear and warrant further investigation;
however,it is clear that intracellular concentrations of DRV are, at least in part, the
product of complex interactions with multiple transport proteins. Rilpivirine does not
appear to be a substrate for ABCB1 or ABCC1 using the CEM model, but the
cellular accumulation of rilpivirine is lowered with the inclusion of HSA. This
suggests that protein binding may have more impact on the intracellular
concentration ofrilpivirine than active transport.
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3.1 Introduction
Antiretroviral drugs have been shownto be substrates for efflux transporters, which can
affect bioavailability, plasma concentrations, clearance and intracellular concentrations
and thereby impact on viral resistance and toxicity. Efflux transporters such as ABCB1
have been extensively studied in relation to pharmacokinetics and druginteractions, but
manyinflux transporters have yet to be characterised.
For studying influx of antiretrovirals, the SLCO sub-family are ideal candidates due to
their well characterised protein and molecular structures as well as their implicit roles in
the transport of xenobiotics. Members of the SLCO family have been reported to
transport bile salts and hormonesas well as xenobiotics such as statins (Kopplow etal.
2005, Hsiang et al 1999, Hirano et al 2004), anti-cancer (Abe et al. 1999, Abeet al
2001) and anti-microbial drugs (Tironaef al. 2003, Tamaief al. 2000).
SLCO family members include SLCO1B1 and SLCO1B3, which have been identified as
major hepatic transporters (Hsiang ef al. 1999, Kénig et al 2000). SLCOIA2 is
expressed in several major organsincludingthebrain, liver and intestines (Bleasbyetal.
2006, Lee et al. 2005). SLCO3A1 has ubiquitous expression including lymphocytes
(Bleasy et al. 2006, Tamaiet al. 2000), which is important dueto the site of action for
antiretrovirals being in CD4+ cells. SLCO2B1 has been identified in various tissues,
including the small intestine (Tamai et al. 2000), placenta (St-Pierre et al. 2002) and
heart (Grube ef al. 2006). SLCOIB1 and SLCO1B3 share over 80% homology, are
exclusively expressed in the liver, and have been shown to affect intracellular
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concentrations in vitro (Hsiang et al. 1999) and also plasma concentrations of xenobiotic
substrates in vivo (Hirano eft al. 2004, Lau et al. 2007). One study suggested that
basolaterally expressed SLCO1A2acted in concert with apically expressed ABCB1 and
ABCC1 to excrete saquinaivr (SQV)into bile. This was demonstrated by the transport of
SQV in SLCOJA2 transfected HepG2 cells and X. laevis oocytes injected with
SLCOIA2 cRNA(Suet al. 2004).
Identification of transporter substrates can help explain drug interactions that alter drug
plasma concentrations. For example, rifampicin, which has been shown to be a
competitive inhibitor of SLCO1B1 in the X /aevis oocyte system (Vavricka et al. 2002),
has subsequently been shownto increase atorvastatin plasma concentrations and affect
drug clearance when given as a single dose to healthy volunteers (Lau et al 2007).
Several SLCOshave been foundto transport various xenobiotics, but many interactions
betweenantiretrovirals and influx transporters have yet to be characterised.
Darunaviris likely to be a substrate of influx transporters because montelukast, which is
a knowninhibitor of influx reduces the accumulation ex vivo (Letschert et al. 2006);
however, the specific transporters are unknown (discussed in Chapter 2). Many known
inhibitors of SLCOsare not specific to individual transporters due to overlap between
substrate transporters.
Several approaches have been used for evaluating individual influx transport in vitro.
These include primary hepatocytes, Xenopus /aevis oocytes, yeast expression systems
and transiently and stably transfected cells (Xia et al. 2007). The aim of this chapter was
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to clone known SLCOs and develop X Jaevis expression vectors for subsequent
determination of whether antiretrovirals are substrates for SLCO1A2, SLCOIB1,
SLCO1B3 and SLCO3A1 in Chapter 4.
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3.2. Methods
3.2.1 Materials
TaqMan Reverse Transcription Reagents were purchased from Applied BiosystemsInc.
(Warrington, UK); Expand High Fidelity PCR System was purchased from Roche
Diagnostics (Burgess Hill, UK). (Huntingdon, UK). Cell lines were purchased from
ECACC (Salisbury, UK), RPMI 1640 and DMEM media were purchased from Gibco
(Invitrogen Ltd, Paisley, UK). Foetal calf serum (FCS) was purchased from Biosera
(East Sussex, UK). TRIzol reagent, chloroform, GenElute PCR clean-up kit, GenElute
gel extraction kit and isopropanol (Fluka) were purchased from Sigma-Alderich
Company Ltd (Poole, UK). TOPO TAcloning kit was purchased from Invitrogen Ltd
(Paisley, UK). DH5-a competent E. coli cells, T4 DNA ligase, Antarctic phosphatase,
NEB 1kb ladder, NEB 500bp ladder andall restriction enzymes were purchased from
New England Biolabs (Hitchen, UK).
pBluescriptII-KSM wasa kind gift from WJ Joiner (Yale University, Connecticut, USA)
and pSPORT1-Oatp1-OATP4 (Cattori et al. 2000, Huber et al. 2006) was a kind gift
from Bruce Steiger (Switzerland).
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3.2.2 Cloning strategy
The majority of SLCOs were cloned from human cell line mRNA, with SZLCO1A2
cloned from A549, SLECOIB1 and SLCO/B3 cloned from Huh7 mRNA. SLCO3A1 was
cloned from a plasmid kindly provided by Dr. BrunoSteiger.
SLCOIA2 was cloned in two fragments, with the introduction of a Kozak consensus
sequenceprior to the start codon of the gene and BglIIrestriction sites at the 3’ and 5’
ends of the gene. SLCO/A2 fragments were then ligated and cloned into pCRII-TOPO
plasmid. SLCO/BI/ and SLCO/B3 were amplified to include 3’ and 5’ UTRsections,
which were cloned into pCR-II-TOPO. From pCRII-TOPO, SLCOIBI and SLCOIB3
were amplified to contain only the genes and introduce the Kozak consensus. These
PCRproducts were cloned into pCRII-TOPO. SZCO3AI was amplified from pSPORT-
oatp4-OATPD plasmid and the Kozak consensus wasintroducedprior to subcloninginto
pCRII-TOPO. With the SLCO genes in pCRII-TOPO, the sequences were verified by
sequencing (GATC Biotech). SLCO genes which contained mutations were converted
into wildtype by using site-directed mutagenesis. Onceall the SLCOs were confirmed to
be wildtype, the genes were subcloned into pBluescriptII-KSM which contains 3’ and 5’
X. laevis B-globin UTR flanking the multiple cloning site. Clones with the correct
orientation were selected and inventoried.
The overall cloning strategy is illustrated in Fig. 1.
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Fig.1 Illustration of the overall cloning strategy of the SLCOtransporters
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3.2.3 mRNAextraction
The humanalveolar basal epithelial cell line A549, and human hepatomacell line Huh-7
was cultured (DMEM supplemented with 10% foetal calf serum) and used as a source of
RNA. TRIzol reagent was used to extract total RNA from A549 cells. A549 cells
(1x10’) were centrifuged (800 x g) to form cell pellets, mixed with TRIzol (1ml) and
lysed by a freeze-thaw cycle (-80°C, 20°C). Chloroform (200ul) was added to the
mixture and shaken before centrifugation (12000 x g, 15mins). The supernatant was
transferred to a new tube and isopropanol (500ul) was added and mixed. The solution
was centrifuged (12000 = g, 10mins) and the supernatant was removed. Thepellet was
washed with 75% ethanol (Iml, 7500 x g, Smins) andair dried before resuspension in
RNase free water (20ul). Quantification of RNA was achieved using a
spectrophotometer and samples with an A260:A280 ratio of over 1.70 were deemed to
be of suitable purity and stored (-80°C).
3.2.4 Reverse transcription
A549 and Huh7 total RNA wasreverse transcribed into cDNA using TaqMan Reverse
Transcription Reagents. The reverse transcription reactions were assembled as follows:
10x RT buffer (10ul, final concentration of 1x), 25mM MgCl, (22u1l,final concentration
of 5.5mM), 10mM dNTP (20yl, final concentrations of 2mM) 50uM oligo dT primers
(Sul, final concentration of 2.54uM), 20U/pl RNaseinhibitor (2ul, final concentration of
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0.4U), 50U/ul Multiscribe reverse transcriptase (2.5ul, final concentration of 1.25U) and
A549/Huh7 mRNA. The reaction was incubated at 25°C for 10min followed by
annealing temperature of 48°C, 1h and finally inactivated at 95°C for Smins using the
Applied Biosystems GeneAmp PCR System 9700.
3.2.5 Primer design
Primers were designed based on published sequences of SLCO1A2 (NM_134431),
SLCOIBI (AB_026257), SLCO1B3 (NM_019844) and SLCO3A1 (NM_013272).
SLCOIA2 primers were designed to amplify the gene in two fragments in a nested PCR
reaction to incorporate the Kozak consensuspriorto the start codon and BglIIrestriction
sites to flank the gene. This was achieved by usingthefirst 19 bases (5°, fragment |
forward), the last 21 bases (3’, fragment 2 reverse) and 20 basesstarting from the +973
position (5’ — 3’, fragment 2 forward) and +1013 (3’ — 5’, fragment 1 reverse). The
productof fragment | forward and reverse was predicted to be 993bp and the product of
fragment 2 forward and reverse was predicted to be 1020bp. A primer was designed to
contain a BgllI restriction site and the Kozak consensus (CCACC), followed by the
fragment 1 forward sequence. A reverse primer was also designed with the BglII
restriction site after the fragment 2 reverse primer.
Suitable primers in the untranslated regions of SLCO/B1 (-76 and + 15), SLCO/B3 (-90
and +2088) were identified by using OligoExplorer 1.2. Primers were chosen bytheir
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GC content (approximately 50%), similar annealing temperatures between the forward
and the reverse primers and limited mono- and dinucleotide repeats. Two additional
forward primers were chosen, one at the start codon of each gene and one with the
Kozak consensus addedprior to the start codon. For SLCO3A 1, the forward primer was
the Kozak consensus and the first 16bp of the gene and the reverse primer was 23bp
from the last base in SLCO3A/,i.e. includes the start of the oatp] 3’ UTR. The primer
sequencesare presented in Table 1.
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3.2.6 PCR amplification and ligation of SLCOLA2
SLCOIA2 was amplified in two fragments using the Expand High Fidelity PCR System
(Roche Applied Science) reagents, the GeneAmp PCR System 9700 (Applied
Biosystems) and the Eppendorf Mastercycler gradient (Eppendorf) machines. For both
fragments the following reagents were assembled: 10x Expand High Fidelity Buffer
with 15mM MgCl. (Sul, 1x final concentration), 10mM dNTP (4ul, 800nM final
concentration), 104M respective forward primer (lul, 200nM final concentration),
10M respective reverse primer (11, 200nM final concentration, Table 1.), nuclease-
free water (35.75 ul), A549 oligo dT cDNA (2.511, 10% of cDNAreaction volume) and
3.5U/pl Expand High Fidelity Enzyme Mix (0.75ul, final concentration 2.63U). The
PCR conditions were as follows: hot start (94°C for 10s), initial denaturation (94°C for
2mins), 40 cycles of denaturation (94°C for 10s), annealing (59°C/56°C: fragment
1/fragment2) 30s, elongation (72°C for Imin) and a final elongation (72°C for 7mins).
The amplified fragment | and fragment 2 were visualised by agarose gel electrophoresis.
The PCR products were loaded into agarose gels (1% w/v in TBE, 0.15pg/ml ethidium
bromide) with Sigma } DNA EcoRI, HindIII digest ladder to mark DNAbandsizes and
appropriate bands were excised and purified using the GenElute Gel Purification kit. The
Kozak consensus and BglII restriction sites were added 5’ to the start codon of
SLCOIA2 fragment | and a BglII restriction site was added 3’ to the stop codon of
fragment 2. The PCR was performed using the same reaction mix as the first round of
PCR, except the Kozak forward primer was used instead of fragment | forward primer
and the BglII reverse primer wasused instead of fragment 2 reverse primer (Table 1.).
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Digestion of SLCO/A2 fragments were performed with Nsil (NEB) using 10x NEBuffer
3 (Sul, 1x final concentration), SLCOIA2 fragment 1 (500ng), SLCOIA2 fragment 2
(500ng), 10U/pl Nsil enzyme (1,1, 0.2U/ul final concentration), nuclease-free water (up
to 50pl) and incubated (37°C, Ihr), followed by heat inactivation (80°C, 20mins).
SLCOIA2 fragments were ligated with T4 DNA ligase using 10x T4 DNA ligase
Reaction Buffer (2ul, 1x final concentration), SECOJA2 fragments | and 2 (17ul of
digest product) and incubated (10mins, room temperature). The ligation products were
visualized and extracted from 1% agarosegel.
3.2.7. PCR amplification of SLCO1B1
SLCOIBI1 was amplified in full using UTR primers in the Expand High Fidelity System.
The following was used to assemble the PCR reaction: 10x Expand High Fidelity Buffer
with 15mM MgCl2 (Sul, 1x final concentration), 10mM dNTP (4ul, 800nM final
concentration), 10uM respective forward primer (lpl, 200nM final concentration),
10uM respective reverse primer (11, 200nM final concentration, Table 1), nuclease-free
water (35.75ul), Huh7 oligo dT cDNA (2.5ul, 10% of cDNA reaction volume) and
3.5U/ul Expand High Fidelity Enzyme Mix (0.75ul, final concentration 2.63U).
The PCR conditions were as follows: hot start (94°C for 10s), initial denaturation (94°C
for 2mins), 40 cycles of denaturation (94°C for 10s), annealing (62°C for 30s),
elongation (72°C for 2mins) and a final elongation (72°C for 7mins). The product was
cloned into the pCRII-TOPO plasmid before performing further PCR steps.
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The samereagents as above were used except the inner forward primer was used instead
of the UTR forward primers and the DNA template used was the SLCO/B1 with UTR
TOPOplasmid. The PCR conditions were the same except for the annealing temperature
used (62°C for 30s). The PCR products were visualised on agarose gels (1%) as for
SLCOJA2 and appropriate bands were excised and purified. The Kozak consensus was
added to the gel purified products by PCR andreplacing the forward primers with Kozak
forward primer (Table 1). The reagents and conditions used were the same as the
previous PCRs. The final product containing the Kozak consensus was cloned into
pCRII-TOPOvector.
3.2.8. PCR amplification of SLCOIB3
Amplification of SLCO/B3 was performed the same as for SLCO/B/ with the exception
of the primers used (Table 1) and the annealing temperature used (68°C for 30s) for
amplifying SLCO/B3.
3.2.9 PCR amplification of SLCO3A1
SLCO3A1 was amplified from the pSPORT1-oatp/-OATP4 vector using the Expand
High Fidelity System. The following was used to assemble the PCR reaction: 10x
Expand High Fidelity Buffer with 15mM MgCl, (Sul, 1* final concentration), 10mM
dNTP (4ul, 800nM final concentration), 101M forward primer (1yl, 200nM final
concentration), 10M reverse primer (11, 200nM final concentration, Table 1), 100%
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DMSO (lul, 5% final concentration) nuclease-free water (35.75ul), pSPORT-oatp1-
OATP4 cDNA (2.5ul, 25ng) and 3.5U/ul Expand High Fidelity Enzyme Mix (0.75ul,
final concentration 2.63U).
The PCR conditions were as follows: initial denaturation (94°C for 2mins), 25 cycles of
denaturation (94°C for 10s), annealing (66°C for 30s), elongation (72°C for 2mins) and a
final elongation (72°C for 7mins).
3.2.10 Cloning of SLCOtransporters using pCRII-TOPO
Cloning was performed with the pCRII-TOPO cloning kit (Invitrogen, UK). The
SLCOIJA2 cloning reaction was assembled with ligated product (15ng), vector (10ng),
salt (1.2M NaCl, 0.06M MgCh,final concentration of 200uM NaCl, 100M MgCl.) and
nuclease free water (up to 6ul) and incubated (10mins, room temperature). The ligation
mixture (2p1) was added to a vial of thawed E. coli (SOul) and incubated on ice
(10mins). The E. coli was heat shocked (42°C, 30s) and then returned to ice before SOC
media was added to the E. coli (200u1) and incubated (37°C, lhr, orbital shaker,
250rpm). Culture plates were prepared with LB agar (35g/l) containing ampicillin
(SOug/ml) and blue-white screening reagent (40u1, IPTG 40mg/ml, X-Gal 40mg/ml in
DMSO) was spreaded on the surface of the agar. The E. coli culture was spreaded
(1001 per plate) and left to grow (37°C,overnight).
For SLCOIBI, SLCOIB3 and SLCO3A1, the cloning reaction was different from that
used for the SLCO1A2asthe reaction contained PCR product (10ng) and pCRII-TOPO
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vector (10ng) in a 20ul reaction whilst the concentration salt remained the same. The
transformation of the E. coli was performed in the same wayas for SLCOLA2.
3.2.11 Clone selection
White colonies were picked and grown in LB containing ampicillin (50ug/ml) and
incubated (37°C, overnight). E. coli plasmids were extracted using the MiniPrep Plasmid
Extraction kit (Sigma-Alderich, UK). Briefly, E. co/i culture (4ml) was centrifuged
(4000rpm, 10mins) and the supernatant was removed. Thecell pellet was resuspended
with Resuspension Buffer (200ul), lysed with Lysis Buffer (200ul, <Smins) and
neutralised with Neutralisation Buffer (300u1). The mixture wascentrifuged (13000 ~ g,
10mins) to pellet cell debris. Spin columns were placed into collection tubes and
prepared with Column Prep (5001, 13000 x g Imin). The flow through was discarded
and the supernatant wastransferred into the spin columns and centrifuged (13000 ~ g,
Imin). The flow-through was discarded and Wash buffer was addedto the spin columns
(6001) and centrifuged (13000 x g). The spin columns were transferred to new
collection tubes, molecular grade water (100u1) was added and the columns were
centrifuged (13000 = g, Imin). The plasmid DNA was quantified by spectroscopy and
verified by restriction digest (Table 2).
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3.2.12 Sequencing and analysis
Clones with the predicted digest patterns following agarose gel electrophoresis were
chosen and sent to GATC Biotech (Germany) for sequencing and the sequences
retrieved were aligned with respective published wild type sequences.
For SLCOIA2, a clone identical to NM_134431 was identified. For other transporters,
differences between clones and published sequences were observed. Therefore site-
directed mutagenesis was performedin orderto correct these clones.
3.2.13 Site-directed mutagenesis
SLCOIBI, SLCOIB3 and SLCO3A/ clones contained 5, 2 and 6 non synonymous
mutations respectively, when compared to their respective wildtype sequences
(NM_006446, NM_019844 and NM_013272). They were corrected using the
QuikChange Multi Site-Directed Mutagenesis kit (Stratagene).
Primers containing wild type SNPs were designed using Stratagene’s QuikChange
Primer Design Program, which designs primers to have similar annealing temperatures
and GC content (Table 2). Sense strand primers were chosen for SLCOJBI1 and
SLCO1B3 whilst anti-sense primers were chosen for SLCO3A/. Primers were dissolved
in nuclease free water to make concentrations of 3uM for SLCOIJBIJ and SLCO3A1
whilst concentrations of 64M were made for SLCO/B3. The following reagents were
assembled at room temperature: 10x QuikChange buffer (2.5ul, final concentration of
1x), dNTP mix (1p), QuikSolution (0.251), respective plasmid DNA (100ng), primers
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(SLCOIBI/SLCO3AJ: 2ul of each, final concentration of each primer, 240nM,
SLCOIB3: 2ul of each, final concentration of each primer, 480nM), 2.5U/ul
QuikChange Multi enzymeblend (1 ul, final concentration of 0.1U/l) and nuclease free
water up to a volume of 25ul. The reaction was cycled through the following
parameters, 95°C for Imin, 30 cycles of 95°C for Imin, 55°C for Imin, 65°C for 12mins
and hold at 4°C. The template plasmids were digested with DpnI (lul, final
concentration 0.38U/ul, 37°C for Ihr). The XL10-Gold ultracompetent cells were
thawed on ice and divided into 45u1 aliquots. Three aliquots were treated with B-
mercaptoethanol mix (2ul) and incubated on ice (10mins, gently mixed every 2min
interval). The DpnI treated SLCO/B/, SLCOIB3 and SLCO3A1 DNA(1.5ul) was added
to the treated XL10-Gold cells and the mixture was incubated (30mins on ice). SOC
medium was pre-warmed to 42°C and the cells were heat shocked in a water bath (30s,
42°C) and placed back on ice (2mins). The SOC medium (5001) was addedto the cells
and the cells were incubated (37°C, Ihr, shaking 250rpm).
Table 2. Primers used for site-directed mutagenesis
 
Gene Mutations Primers
SLCOIB1 C296T caaactacatagaccaaagttaattggaatcgettgtttcattatg
G388A caggtattctaaagaaactaatatcaattcatcagaaaattcaacatcgac
C833T ccattatttcttccataccattctttttcttgcecccaaactcc
GI541A gtaactggtctccagaacagaaattactcagcecca
C1910T tgggcttetcttcaatgttaagagtctcatcacttgttttatatattatattaatttat
SLCO1B3) G334T ccatgaagaaatgtgetaaagatetcaaaatacttccagttcc
A699G tccaatatccacgtacattttagcaaacagagatcccagtg
SLCO3A1 C253T ggttcccgatctcgaagctgctagcgatcac
A604T and T605A gcacgtggtcgtcgtagtaggagacgccca
G1690A agttcaggectgactgtcctgatgaggatgatg
A1826G gecgccttgctccccacagaacetgct
G2111A aaacggactccatgttttcacaccactcatggtct
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3.2.14 Subcloning of SLCO1A2into pBluescriptII-KSM vector
The pBluescriptII-KSM vector, which contained X. laevis 5’ and 3’ B-globin UTR, was
linearised by BglII (10x NEBuffer 3 (Sul, final concentration 1x), BglII enzyme, (Il,
final concentration 10U), pBluescript-KSM vector(lpg) and nuclease free water (up to
50ul, 37°C, Ihr). This was stabilised by using 1x Antarctic Phosphatase Reaction Buffer
(6u1, final concentration 1x), Antarctic phosphatase (ll, final concentration 5U), p-
BluescriptlII-KSM vector (lg), nuclease free water (up to 60ul, incubation at 37°C,
I5mins, heat inactivation 65°C, Smins). SLCO/A2 was digested from pCRII-TOPO-
SLCOIA2 by BglII, as for pBluescriptlII-KSM vector and purified by agarose gel
extraction (GenElute Gel Extraction kit, as per manufacturer’s protocols). SLCO1A2 was
inserted in between the 5’ and the 3’ UTR ofthe pBluescriptII-KSM vector by T4 DNA
ligase with a molar ratio of 3:1, SLCOJA2 insert to p-Bluescript-KSM vector. The
ligation product (10ng) was transformed into NEB5-a competentE. coli cells and plated
on LB agar containing ampicillin (100ug/ml) and incubated (37°C, overnight). Colonies
were picked, grown and plasmids were extracted for digestion according to
manufacturer’s protocolto verify insert orientation.
3.2.15 Subcloning of SLCO1B1, SLCO1B3 and SLCO3A1 into pBluescriptII-KSM
The subcloning of SLCOJBI, SLCO1B3 and SLCO3AI required the digestion of
pBluescriptII-KSM with Spel, double digestion of SLCOIB1, SLCOI1B3 or SLCO3A1
with Spel and Xbal and the usage of a 1:1 molar ratio of insert to vector for ligation.
pBluescriptII-KSM was digested with Spel as follows: 10x NEBuffer 2 (5yl, final
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concentration 1x), 100x BSA (0.5ul, final concentration 1x), Spel enzyme (1ul, final
concentration 10U), pCRII-TOPO-SZCOJ/B/ (lug) and nuclease free water (up to 50ul,
37°C). Spel and Xbal digestion of the genes from pCRII-TOPO were performed as for
Spel digestion but with the inclusion of XbaI (1ul XbaI enzyme, final concentration
20U). The genes (DNA mixed with 6x crystal violet loading buffer (100ug/ml crystal
violet, 20mM EDTA, 30% glycerol), final concentration 1x) was separated from the
TOPO plasmid by crystal violet gel electrophoresis (40ul, crystal violet 2mg/ml, final
concentration in 1.6ug/ml, 0.8% agarose gel) and isolated by using the GenElute Gel
Extraction kit (as per manufacturer’s protocol) and incubated with linear pBluescriptlI-
KSM(65°C, 5mins). The vector and insert was ligated and transformedin E. coli as for
SLCOIA2.
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3.3. Results
3.3.1. Construction of a SLCOJA2 X. laevis oocyte expression vector
Optimisation of SZCOIA2 showed that fragment | and fragment 2 annealing
temperatures were optimal at 59°C and 56°C respectively. The products were visualised
on agarose gel (1%) and bands were excised and purified using the GenElute Gel
Purification kit. SECOlA2 with Kozak and BgllI restriction sites were amplified from
the gel purified products. These products were also visualised on agarose gels (1%), gel
purified and ligated. The ligated product was approximately 2000bp.
Digestion of the SLCO/A2 clone with BglII produced 4 bands, the largest being the full
plasmid and the 3 smaller bands being the digest products (Table 3). The digest products
wereall the expected sizes 1kb, 2kb and 3kb (Fig. 2). The SLCO/A2 clone sequence was
aligned with wild-type (NM_134431) and no mutations were found.
The ligation of BglII digested SLCO/A2 and BglII digested pBluescriptII-KSM vector
produced numerousproducts. This included the desired product (5234bp) of one copy of
SZCOJA2in the correct orientation in the pBluescriptII-KSM plasmid (Fig 3).
E. coli colonies containing pBluescriptII-KSM-SLCO/A2 plasmids were verified by
BamHI digestion (Table 3, Fig. 3), and one of the clones produced bands with the
expected sizes and in the correct orientation. The pBluescriptII-KSM-SZCO/A2 clone
wasfurther digested with BpmlIto confirm findings in the BamHIdigests. The digestion
of a clone with BpmlIalso showedthe expected bandsizes (Table 3, Fig. 3).
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Table 3. Predicted fragments postrestriction digestion of plasmids.
 
 
 
Plasmid Restriction enzyme Predicted sizes (base pairs)
pCRIU-TOPO-SLCO/A2 Belll 993, 2024, 2985
pCRIH-TOPO-SLCO/B1/ BamHI 1886, 4202
Bglll 1718, 4370
BpmI 2011, 4077
BstAPI 6088
HindIII 659, 1294, 4135
pCRI-TOPO-SLCO1B3 BamHI 6102
Bell 1732, 4370
BpmI 2011, 4091
BstAPI 1838, 4264
HindIll 1953, 4149
pCRIH-TOPO-SLCO3A1 Bglll 1117, 5016
Nhel 6133
BstAPI 1613, 4520
Neol 765, 2481, 2887
Stul 6133
Xceml 1387, 1690, 3056
pBluescriptII-KSM-SLCOIA2  Bpml 2239, 2995
BamHI 454, 918, 3862
pBluescriptII-KSM-SLCO/BI BpmlI 2333, 3046
Notl 2374, 3005
BsrDI 174, 575, 1596, 3034
pBluescriptI]-KSM-SLCO/B3 Bpml 2366, 3046
Notl 2407, 3005
BsrD1 174, 805, 835, 1596, 2002
pBluescriptl]-KSM-SLCO3A1 NotI 3005, 2453
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Fig.2 Verification of TOPO-SZCO/A2 by Bglll restriction digest, a) a diagrammatic
representation of TOPO-SLCO/A2 with BglII restriction sites and b) agarose
gel (1%) visualisation of TOPO-SLCO/A2 clones with Sigma 4 DNA EcoRI,
HindIII digest ladder.
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Boel
Diagrammatic representation of SLCOJA2 subcloning from pCRII-TOPO-
SLCOIA2 into pBluescriptII-KSM a) pBluescriptII-KSM with BglII restriction
site, b) pCRII-TOPO-SLCOJA2 with BglII restriction sites, c) pBluescriptlI-
KSM-SZCOJA2 with Bpml restriction sites and d) verification of
pBluescriptII-KSM-SLCO/A2 clones by BpmIdigestion visualised on agarose
gel (1%) with NEB Ikb ladder.
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3.3.2 Construction of a SLCOIB1 X. laevis oocyte expression vector
Preliminary optimisation of SLCO/B1/ with UTR primers by gradient PCR using A549
cDNA showedthat the optimal annealing temperature was 62°C. SLCO/B/ with UTR
was successfully amplified from Huh7 cDNA using an annealing temperature of 62°C.
Clones of SLCOIB/ with UTR insert were digested with HindIII and one clone
produced the expected digest pattern. Further digests of this clone using BamHI, Bglll,
BpmIandNsil also produced expected banding patterns (Table 3).
SLCOIBI was amplified using inner forward primer and UTR reverse with 62°C
annealing temperature. The gel purified PCR product was amplified using Kozak
forward primer and UTR reverse primer and an annealing temperature of 62°C.
SLCOJBI clones containing Kozak consensus were digested with HindIII. All the clones
except one clone produced the expected banding patterns. Further digests of one of the
SLCOIBI clones using BamHI, BglII, BstAPI and HindIII (Table 3) produced the
expected bandingpatterns (Fig. 4).
Alignment of SLCO/B/ with the published wild-type revealed there were 7 mutations.
The non-synonymous mutations were T296C, A388G (published polymorphism,
182306283), T833C, A1541G and T1910C and the synonymous mutations were C571T
and C597T. SLCOJB/ site-directed mutagenesis clones were sent for sequencing by
GATC and alignment of clone sequences with wild-type showed that one clone was
successfully reverted to the wild-type sequence. The pBluescriptII-KSM-SLCO/B1
plasmids were digested with NotI, which produced several plasmids with the expected
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band pattern (Table 3). Further digestion of the clone with BpmI and BsrDI also showed
the expected bandsizes (Table 3, Fig. 5).
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Fig.4 Verification of TOPO-SZLCO/B1 by BamHI, BglII, BpmI, BstAPI and HindIII
restriction digest, a diagrammatic representation of TOPO-SZCO/B1 with a)
BamHIrestriction sites, b) BglII restriction sites, c) BpmlIrestriction sites, d)
BstAPIrestriction site, e) HindIII restriction sites and f) agarose gel (1%)
visualisation of TOPO-SLCO/B/ clones digested with BamHI (1), BglII (2),
BpmI (3), BstAPI (4) and HindIII (5) with NEB 1kb ladder.
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Fig.5 Diagrammatic representation of SLCOJ/BI subcloning from pCRII-TOPO-
SLCOJB1 into pBluescriptlII-KSM a) pBluescriptII-KSM with Spelrestriction
site, b) pCRU-TOPO-SZCO/B1 with Spel and Xbal restriction sites, c)
pBluescriptII-KSM-SLCO/B/ with BpmlIrestriction sites, d) pBluescriptll-
KSM-SLCOJ/B1 with Notl restriction sites, e) pBluescript-KSM-SZCO/B1
with BsrD1 restriction sites and f) verification of pBluescriptII-KSM-
SLCOIBI1 clone by BpmlI(1), NotI (2) and BsrDI (3) digestion visualised on
agarose gel (1%) with NEB 1kb ladder.
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3.3.3 Construction of a SLCOI1B3 X. laevis oocyte expression vector
The optimal annealing temperature for SLCO/B3 amplification from A549 cDNA using
UTR forward and reverse primers was 66°C. Amplification of SZCO/B3 from Huh7
cDNA using UTR forward and reverse primers was successful as a 2000bp band was
observed. SLCO/B3 with UTR clones were digested with HindIII and five clones
produced digests with the expected banding patterns (Table 3). Further digests with
these clones using Bpml, BglII and BamHI showed that four clones had the expected
banding patterns (Table 3).
SLCOIB3 was amplified from Huh7 cDNA using inner forward and UTR reverse
primers successfully. SECO/B3 amplification using Kozak forward and UTR reverse
was successful. SLCOIB3 clones were verified by HindIII digest and all the clones
produced the expected banding pattern. The SLCO/B3 with Kozak consensus clone was
further digested and yielded the expected banding patterns when digested with BamHI,
Beglll, BpmI, BstAPI and HindIII (Fig. 6). The SLCO/B3 clone alignment with wild-
type sequence showedthat the clone contained two non-synonymous mutations, T334G
(rs4149117) and G699A (rs7311358), which have been documented (Letschert et al,
2004) and 2 synonymous mutations G33A and A1557G.
Four SLCO/B3 site-directed mutagenesis clones were sent for sequencing by GATC and
alignment of clone sequences with wild-type showed that one clone was successfully
reverted to the wild-type sequence. The pBluescriptII-KSM-SLCO/B3 plasmids were
digested with EcoRI and the clone produced the correct banding pattern (Table 3).
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Further digests were performed with BglII, BpmlI, BsrDI and Neol (Table 3) for
verification (Fig. 7).
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Fig.6 Verification of TOPO-SLCO/1B3 by BamHI, BglII, BpmI, BstAPI and HindIII
restriction digest, a diagrammatic representation of TOPO-SLCO/B3 with a)
BamHIrestriction sites, b) BglII restriction sites, c) Bpml restriction sites, d)
BstAPI restriction site, e) HindIII restriction sites and f) agarose gel (1%)
visualisation of TOPO-SZLCO/B3 clones digested with BamHI (1), BglII (2),
Bpml (3), BstAPI (4) and HindIII (5) with NEB Ikb ladder.
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Fig.7 Diagrammatic representation of pBluescriptII-KSM-SLCO/B3 restriction
digest by a) EcoRI b) BglII, c) Ncol, d) BpmI and e) BsrD1 andf) verification
of pBluescriptII-KSM-SZCO/B3 clone by EcoRI (1), BglII (2), Neol (3),
BpmlI(4) and BsrDI (5) digestion visualised on agarose gel (1%) with NEB
lkb ladder.
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3.3.4 Construction of a SLCO3AI X. laevis oocyte expression vector
Preliminary SLCO3AI PCRs revealed 66°C as the optimal annealing temperature.
SLCO3AI1 was successfully amplified from the pSPORT-oatp/-OATP4 plasmid using
the SLCO3A1 Kozak forward primer and the oatp/-UTRreverse primer when DMSO
was used. Subsequent cloning into TOPO was also successful when verified by
restriction digest using BglII, Nhel, BstAPI, Ncol, Stul and XcmI (Table 3, Fig. 8),
followed by sequencing of the clone. Alignment of this clone with wild-type SLCO3A/
revealed that 6 non synonymous (C253T, A604T, T605A, G1690A, A1826G, G2111A)
and 2 synonymous mutations (C361T, C1716T) werepresent.
After one multi site-directed mutagenesis reaction, eight clones were sent for
sequencing, of which seven clones had positions C253T, Al1826G and G2111A
successfully reverted to wild type. One clone had only positions C253T and G2111A
reverted back to wild type. One clone was picked for a repeated multi site-directed
mutagenesis reaction but only with primers A604T_T605A and G1690A. Three clones
were sent for sequencing and once aligned two clones were revealed to have reverted to
wild typeat all 6 positions.
The pBluescript-KSM-SLCO3A/ plasmids were digested with NotI and four clones
contained the predicted band sizes (Table 3, Fig. 9). Two clones were selected for
sequencing to verify the orientation of the insert and both clones contained the insert in
the correct orientation. One of these was stored and used for subsequentapplications.
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Verification of TOPO-SZCO3A/ by restriction digest, a diagrammatic
representation of TOPO-SLCO3A/ with a) BglII restriction sites, b) Nhel
restriction sites, c) BstAPI restriction sites, d) Ncol restriction site, e) XcmI
restriction sites and f) agarose gel (1%) visualisation of TOPO-SLCO3A1
clone | digested with BglII (1), Nhel (2), BstAPI (3) NcoI (4) and Xcml (5)
with NEB 1kb ladder.
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Verification of pBluescriptII-KSM-SLCO34A/ a) a diagrammatic representation
of pBluescriptII-KSM-SLCO3A/ with NotI restriction sites, b) visualisation of
pBluescriptII-KSM-SLCO3A/ clones (1 to 4) digestion by NotI on agarose gel
(1%) with NEB 1|kb ladder.
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3.4 Discussion
The transport of many antiretrovirals by efflux transporters has been well defined but
antiretrovirals have yet to be characterised as substrates for influx transporters. SLCO
transporters have been shownto affect plasma concentration and drug clearance of some
xenobiotics and hence it is important to characterise the transport of antiretrovirals by
influx transporters. It has been reported that statins are substrates for SLCO1A2,
SLCO1B1 and SLCO1B3 (Hiranoef al. 2004; Fujino et al. 2005) and PIs have also been
shownto interact with statins and alter their pharmacokinetics (Busti et al. 2008; Kiser
et al. 2008) but these interactions have yet to be linked directly to SLCO transport.
SLCOI1A2, SLCOIB1, SLCO1B3 and SLCO3A1 are organic anion transporters, with
varying tissue distribution. The differences in expressions of these transporters may have
the potential to explain variability in the pharmacokinetics and pharmacodynamics of
antiretrovirals.
Humangenesare available from cDNAlibraries, which can be purchased commercially
and the advantage of using these libraries is the efficiency of amplification from them.
Many SLCOs have been cloned byother research groups using commercially available
cDNA libraries (Tamai ef al. 2000; Kullak-Ublick et al. 2001; Huber et al. 2007).
Alternatively, genes can be cloned from cell lines or primary tissues (Tirona et al. 2001)
which express the genesofinterest and this approach was adoptedfor this chapter.
Cloning of full length SCCOJA2 gene from A549 was unsuccessful because we were
unable to amplify the correct fragment. Therefore, additional primers were designed to
amplify the gene in two fragments. The primers overlap at an Nsil restriction site to
allow digestion of the fragments by Nsil and ligation to form the whole SLCO1A2 gene.
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This method of ligating gene fragments to produce full length cDNA wasalso utilised
by Konyaet al. (2006), who cloned ABCBIbyligating 5 gene fragments. The Kozak
consensus (CCACC) and BgllI restriction sites were added to the gene, because the
Kozak consensus is highly conserved in mammalian genes and greatly improves the
initiation of translation of mRNA (Kozak 1987). The Kozak consensusis described as
GCCRCCATGG, where ATG is the start codon and with 97% conservation in
vertebrates (Kozak 1987). Engineering BglII restriction sites to flank the gene allowed
easier recovery from the vector. pCRIH-TOPO-SZCOJA2 wasverified by sequencing
and no mutations were found. Subcloning ofSLCO/A2 into pBluescriptII-KSM wasalso
successful as shownbya selection of restriction digests.
The pCRII-TOPO vector was used for the initial cloning step due to ease of use. The
vector is supplied as a linear plasmid and contains DNA topoisomerase I, which is
covalently bonded to 3’ T bases of the plasmid to facilitate fast ligation of Tag amplified
PCR products, as they contain extra A overhangs (Invitrogen 2004). The plasmid has the
lacZ operon, which allows blue-white screening of clones. Ampicillin and kanamycin
resistance genesare also in the plasmid to allow antibiotic selection of bacterial cultures
(Invitrogen 2004). The pCRII plasmid contains dual promoters, T7 and Sp6, which
allowsin vitro transcription without directional cloning (Invitrogen 2004).
The pBluescriptII-KSM vector has 5’ and 3’ X Jaevis B-globin UTR flanking the
multiple cloning site to increase the translational efficiency of the gene of interest and
has also been used by other research groups using the X /aevis expression model (Beck
et al. 2002; Virkki et al. 2002). It also has an ampicillin resistance gene for selection in
bacteria cultures and contains the T3 promoter for in vitro transcription. Other X laevis
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expression vectors have been used by other groups such as the pBSTA plasmid (Very et
al. 1995) and the pXBG plasmid (Preston et al. 1992; Francis et al. 2000) which also
contains the 3’ and 5’ X /aevis B-globin UTR flanking the multiple cloningsite.
SLCOIBI and SLCOJB3 were cloned from Huh7 (human hepatic cell line) mRNA
because amplification from A549 (human lungcell line) was unsuccessful. This may be
due to the expression levels of SLCO/B/ and SLCO1B3 as these genes have been found
to be highly expressed in hepatocytes (Jung et al. 2001; Bleasby et al. 2006). Nested
PCR of SLCOJBI and SLCO/B3 from Huh7 cDNA using UTR primers during the
initial round of PCR, followed by a second round of PCR using forward gene primers
(comprising of the first 21bps) and UTR reverse primers were unsuccessful. However,
amplification of SLCOIBI and SLCO/B3 using UTR primers were successful and these
PCRproducts were cloned into pCRII-TOPO.
SLCOIBI1 and SLCOIB3 genes were successfully amplified using the forward gene
primers with UTR reverse primers and the plasmids as templates. All PCR products
were gel purified and amplified using UTR forward and UTR reverse primers. The
agarose gels used for gel purification were stained with crystal violet instead of ethidium
bromide, as crystal violet can be visualised without the use of UV and thus reduces the
damage to the DNA (Turgut-Balik et al. 2005). Maintaining the integrity of the DNA
improves the cloning efficiency and is particularly important with larger PCR products
(Turgut-Balik et al. 2005). The resulting product was cloned into pCRII-TOPO and
verified by sequencing. The second step of amplification, which removes the UTR from
the genes, worked well when using the plasmids as templates as opposed to gel purified
PCR products. This may be dueto higher purity of the template when using mini-prep
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extracted plasmids, whilst PCR products from tissues and cell lines may contain non-
specific DNA sequencesand the geneofinterest. Furthermore, gel purification often has
lower yields and poorer quality of DNA due to electrophoresis and with ethidium
bromidestaining in particular, there is increased UV damage.
The site-directed mutagenesis reaction to convert 5 non-synonymous mutations present
in SLCO/B/ and 2 non-synonymous mutations in SLCO/B3 into the wild-type sequence
was successful as verified by sequencing. SLCOJB/ and SLCO/B3 clones with the
wildtype sequences were subcloned into pBluescriptII-KSM vector.
Cloning of SLCO3AJ from A549 and Huh7 was unsuccessful. Therefore, the pSPORT1-
oatpl-OATP4 plasmid was used as a template for PCR. Using the standard reaction
mixture on a gradient PCR did not yield the correct band, but the inclusion of DMSO
into the reaction gave the expected band. The use of DMSO as a PCR additive is
common as DMSO has been shown to inhibit secondary structures and self
complementarity of DNA and thus improve the efficiency of amplification (Winship
1989; Hube ef al. 2005). The difficulty in amplification of SZLCO3A1, which was
resolved by the use of DMSO,is likely to be due to the GC-rich regions within the
SLCO3AI1 gene. The SZCO3A1 PCR product was subsequently cloned into pCRII-
TOPOand verified by sequencing. Site directed mutagenesis reactions were performed
to convert SLCO3A/ into wildtype, which wasverified by sequencing. The clone which
contained the SLCO3AI1 wildtype gene was used to subclone SLCO3A/ into
pBluescriptII-KSM.
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Cloning is an important process for building transporter cDNA libraries, from which the
function of individual transporters can be assessed. There are a numberof systems used
for assessing functionality of proteins such as stable and transient transfections ofcell
lines and the X. laevis oocyte model, it is the latter model which is used in subsequent
studies.
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Chapter 4
Assessing the impact of SLCOtransporters on
the cellular accumulation of antiretrovirals in X.
laevis oocytes
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4.1 Introduction
X. laevis oocytes were first used to analyse ion channels and have since been used
extensively as a model for functional expression of integral membraneproteins (Sigel,
1990). This model is favoured for evaluating transporters, as oocytes can be micro-
injected with extracted mRNA from other cells or synthesised cRNA, and adequate
expression of many transporters, including the SLCOs is achieved after 3 days
(Mahagita et al. 2007; Anderson et al. 2008; Markovich 2008). The main advantages of
this system over other functional models are low levels of endogenous transporters,
expression of most mammalian proteins with a high efficiency (Sigel 1990; Xia ef al.
2007) and the ease of handling as the oocytes are large cells, approximately 1000nl
(Wilhelm ef al. 2000). This model has been used for characterising interactions between
transporters, their substrates and inhibitors, leading to subsequent studies on the effect of
relevant polymorphisms (Badagnaniet a/. 2006; Smith et al. 2007).
Influx transporters are easier to assess using the X. laevis oocytes than efflux
transporters, the latter requiring pre-loading of the compoundofinterest into the oocyte
prior to drug transport experiments. There are two main waysto assess the presence of
translated protein in injected oocytes, either by analysis of oocyte membrane expression
or functional assessment by knownradioactive substrates.
Increasing numbersof influx transporters are being identified but antiretrovirals are yet
to be characterised for influx transport. Saquinavir (SQV) has been reported to be a
substrate of SLCO/A2 using X. laevis oocytes and the transfected HepG2 model (Su et
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al. 2004). It is important to evaluate antiretrovirals as substrates for influx, as these
transporters also have the potential to alter pharmacokinetics of compounds.
The aim of this chapter was to develop a X. /aevis model for evaluating antiretrovirals as
substrates of SLCO transporters. Vectors described in Chapter 3 were used for this
analysis. The panel of compounds investigated included SQV, which has been well
characterised for several transporters; other commonly used antiretrovirals such as
lopinavir (LPV), efavirenz (EFV) and nevirapine (NVP); and more recently licensed or
experimental compounds such as darunavir (DRV) and rilpivirine. Since estrone-3-
sulphate (E3S) has been reported to be an endogenoussubstrate for various SLCOs,
including SLCO1A2, SLCOIB1 and SLCO1B3 (Tamaie¢ al. 2000), and prostaglandin
E2 (PGE2) has been shownto be a substrate for SLCO3A1 (Adachief al. 2003; Huberet
al. 2007), these compoundswere included as paradigm control substrates.
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4.2 Methods
4.2.1 Materials
T3 and Sp6 mMessage mMachine Transcription kits were purchased from Ambion
(Europe) Ltd. (Huntingdon, UK). Ultima Gold scintillation fluid was purchased from
Perkin Elmer (Boston, USA). NaCl, HEPES, PS, CaCNO3-6H20, CaCl2:6H20 and KCl
(Fluka) was purchased from Sigma-Aldrich Company Ltd (Poole, UK). MgSO4°7H20
was purchased from (BDH) VWR (Leicestershire, UK). Restriction enzymes were
purchased from New England Biolabs (Hitchen, UK). Adult female X. /aevis frogs were
purchased from XenopusExpress (Lyon,France).
[7H] E3S (specific activity, SOCi/mmol) was purchased from American Radiolabeled
Company Inc. (Missouri, USA), (H] PGE2 (specific activity, 184Ci/mmol) was
purchased from GE Healthcare (Buckinghamshire, UK), CH] SQV (specific activity,
1Ci/mmol), [H] LPV (specific activity, 1Ci/mmol), and [7H] NVP (specific activity,
1.6Ci/mmol) was purchased from Moravek Chemicals (California, USA). [Cc'*] DRV
(specific activity, 0.21mCi/mmol) and (H] rilpivirine (specific activity, 20mCi/mmol)
was provided by Tibotec (Mechelen, Belgium) and ['“C] EFV (specific activity,
12.7Ci/umol) was provided by Bristol-Myers-Squibb. pBluescriptII-KSM was a kind
gift from WJ Joiner (Yale University, Connecticut, USA).
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4.2.2 Experimentalstrategy for expressing SLCOs
Ovary lobes were extracted from adult female Xenopus /aevis frogs. Initial experiments
(SLCO1A2-TOPO, SLCOIA2-KSM, SLCOIBI-KSM injected oocytes with respective
water injected controls) were conducted using oocytes extracted by collagenease
treatment and oocytes were incubated for 3 days post injection. The platinum loop
extraction method wastrialled using SLCOIBI-KSM cRNA. SLCO/B3-KSM and
SLCO3A1-KSMinjected oocytes were extracted using the platinum loop method and the
effect of the number of days post injection was investigated. The overall strategy is
illustrated in Fig. 1
 
Ovary lobe| Seo Selection ofextraction Platinum loop healthy oocytes
extraction wae,
@  rsCollagenaseextraction  cRNA micro-injection “Water SLCO1A2
Analyse results
pCRII-TOPO in vitro
& transcription
Ww ow
pBluescriptll- f
KSM
Fig. 1 The experimental strategy for expression of SLCOsin X.laevis oocytes.
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4.2.3 In vitro transcription
The Sp6 mMessage mMachine in vitro transcription kit was used to generate SLCO1A2
CRNA. TOPO-SLCOJA2 waslinearised with PflF1 (1x final concentration of NEBuffer
4, 1x BSA,0.2U/ul, lug DNA, 37°C, 1 hr) and purified using GenElute PCR Clean-Up
kit. The linearised DNA was concentrated by LiCl DNAprecipitation, 8M LiCl was
added to the DNA (final concentration LiCl 800mM, 30mins), precipitated with
isopropanol (equal volume, centrifuge 13000 x g, 4°C, 15mins) and washed with
absolute ethanol (1ml, centrifuge 13000 x g, 4°C, 15mins). The DNA pellet was
solubilised in nuclease free water to a concentration of lyg/ul. 10X Reaction Buffer
(101, 1x final concentration, room temperature), 2x NTP/CAP (2ul, 1x final
concentration), template DNA (lug), RNA Polymerase Enzyme Mix (1l) and nuclease-
free water (up to 20ul) were assembled at room temperature and incubated (37°C, 2
hours). The DNase treatment was performed following the incubation (1u] TURBO
DNase, 37°C, 15mins). The cRNA waspurified by LiCl precipitation. The reaction mix
was incubated with nuclease-free water (30u1) and LiCl precipitation solution (30ul, -
20°C, 30mins). The mixture was centrifuged (13000 x g, 4°C, 15mins) to pellet the
cRNA. The supernatant was removed and the pellet was washed with ethanol (70%,
Iml) and again centrifuged (13000 x g, 4°C, 15mins). The ethanol was removedandthe
pellet was resuspended in nuclease-free water, quantified with spectrophotometry and
diluted to lug/ul and stored in aliquots (Syl, -80°C).
The T3 mMessage mMachineinvitro transcription kit was used to generate SLCOswith
5’ and 3’ flanking UTR cRNA from pBluescriptII-KSM. The pBluescriptII-KSM-
SLCOIA2,  pBluescriptII-KSM-SLCO/B/, pBluescriptII-KSM-SLCO/B3 and
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pBluescriptII-KSM-SLCO3A1_ plasmids were linearised with SacI (1x final
concentration of NEBuffer 1, 1x BSA, lug DNA, 37°C, 10mins) and purified using the
GenElute PCR Clean-Up kit. The following procedures were the sameas using the Sp6
kit except the enzyme mix and reagents used were for T3 transcription.
4.2.4 X. laevis maintenance
Adult female X. /aevis frogs were kept in fresh water and cleaned once a week. Frogs
were handled with a net and fed dried frog pellets twice a week. Frogs were sacrificed
by an anaesthetic solution (MS222, 5g/l, 45mins).
4.2.5.1 X. laevis oocyte isolation by collagenase treatment
Oocytes wereisolated by dissection of the abdomenofthe frog and excising ovary lobes
with forceps into Barth’s solution without calcium (NaCl 88mM, KCI ImM, HEPES
15mM,pH 7.6) containing collagenase (1mg/ml, shaking, 2h). The oocytes were washed
twice with Barth’s solution without calcium, followed by a wash with Barth’s solution
containing calcium (NaCl 88mM, KCI ImM, HEPES 15mM, CaCNO3:6H2O 0.3mM,
CaCl,6H20 414M, MgSOx:7H20, 0.82mM,pH 7.6). The cells were incubated (18°C
Ih) and healthy stage V-VI oocytes were selected and maintained in Barth’s solution
with calcium and PS (10pg/ml, 18°C, overnight).
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4.2.5.2 X. laevis oocyte isolation by platinum loop extraction
Oocytes were isolated by dissection of the abdomenofthe frog and excising ovary lobes
with forceps into Barth’s solution with calcium and PS and individual oocytes were
picked usinga platinum loop. Healthy stage V-VIcells were selected, placed into fresh
Barth’s with calcium and PS (10pg/ml) and incubated overnight (18°C).
4.2.6 X. laevis microinjection
Needles were made from thin wall glass capillaries (Imm diameter, 102mm length)
using the PUL-1 machine (World Precision Instruments). One needle was loaded onto
the micro-manipulator and trimmed using forceps. SLCOIA2-TOPO (ug/pl, 7.5ul,
TOPO origin) or DEPC treated water (7.511) was loaded into the needle by the vacuum
pump DA7C (Charles Austen Pumps) andheld in the needle using the picopump PV830
(World Precision Instruments) supplied with compressed air. The drop size of the
sample wascalibrated to onethird the size of an oocyte (~5Onl). Twenty oocytes were
injected per condition and uptake wasperformed 3 days following injection. SLCO/A2-
KSM and SLCO/BI-KSM cRNAwerealso injected (as described above) into oocytes
isolated by the collagenase treatment.
SLCOIA2-KSM, SLCOIBI-KSM, SLCO1B3-KSM and SLCO3A1-KSM were injected
as described, into cells which were isolated with the platinum loop extraction method.
These cells were incubated 3-5 days following injection and were treated with
collagenase (mg/ml, shaking, 20mins) 2-3hrs prior to the uptake experiments.
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4.2.7 Uptake experiments using X. /aevis oocytes
Radiolabelled drugs were diluted in Hanks balanced salt solution and oocytes were
incubated (room temperature, Ihr, in eppendorfs) with either of the following: [*H] E3S
(1uM, 0.33nCi/ml), [PH] SQV (1uM, 0.33pCi/ml), PH] LPV (1uM, 0.33nCi/m)), ['4C]
DRV (3uM,0.60uCi/ml), ['*C] EFV (1M, 0.33Ci/ml), [7H] NVP (1uM, 0.33nCi/ml),
or [°H] rilpivirine (3uM, 1.18uCi/ml) in the presence or absence of HSA (HSA, 2%).
After incubation, oocytes were transferred into cell strainers and washed with ice cold
Hanks balanced solution (3 wells in a 6 well plate) and individual oocytes were
transferred into scintillation vials. Scintillation fluid was added to the vials and
radioactivity was counted by liquid scintillation spectroscopy (Packard 1900CA Tri-
Carb Liquid Scintillation Analyser).
SLCOIA2/1B1/1B3/3Al with X. laevis B-globin UTR flanking region cRNA (50nl,
I1g/p1) or DEPC water wasinjected into oocytes. Uptake was performed using the same
compoundsandrelative concentrations as above and in the presence and absence of
human serum albumin (HSA, 2%) in a 24 well plate (<10 oocytes per condition, room
temperature, Ihr, | well in a 24 well plate, shaking 150rpm). After incubation, oocytes
were washed as above, lysed with 10% SDS and scintillation fluid was added.
Radioactivity was then countedbyliquid scintillation spectroscopy.
The time at which optimal expression was present for SLCO/B3 and SLCO3A1 wasalso
explored using SLCO/B3-KSM, SLCO3A1-KSM andwater injected oocytes incubated
in PH] E3S (luM, 0.33nCi) and for SLCO3A1, [7H] PGE2 (0.33 pCi) was also
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included. Uptake was performed at 24hrintervals between 3-6 days post-injection of the
oocytes. The incubations werecarried out as described above.
To test PIs and NNRTIsas potential substrates of SLCO/B3, SLCO1B3-KSM injected
and water injected oocytes uptake of radioactive compounds wereobservedafter 5 days
post-injection and the incubations were performed as described for SLCO1A2-KSM.
4.2.8 Statistical analysis
Data from oocyte uptake experiments were processed in Microsoft Excel 2007 and
statistical analyses were performed using GraphPad Prism 3.0 andStatsDirect 2.4.5. All
data wastested for normality using the Shapiro-Wilk test. For SLCO1A2-TOPO data,
Mann-Whitney U-test was applied to test for significance. For SLCOIA2-KSM,
SLCOIBI-KSM and SLCO/B3-KSM,the data was log;o-transformed and the paired t-
test was used totest for significance.
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4.3 Results
4.3.1 SLCO1A2 uptake experimentsin the X. /aevis model
In the absence of HSA, E3S was the only compound with significantly higher
accumulation in SECOJA2-TOPOinjected oocytes (mean pmol/oocyte + s.d, where n is
1 oocyte, 0.86 + 0.27, n=10) compared to water injected oocytes (0.19 + 0.04, n=13,
p<0.001, 4.95-fold). In the presence of HSA, E3S accumulation wasstill higher in
SLCOIA2-TOPO (0.14 + 0.04, n=12) injected compared to water injected controls (0.08
+ 0.02, n=8, p<0.01, 1.75-fold, Fig. 2). The addition of HSA lowered the amount of
radiolabelled compoundsin both water and SLCO/A2-TOPOinjected oocytes but none
of the antiretrovirals tested were significantly different between water and SLCOIA2-
TOPOinjected oocytes (Fig. 3-8).
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Fig. 2 Water injected and SLCOIA2-TOPOinjected X. laevis oocytes uptake of [°H]
E3S in a) the absence and b) the presence of HSA. *** p < 0.001, ** p<0.01
compared to waterinjected control, n>8.
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SLCOIA2-KSM (X. laevis B-globin UTR flanking region) injected oocytes have
significantly increased accumulation of E3S by 3.2-fold (median pmol/oocyte + s.d,
where is | frog, 0.51 + 0.17, n=4) compared to water (0.16 + 0.04, n=4, p<0.05, 3.21-
fold). In the presence of albumin, there was a trend towards increase in accumulation of
E3S in SLCOIA2-KSM injected oocytes (0.15 + 0.03 n=4) compared to the water
control (0.07 + 0.01, n=4, p=0.057, 1.9-fold). A significant increase in accumulation was
also observed for SQV (1.78 + 0.44, n=4 compared to water 0.94 + 0.26, n=4, p<0.05,
1.9-fold), LPV (4.31 + 0.72, n=4 compared to water 2.14 + 0.43, n=4 p<0.05, 2.01-fold)
and DRV (4.13 + 0.40, n=4 compared to water 2.12 + 0.55, n=4, p<0.05, 1.95-fold). In
the presence of HSA, increased cellular accumulation of SQV (0.64 + 0.23, n=4,
compared to water 0.21 + 0.06, n=4, p<0.01, 3.07-fold), LPV (1.14 + 0.41, n=4,
compared to water 0.66 + 0.22, n=4, p<0.05, 1.73-fold) and DRV (2.14 + 0.82, n=4,
compared to water 0.72 + 0.18, n=24, p<0.05, 2.96-fold) were still observed. There were
no significant differences in EFV, NVPorrilpivirine accumulation between water and
SLCOIA2-KSMinjected oocytes in the presence or absence of albumin (Fig. 9 and 10).
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4.3.2 SLCO1B1 uptake experiments in the X. /aevis model
In the absence of HSA, E3S (2.02 + 0.52, compared to water 0.19 + 0.05, n=4, p<0.01,
10.90-fold), SQV (2.16 + 0.71, compared to water 1.01 + 0.21, n=4, p<0.05, 2.14-fold),
LPV (4.07 + 0.67, compared to water 2.5 + 0.36, n=4, p=0.054, 1.61-fold), DRV (4.32 +
0.75, compared to water 2.18 + 0.40, n=4, p<0.05, 1.98-fold) and rilpivirine (24.03 +
9.11, compared to water 10.67 + 3.3, n=4, p=0.05, 2.25-fold) had significantly increased
accumulation in oocytes injected with SLCOIBI-KSM comparedto watercontrols (Fig.
9). In the presence of HSA, E3S (0.35 + 0.15, compared to water 0.1 + 0.03, n=4,
p<0.05, 3.55-fold), SQV (0.45 + 0.05, compared to water 0.27 + 0.03, n=4, p<0.01,
1.65-fold), LPV (1.65 + 0.60 compared to water 0.82 + 0.24, n=4, p<0.05, 2.02-fold) and
DRV (2.85 + 1.26 compared to water 0.96 + 0.37, n=4, p=0.055, 2.98-fold) had
significantly higher accumulation in SLCOIBI-KSM injected oocytes compared to
water controls. No difference in accumulation was observed in SLCO/BI-KSM injected
oocytes and water injected oocytes incubated with rilpivirine. No significant increases in
cellular accumulation were observed between SLCOIJBI-KSM and water injected
oocytes incubated with NVP or EFV in the presence or absence of HSA (Fig. 11 and
12).
129
b)
[S
QV
]
pm
ol
/o
oc
yt
e
=
nd
»
>
<
z
[
7
So o L
Qa oa o j
> So 1
[D
RV
]
pm
ol
/o
oc
yt
e
nN o  0.0-
[E
FV
]
pm
ol
/o
oc
yt
e
a
3
o
o
The impact of SLCOson antiretroviral accumulation in X. /aevis oocytes
Water
[ES
S]
pm
ol
/o
oc
yt
e
 
 
ee
a
a
a®
etye
e
Water SLCO1B1
*Vv—_—_
a
a
a
®
e®?
Water SLCO1B1
 
SLCO1B1
water injected control. 
Water SLCO1B1 *C) 60. reo
a
4.0- ae
a®
[L
PV
]p
mo
l/
oo
cy
te
5 °;
> > L
  4.0-e a2 e8 3.0- ® —_s1,—s °£204 .aa> 10-4= 0.0- Water SLCO1B1
8) e Ps ° o
w © °
nN S o
= = °
 
[Ri
lpi
vir
ine
]p
mo
l/
oo
cy
t
© o SLCO1B1
Fig. 11 Water injected and SLCOIBI-KSMinjected X. /aevis oocytes uptakeofa) PH]
E3S, b) PH] SQV,c) [PH] LPV, d) ['*C] DRY,e) PH] NVP,f) ['*C] EFV and g)
(°H] rilpivirine in the absence of HSA (n=4). ** p<0.01, * ps<0.05 compared to
Water
130
The impact of SLCOsonantiretroviral accumulation in X. /aevis oocytes
  
    
a) 06
a
s8 0.4
°£
Qa0.2
©uw
0.0
Water SLCO1B1
* *
b) 0.6 | c) 3.0- EE"
® | @ a5 Li 38 0.4 a® 8 2.04
3° o a£ = s
2S 2 a5 = 1.04 é
2, — °
0.0+——$$, ___——
Water SLCO1B1 Water SLCO1B1
d) e) 40-
@ @ .Pp * 3 3.0-
8 2 2£ £ 2.0- * ir
Qa Qa ae
> aXx > 1.0-Q =
0.0-
Water SLCO1B1 Water SLCO1B1
f) 265 8) o50
© 2$2.0 8 4.03 3215 £ 3.02 S21.0 £ 2.0; 5Ww 0.5 ‘21.0
©,0.0 0.0Water SLCO1B1 Water SLCO1B1
Fig. 12 Water injected and SLCOIBI-KSMinjected X. /aevis oocytes uptake of a) PH]
E3S,b) PH] SQV, c) (>H] LPV, d) ['*C] DRY,e) PH] NVP,f) ['*C] EFV and g)
[°H] rilpivirine in the presence of HSA (n=4). ** p<0.001, * p<0.05 compared to
water injected control.
131
The impact of SLCOsonantiretroviral accumulation in X. /aevis oocytes
When collagenase extracted oocytes were compared to loop extracted oocytes, both
methods showed comparable fold increases in accumulation of E3S compared to their
respective water injected controls (collagenase fold increase of 20.22, platinum loop fold
increase of 13.26, Fig. 13). PGE2 also showed increased accumulation in SLCO/B1-
KSMinjected oocytes compared to water injected control using both extraction methods
(collagenase fold increase of 1.54, platinum loop fold increase of 3.07).
 
 
Collagenase Platinum loop
4000 4000
: ° :3000 3000
2 wer 22 2000 ° 2 2000
eo o8 83 1000 . 3 1000fig fi
T “T 0Water SLCO1B1 Water SLCO1B1 Water SLCO1B1 Water SLCO1B1
E3S PGE2 E3S PGE2
Fig. 13 Water injected and SLCO/BI-KSMinjected X. laevis oocytes uptake of PH]
E3S and [*H] PGE2, comparing oocytes extracted by platinum loop and by
collagenase treatment (n=1).
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4.3.3 SLCO1B3 uptake experiments in the X. /aevis model
Following three day incubation, in the presence or absence of HSA,neither the positive
controls E3S nor the antiretrovirals (Fig. 14) showed increased accumulation in
SLCOIB3-KSM injected oocytes versus controls. During the 6 days incubation with
functional experimentscarried out at 24hr intervals, E3S showed increased accumulation
in SLCO1B3-KSMinjected oocytes versus controls at day 4 (fold increase 1.64), day 5
(fold increase 2.04) and day 6 (fold increase 1.57x, Fig 15). Using oocytes which were
incubated 5 days post-injection, E3S showed a trend towards increase in SLCO1B3-
KSMinjected oocytes (mean pmol/oocyte + s.d., 0.50 + 0.20, p=0.059) compared to
water injected control (0.21 + 0.01, 2.38-fold, n=4). The accumulation of SQV was
significantly increased in SLCO]B3-KSMinjected cells (2.17 + 0.61) compared to water
injected cells (1.62 + 0.45, 1.34-fold, p<0.05, n=4) and rilpivirine also exhibited
significantly increased accumulation in SLCO1B3-KSMinjected cells (37.00 + 12.43)
compared to water control (16.18 + 3.54, 2.29-fold, p<0.05, n=4). DRV showed a trend
towards increase (SLCO1B3-KSMinjected 5.41 compare to water injected control 3.29,
1.64-fold, n=1, Fig. 16) and none of the other antiretrovirals showed statistically
significant increases in cellular accumulation.
133
The impact of SLCOsonantiretroviral accumulation in X. /aevis oocytes
  
 
a) 93- b) o.46-
© a2 oeFy ", 3S02, 4 a 8 0.104= — °8 eE a
7-19 9 0.05 -
w.
0.0+-——_,—______,____ 0.00 $$$—__$___Water SLCO1B3 Water SLCO1B3
Cc) 25- d)  40-
© |
@®> 2.0 ® > ay =
° °S154 2e° = ° eo£ £ 2.0-
Qa a- 1.0- Qa *5 y® »8 os- a a; 10 "
0.0-——_—$$$__,___ 0.0———]_——————c——“—q«Water SLCO1B3 Water SLCO1B3
e) 4.0- f) 25.0
a a
20.03 3.04 3
2 = 2 150° >£ 2.0- ™ E2 * © 10.0
5 5x 1.04 ti 80
er 0.0Water SLCO1B3 Water SLCO1B3
8) 40 h) » 40.07 22 * 9o 3.0 2 30.09° °°2 é E
Oo ag£204 © — 20.0
2. c
a =
>= 1.0 é 10.0
©0.0 0.0
Water SLCO1B3 Water SLCO1B3
Fig. 14 Water injected and pBluescriptlI-KSM-SLCO/B3 injected X. laevis oocytes 3
day post-injection uptake of a) [7H] E3S (n=3), b) ?H] PGE2 (n=2), c) PH] SOV
(n=3), d) [PH] LPV (n=3), e) ['4C] DRV (n=3), f) PH] NVP (n=3), g) ['4C] EFV
(n=3) and h) [°H]rilpivirine (n=3) in the absence of HSA.* p<0.05 compared to
water injected control.
134
The impact of SLCOsonantiretroviral accumulation in X. laevis oocytes
 
E3S
0.50
0.45
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
=@=—=water
—f— 1B3pm
ol
/o
oc
yt
e
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injected oocytes between 3-6 days post injection (n=1).
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4.3.4 SLCO3A1 uptake experimentsin the X. /aevis model
Following three day incubation and in the presence or absence of HSA,neither E3S nor
PGE2 (Fig. 17) showed increased accumulation in SLCO3A/ injected oocytes versus
controls. No increases in cellular accumulation were observed for any of the
antiretrovirals. During the 6 days incubation with functional experiments carried out at
24hr intervals, neither E3S nor PGE2 showed increased accumulation in SLCO3A]
injected oocytes versus controls for SLCO3A/ at any ofthe time points taken (Fig. 18
and 19).
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Fig. 17 Water injected and pBluescriptII-KSM-SLCO3A]/ injected X. laevis oocytes 3
day post-injection uptake ofa) [7H] E3S (n=3), b) 7H] PGE2 (n=2), c) 7H] SQV
(n=3), d) [7H] LPV (n=3), e) ['4C] DRV (n=3), f) 7H] NVP (n=3), g) ['4C] EFV
(n=3) and h) [°H]rilpivirine (n=3) in the absence of HSA.
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4.4 Discussion
The transport of many antiretrovirals by efflux transporters has been well defined, but
antiretrovirals have yet to be characterised by influx transporters. SLCO transporters
have been shownto affect plasma concentration and drug clearance of some xenobiotics
and henceit is importantto characterise the transport of antiretrovirals.
Uptake experiments using SLCOJA2-TOPO cRNA did not show any of the
antiretrovirals tested as substrates, but E3S accumulation was higher in SLCO1A2-
TOPOinjected compared to waterinjected oocytes. In experiments where the SLCO/A2
gene with X. /aevis 5’and 3’ flanking UTR were used, E3S and the Pls appear to be
substrates with higher accumulation in SLCO1A2-KSM injected compared to water
injected oocytes. The difference in accumulation between SLCOIA2-TOPO and
SLCOIA2-KSMexperiments may bedueto the level ofSLCO/A2 expressionin injected
oocytes. The low expression ofSLCO/A2-TOPOinjected oocytesstill showed increased
accumulation of E3S compared to water injected oocytes, which may be due to a strong
affinity for E3S and relatively loweraffinity for the PIs. The use of plasmids containing
3’ and 5’ X. laevis B-globin UTR to generate cRNA for X. laevis oocyte uptake
experiments is common(Preston etal. 1992; Francis et al. 2000; Virkki et al. 2002) due
to the increase in translational efficiency of the gene of interest by up to 300-fold
(Falcone and Andrews 1991). Subcloning SLCO/A2 into the pBluescriptlI-KSM vector
improved the transport by SLCO/A2in the oocytes, which suggests that future cloning
of transporters should involve subcloninginto this vector. The NNRTIs did not appear to
be substrates of SLCO/A2 with or without the 5’ and 3’ UTR orin the presence or
absence of HSA.
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HSA reduced the accumulation in both water and SLCO1A2-KSMinjected oocytes but
the PIs still accumulated more in SLCO/A2-KSMinjected compared to water injected
oocytes. A reduction in accumulation with the addition of HSA was observed dueto the
protein binding properties of the antiretrovirals, which vary between the drugs (for
binding to plasma proteins, SQV: 98% (Roche 2007), LPV: 98-99% (Abbott 2008),
DRV: ~95% (Tibotec 2006), EFV: >99% (Bristol-Myers-Squibb 2008), NVP ~60%
(Boehringer-Ingelheim 1999)). PIs have higher binding affinities to al-acid-
glycoprotein, but they also bind to HSA, which is the most abundant plasma protein
(Hazenet al. 2007).
SLCOIBI-KSM cRNA injected oocytes also had higher accumulation of the Pls
compared to water injected controls. In addition to the PIs, concentrationsofrilpivirine
were also significantly higher in SLCO]BI-KSM cRNAinjected oocytes than in water
injected oocytes. However, in the presence of HSA, no difference in accumulation of
rilpivirine was observed, whereas the Pls still accumulated higher in SLCOIBI-KSM
cRNAinjected oocytes. This suggests thatrilpivirine is highly protein bound to HSA
and is in agreement with the findings in Chapter 2; protein binding had more influence
on the intracellular accumulation ofrilpivirine than drug transport.
X. laevis oocytes were extracted using the collagenase treatment method for SLCO1A2
and SLCOIBI1 uptake experiments. The platinum loop extraction method, which
includes a collagenase treatment step prior to uptake experiments, was tested using
SLCOIBI to compare with the collagenase treatment method to observe whether the
extraction treatments altered accumulation of positive control substrates in SLCO/BI-
KSMinjected oocytes. For E38, there was higher accumulation in collagenase extracted
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oocytes, but the platinum loop extracted oocytes also had a large accumulation of E3S in
SLCOIBI-KSM injected oocytes when compared to their respective water injected
controls. For PGE2,there was higher accumulation in the oocytes extracted by platinum
loop than the collagenase extracted oocytes. Interestingly, platinum extracted oocytes
were more robust post-injection than collagenase treated oocytes, as many of the
collagenase treated oocytes looked unhealthy at 4 days post-injection. Both the
collagenase (Sacchiet al. 1995; Hagenbuchet al. 1996; Hammermannetai. 2001) and
the platinum loop extraction methods (Sigel 1987; Hammermannetal. 2001; Boileau ef
al. 2002) have been used to extract oocytes and a third method, which requires the use of
forceps, is used by someresearchers (Sigel 2001). The advantage of using collagenase
compared to the other methods is the ease of extraction and defolliculation of the
oocytes. The use of forceps or the platinum loop is relatively labour intensive and
requires a separate collagenase treatment prior to uptake experiments to remove the
follicular membrane. However, the oocytes appear to survive for longer post-
microinjection (personal observation).
SLCOIB3-KSM injected oocytes did not accumulate E3S, PGE2 or any of the
antiretrovirals at 3 days post injection. A post-injection time course was performed to
observe whether incubation time prior to uptake experiments increased the expression of
SZCO1B3 and hence accumulation of control substrates E3S or PGE2. At 4-6 days post-
injection, the accumulation of E3S was higherthan at day 3. The ability of SLCO/B3 to
transport the antiretrovirals was investigated by using oocytes at 5 days post-injection.
SQV andrilpivirine accumulation wasstatistically higher in SLCO/B3-KSM injected
oocytes than water injected controls whilst DRV and E3S showed a trend towards
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increase. Other studies have shown that 3 days post injection and lh incubation for
uptake wassufficient to detect differences in accumulation of E3S in SLCO1A2 (Maeda
et al. 2007), SLCO1B1 (Mahagita et al. 2007; Nakakariya ef al. 2008) and SLCO1B3
expressed oocytes (Mahagita ef al. 2007; Nakakariya et al. 2008). SLCO1B3 appears to
transport similar antiretrovirals to SLCOIB1, as the PIs andrilpivirine showed increases
in SLCOIBI-KSM as well as SLCO1B3-KSMinjected oocytes. The effect of HSA on
the accumulation of antiretrovirals by SLCO1B3 was inconclusive as the detection of
manyofthe radiolabelled compoundsincluding the positive control substrate, E3S, did
not accumulate more in SLCO/B3-KSM injected oocytes than water injected control
(data not shown).
The lower fold increases of E3S and the requirement of increased post-injection
incubation time of SLCO/B3-KSM than SLCO/BI-KSM injected oocytes suggests
either that the oocytes are not translating SLCOJ/B3 into protein as efficiently as
SLCOJB1, or that E3S is not as good a substrate for SLCO1B3 as for SLCO1B1. The
amount of SLCO protein in the oocytes could be compared by Western blotting, but this
would require specific antibodies for each SLCOtransporter. Unfortunately, at present,
there are no reliable commercially available antibodies for the SLCOsstudied in this
thesis.
SLCO3A1-KSM injected oocytes at 3 days post-injection did not have increased uptake
of the control substrates E3S and PGE2or anyofthe antiretrovirals. A time course for
days post-injection was performed to observe whether increased incubation time would
increase SLCO3A1 function, but no difference was observed between SLCO3A1-KSM
and water injected oocytes at any of the time intervals. E3S, which wasidentified as a
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substrate for several SLCOs, did not accumulate more in SLCO3A1-KSM injected
oocytes, which was similar to observations made by Adachi ef al. (2003). PGE2 was
identified as a substrate for SLCO3AI and was demonstrated to have increased
accumulation in SLCO3A1-KSM injected oocytes by 1.4-fold at 20nM (Huberer ai.
2007) and 3.4-fold at 15nM (Adachi ef al. 2003). Both studies conducted uptake
experiments at 3 days post-injection. The lack of accumulation of PGE2 in SLCO3A1-
KSM injected oocytes contradicts the observations made by Huber et al. (2007) and
Adachi ef al. (2003) where increases in accumulation were reported. However, the
difference in fold-increase between these two studies varies and the study by Huberetal.
(2007) showed that whilst increases in accumulation were detected, this was only a
modest increase. To examine whether SLCO3A1 protein is present on the oocytecell
membrane, Western blotting could be applied, but antibodies for SLCO3A1 areto date,
not commercially available.
As manyPIs are boosted with ritonavir to improve the pharmacokinetic profile of the
Pls, future studies should also evaluate the interactions between ritonavir and SLCOs,as
ritonavir may inhibit influx transport.
The disadvantagesof this type of assay include the variations in quality of oocytes and
that they are relatively low-throughput and labour intensive (Sigel 1990; Markovich
2008). However, despite large variations in oocyte uptake, there were statistically
significant differences between SLCO]A2-KSM, SLCOIBI-KSM and SLCO1B3-KSM
injected oocytes uptake of E3S compared to their respective water injected controls. The
issue of why albumin should have a marked effect on the uptake ofrilpivirine is not
clear, but it might relate to lowering the concentration of available drug for the transport
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protein. Despite these limitations, the X. /aevis model is a good model for evaluating
influx transporters as it has very few endogenoustransporters (Xia et al. 2007) and will
readily express mammalian transporters which contain the Kozak consensus and are
flanked by X. laevis 3’ and 5’ UTR.
In conclusion, SLCO1A2, SLCO1B1 and SLCO1B3 transport PIs and SLCO1B1 and
SLCO1B3transport rilpivirine in the absence of HSA. This suggests that intracellular
accumulation of these drugs may be influenced by these transporters. This validates
these genes for pharmacogenetic studies which mayprovide aninsight into the impact of
SLCOs on the pharmacokinetics of antiretrovirals. However, the importance of these
SLCO transporters at basal levels of expression and their albility to alter
pharmacokinetics ofantiretrovirals has yet to be elucidated.
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Chapter 5
Association between SLCO SNPsandlopinavir
plasma concentrations
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5.1. Introduction
Many synonymousand non-synonmyous SNPs for SLCO/B/ have been identified and
several have been foundto alter function, with 521T>C and 388A>G being the best
characterised. 521T>C and 388A>G are found at higher frequencies than other SNPs
andare to be in linkage disequilibrium. 388A>G reducesthetransport of rifampicin, but
not other SLCO/B1/ substrates andhas a high allele frequency in Caucasians (30%) and
Africans (74%) (Tirona ef al. 2001). 521T>C is located in the transmembrane region of
SLCO1B1 and was shownto significantly lower expression of SLCOIBI (Tironaetal.
2001). This SNP hasbeen reported to havea large influence on uptake of compoundsin
vitro (Tironaet al. 2001; Kameyamaet al. 2005) and also on the pharmacokinetics of
statins, including atorvastatin (Lau et al. 2007), pravastatin (Niemi ef al. 2006) and
simvastatin (Pasanen ef al. 2006). The frequency of this SNP is also high amongst
Caucasians at 14% compared to Africans at 9% (Tironaef al. 2001).
467A>G, 1058T>C and 1964A>G SNPs have also been associated with reduced
transport function of SLCOIB1 in vitro, but these SNPs are very rare (Tirona etal.
2001). The 1463G>C variant has been shownto reduce transport of estrone-3-sulphate
(E3S). This SNP has an allele frequency of 9% in African-Americans, but was not
detected in Caucasians (Tirona et al. 2001). In addition, the 578T>G variant is
associated with significant defects in protein maturation andin transport function,butit
was found in only | out of 81 liver samples (Michalskiet al. 2002).
To date, 3 SNPs for SLCO/B3 have been described, 1564G>T, 334T>G and 699G>A.
334T>G is in complete linkage disequilibrium with 699G>A (Tsujimoto et al. 2006)
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and has an effect on the transport of digoxin, a SLCO1B3 substrate, although this was
notstatistically significant (Tsujimoto et al. 2008). However, a study by Smith ef al.
(2007), which showedthat paclitaxel was a substrate for SLCO1B3 using the X laevis
model, showed no association between 334T>G or 699G>A and_ paclitaxel
pharmacokinetics in 475 individuals.
SLCOIA2 516A>C and 38T>C wereidentified along with 404A>T, 2003C>G, 559G>A
and 382A>T (Leeet al. 2005). Of these SNPs, 516A>C, 404A>T and 2003C>G have an
impact on the functional transport of SLCO1A2 substrates such as estrone-3-sulphate
(E3S) (Lee e¢ al. 2005). Using the X. laevis oocyte model, Badagnani et al. (2006)
confirmed that 516A>C decreased accumulation of E3S and methatrexate whilst 38T>C
increased the accumulation of these two compounds compared to wildtype SLCO1A2.
38T>C (11.1-16.3%) and 516A>C (1.9-5.3%) have been reported to be at higher
frequencies in Caucasian populations than the other SLCOIA2 SNPs, whilst 382A>T
(0.5-1.3%) and 559G>A (1.5%) were higher in African and Hispanic ethnicities with
2003C>G observed in both African (3.7-4.4%) and Hispanic populations (1.0%) (Lee et
al. 2005; Badagnaniet al. 2006). 404A>T wasnot observedin the sample population by
Lee et al (2005).
Therapeutic drug monitoring (TDM)is a strategy employed to measure drug plasma
concentrations and is used to assess efficacy, toxicity and patient compliance to drug
regimens (Duongefal. 2004). In Liverpool, there is a TDM program for antiretrovirals,
which has appropriate retrospective consent for genetic analysis and hence provides a
large sample population for pharmacogenetic studies. The disadvantages of using a
TDM sample population include unknownethnicity and different sampling times post-
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dose. Despite these limitations, using a TDM cohort enables the use of a large sample
population which would otherwise bedifficult to recruit.
In Chapter 4, the ability of the SLCOsto transport antiretrovirals was explored and the
PIs and rilpivirine were found to be substrates for SLCOIA2, SLCOIBI and
SLCO1B3. However, many PIs are co-administered with ritonavir and the effect of
ritonavir on lopinavir (LPV) uptake, using the X. /aevis model, wasfirst ascertained.
The effect of characterised SNPs, which are abundant in the Caucasian population, in
SLCO1A2, SLCOIBI1 and SLCOIB3 on the pharmacokinetics of LPV, the most
commonlyprescribed PI, was then investigated using the Liverpool TDM cohort.
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5.2 Methods
5.2.1 Materials
TaqMan Reverse Transcription Reagents and TaqMan Gene Expression Assays were
purchased from Applied Biosystems Inc. (Warrington, UK). Absolute QPCR Mix was
purchased from ThermoFisherScientific (Loughborough, UK). All other chemicals were
purchased from Sigma-Aldrich (Poole, UK).
5.2.2 Lopinavir uptake in the presenceof ritonavir in the X. /Jaevis oocyte model
X. laevis oocytes were extracted andinjected as described in Chapter 4 (sections 4.2.3,
4.2.4, 4.2.5.1 and 4.2.6). At 3 days post injection, SLCO1BI-KSM and waterinjected
oocytes were used in uptake experiments as described in Chapter 4 (section 4.2.7) with
CH] LPV (1 uM, 0.33uCi/ml) and a range ofritonavir concentrations (0-11M).
5.2.3. Selection of plasma samples from the Liverpool TDMregistry for SLCO
genotyping
Ethics committee approval to genotype archived plasma blood samples without written,
informed consent from individuals listed on the Liverpool TDMregistry had previously
been granted. Plasma samples were selected from 400 individuals that received
lopinavir/ritonavir 400mg/100mg b.d. regimes, were aged above 18 years and had
recorded lopinavir concentrations. 326/400 patients had plasma samples 10-14h post-
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dose (designated Cmin) and 293/400 patients had plasma samples 2-6h post-dose
(designated C2). Exclusion criteria included pregnancy, undetectable plasma LPV
concentrations (suggesting non-adherenceto the regimes) and concomitant medications
with: sodium valproate, carbamazepine,rifampicin (or any other TB treatment) and acid
reducing agents. Prior to plasma sample analysis, all patient data were completely
anonymised. Of the samples included in the analysis, 78% were male (4% unspecified),
median age was 40 (range 19 to 64), median weight was 72 Kg (range 44 to 113) and
median lopinavir concentration was 5072ng/ml(range 114 to 24432).
5.2.4 Plasma DNAextraction and SLCO genotyping
DNAwasextracted from plasma (600 pL) using a GenElute Blood Genomic DNAkit
(Sigma-Aldrich, Poole, UK), according to the manufacturer’s instructions. Genotyping
for the SLCO1A2 516A>C and 38T>C, SLCOIBI 521T>C SNP and SLCO/B3 334T>G
SNPs were performed using a real-time gPCR based allelic discrimination assay.
Polymerise chain reactions (PCR) were performed using a reaction volume of 251
containing assay-specific primers (final conc. 0.5uM each primer), allele specific
TaqMan MGBprobes (0.1uM each probe), ABgene qPCR mix and 2 ulofthe eluted
sample genomic DNAsolutions (100 ul). Thermal-cycling conditions consisted of 60
cycles of 95°C for 10 minutes, 92°C for 15 seconds and 60°C for 1 minute.
Fluorescence, proportional to amplification, was measured using the Opticon 2 and
Chromo4 real-time detector (Biorad, Hemel Hempstead, UK). All genotyping
experiments were performed in duplicate and included no template controls and positive
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controls for each of the possible genotypes. Genotype was only assigned when both
duplicates were in agreement.
5.2.5 Statistical analysis
SNPs were tested to assess whether they were in Hardy-Weinburg equilibrium by Chi
squaredtest of observed versus predicted genotype frequencies. The data set was tested
for normality by Shapiro-Wilk. Genetic associations with LPV plasma concentrations
were tested by Mann-Whitney and demographic associations were tested by Spearman’s
rank correlation coefficient on log transformed plasma concentrations. Multivariate
analyses were also conducted by linear regression with backward subtraction using
SPSS 16.
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5.3. Results
5.3.1 Inhibition of SLCO1B1 transport by ritonavir
SLCOIBI-KSM cRNAinjected oocytes had increased accumulation of both E3S and
LPV compared to water injected oocytes. The addition ofritonavir (0-1000ng/ml) did
not change the accumulation of E3S (Fig. 1a) or LPV (Fig. 1b) in SLCO1BI-KSM
cRNA-injected or water-injected oocytes.
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5.3.2. SLCO SNPsandassociation with lopinavir plasma concentrations
The frequenciesof the minoralleles for SLCOLA2 38 (C), SLCOIA2 516 (C), SECOIB1
521 (C) and SLCO/B3 334 (T) were 9%, 4%, 11% and 32% respectively. All SNPs
were in Hardy-Weinburg equilibrium.
No significant associations were observed between SLCOIA2 38, SLCOIA2 516 and
SLCOIB3 334 genotypes and LPV Cmin or C26 (Fig. 2a-2f).
LPV Cmin was significantly higher in SLCOJBI 521C homozygotes (plasma
concentration [range], 11141 [3409 - 19209] ng/ml) thanin either heterozygotes (5353
[828 - 14615] ng/ml; p=0.03) or 521T homozygotes (4912 [114 - 35791] ng/ml; p=0.02;
Fig. 2g). LPV C2.¢ was higher in SLCOIBI 521C homozygotes (9671 [3593 - 21399]
ng/ml; p=0.13) and in heterozygotes (7514 [1617 - 17313] ng/ml; p=0.03) than in 521T
homozygotes (6516 [312 -39894] ng/ml; Fig. 2h). Univariate and multivariate
regression analyses are summarised in Table 1. For Cmin, the multivariate model had an
adjusted R*=0.068; F=10.7, p<0.001 and for C2, the multivariate model had an
adjusted R?=0.062; F=7.6, p<0.001. SLCOJBI 521T>C was independently associated
with LPV Cmin (15.6% higher for eachallelic variant) and Co. (13.9% for eachallelic
variant) when multivariate analysis was performed.
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5.3.3 Demographic associations with lopinavir plasma concentrations
No significant associations were observed between age or gender with LPV plasma
concentrations (Fig. 3a-3d). Body weight and co-administered PI were independently
associated with LPV Cmin and C2 in both univariate and multivariate analysis. Cmin
was 10.3% lower for every 10kg increase in body weight (Fig 3e) and was also 25.9%
higher in patients receiving an additional PI (Fig. 3g). An increase in body weight of
10kg lowered LPV plasma concentrations at Co6 by 6.9% (Fig. 3f) and co-
administration with other PIs increased LPV C>.¢ plasma concentrations by 23.2% (Fig.
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Table. 1 Multivariate analysis by best subset selection of factors influencing LPV
plasma concentrations in the Liverpool TDMregistry.
 
 
Independent Variable Dependent Univariate P Multivariate P
variable (Effect size %) (Effect size %)
SLCOIBI 521T>C Cmin (ng/ml) 0.025 (22.5) 0.046 (15.6)
C2.6 (ng/ml) 0.019 (23.1) 0.041 (13.9)
SLCOIB3 334T>G Cmin (ng/ml) 0.72 -
C26 (ng/ml) 0.98 -
SLCOIA2 38T>C Cmin (ng/ml) 0.40 -
C26 (ng/ml) 0.25 -
SLCOIA2 516A>C Cmin (ng/ml) 0.85 -
C26 (ng/ml) 0.24 -
Age Cmin (ng/ml) 0.83 -
C26 (ng/ml) 0.20 -
Male Gender Cmin (ng/ml) 0.25 -
C>-6 (ng/ml) 0.43 -
Body Weight (per 10kg) Cmin (ng/ml) <0.001 (-14.9) <0.001 (-10.3)
C2.6 (ng/ml) 0.003 (-9.1) 0.003 (-6.9)
Coadministered PI Cmin(ng/ml) 0.001 (33.8) 0.001 (25.9)
Co.6 (ng/ml) 0.001 (31.7) 0.001 (23.2)
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5.4 Discussion
ManyPIsare boosted with ritonavir and hencetheeffect of ritonavir on the transport of
E38,the paradigm control substrate, and LPV, the paradigm PI, was examined. Using
the X. laevis oocyte model, no effect on E3S or LPV transport by SLCOIB1 was
observed with increasing concentrationsofritonavir, up to 1 g/ml.
Genotyping from the Liverpool TDM plasma samples was performed in duplicate or
triplicate where genotyping results were contradicting. This may be due to the low
levels of DNA found in plasma samples (Lee et al. 2001), which may reduce the
accuracy of genotyping byreal-time PCR.
SLCOIBI 521C>T was foundto be associated with LPV plasma concentrations at both
Cmin and C2. TT homozygotes had significantly lower LPV plasma concentrations
than individuals with the CC or CT genotypes. This is consistent with other studies
which found an association between 521C>Tandstatin plasma concentrations (Niemief
al. 2006; Pasanen et al. 2006; Lau et al. 2007). No correlations were observed between
SLCOIB3 334T>G and LPV pharmacokinetics, which is consistent with data on this
SNP and paclitaxel pharmacokinetics (Smith ef al. 2007). There were also no
associations observed between SLCOIJA2 38T>C and 516A>C SNPs and LPV
pharmacokinetics. Whilst this contradicts the in vitro studies by Badagnanief al. (2006)
and Lee at al. (2005), little is known about the effect of these SNPs on in vivo
pharmacokinetics. The lack of correlation between these SNPs and LPV
pharmacokinetics warrants further investigation with other SLCO1A2 substrates, such
as fexofenadine, to observe whether these results can be generalised. This would be
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informative as to whether these candidate SNPs impact pharmacokinetics of other
substrates or whether they only have an effect in vitro. It is also possible that this
transporter may not be important for pharmacokinetics, but it may havea role in brain
penetration, whereit is found to be highly expressed.
From the demographic information available for the TDM cohort, body weight and co-
administered PIs were the only variables which were significantly associated with
changes in both LPV Cmin and C2. The association with body weight is similar to
studies which found a weak association between increasing body weight and decreases
in saquinavir Cmax (Lotsch e¢ al. 2007) and LPV Cmax (Oki e¢ al. 2004). In another
study, co-administration of LPV with atazanavir (ATV) was demonstrated to increase
plasma concentration of both LPV and ATV (Ribera et al. 2006); however, co-
administering LPV with other PIs is not currently common practice due to the
availability of newer drugs (Ribera and Curran 2008).
To validate the effect of the polymorphisms or characterise novel SNPs on transporter
affinity for substrates in vitro, the oocyte system may be used by injecting cRNA
containing polymorphismsintroduced by site-directed mutagenesis. Antibodies will be
required to detect the expression of the mutated proteins, which is important for
discerning whether a lack or reduced accumulation in the oocytes is due to the
polymorphism or lack of expression. For transporters which currently do not have
commercially available antibodies, the transporters can be His-tagged and detected
using generic secondaryantibodies.
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This study shows that the SLCOJBI 521T>C SNP is associated with LPV
pharmacokinetics; however, it is unlikely that it can be used as a genetic predictor of
LPV pharmacokinetics. Whilst no correlations were observed between SLCOIA2 or
SLCO1B3 SNPs and LPV plasma concentrations, LPV and other Pls are substrates for
multiple SLCO transporters, hence a more comprehensive pharmacogenetic study
combined with a haplotype analysis is required to fully characterize the impact of SLCO
transporters on PI pharmacokinetics. However, population demographic factors such as
body weight werealso significantly associated with LPV pharmacokinetics. Due to the
multi-factorial nature of variability in pharmacokinetics, developing personalized
medicines andpredictors of drug toxicity and efficacystill remains a challenge.
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Chapter 6
Investigating the effect of siRNA knockdownof
SLCOtransporters in immortalised humancell
lines
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6.1. Introduction
Influx transporters, including SLCOs, are expressed in different tissues and at various
levels. In the liver, SLCO1A2, SLCOIB1, SLCO1B3 and SLCO3A1are expressed with
higher levels of SLCO1B1 and SLCO1B3 (Tamaiet al. 2000; Bleasby et al. 2006).
However, in the intestine, SLCOIBI and SLCOI1B3 are not expressed and the
expression of SLCO1A2 remains controversial (Lee et al. 2005; Bleasby et al. 2006;
Hilgendorf et al. 2007). SLCO3A1 is expressed ubiquitously, with high levels of
expression found in the blood mononuclear cells (Bleasby et al. 2006; Janneh etal.
2008). SLCO1A2 has varied expression with studies reporting expression in brain,
intestine, kidney and lungs (Tamai etal. 2000; Lee er al. 2005; Bleasby et al. 2006).
The SLCO transporters have overlapping substrate specificities and varied tissue
distribution, which should be appreciated when considering drug distribution.
Cell lines are commonly used to observe the effect of basal levels of transport proteins
on drugs andvice versa. Cell lines are also used for over-expression of target proteins
by drug selection (Daveyef al. 1996), or by transfection of plasmids containing the gene
of interest (Bakoset al. 1998). Whilst cell models which over-express transport proteins
are used to evaluate substrate specificity, this may not be an accurate representation of
levels of expression or function in different tissues in vivo. Inhibitors of transporters are
commonly used to ascertain the function of specific transporters but the limitations of
this approach are the expression of various known and unknowntransporters in the cell
lines and also the lack of specificity of some inhibitors (as was observed in Chapter2).
Immortalised cell lines may not completely represent the expression levels of
transporters present in their respective primary tissue counterparts (Hilgendorf er al.
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2007), but they are similar and are easy to culture and manipulate compared to primary
cells.
RNAiis a widely used approach for gene silencing to understand functions of specific
proteins. There are two main methodologies for conducting RNAi knockdownstudies,
shRNAand siRNA.For stable knockdownoftarget genes, shRNA is commonly used,
which involves cloning DNAinto plasmidsand transfection into cells (McCaffreyef al.
2002). These plasmids generate shRNA, which become siRNA after cleavage by dicer,
a cellular enzyme(Preall and Sontheimer 2005). siRNAis used for transient knockdown
and can be chemically synthesised. siRNA are short (20-25 nucleotides), double
stranded RNA sequences which are complementary to, and bind to, the gene ofinterest
(Elbashir ef al. 2001; McCaffrey et al. 2002). This recruits cellular mechanisms to
degrade the siRNA/gene complex and the reduction of gene specific mRNA
consequently reducesthe level of protein expression (Preall and Sontheimer 2005).
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Dicer-RDE-1 cornplex
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Fig. | Degradation of gene specific mRNA by siRNA (modified from McManusand
Sharp 2002)
Introducing siRNA can also cause non-specific gene silencing (off-target effects) due to
the incomplete complementarity of the siRNA with non-target genes (Jackson eral.
2003). This incomplete complementarity of siRNA also has a similar effect to
microRNAs and has been reported to cause knock-up effects, especially of genes
associated with the interferon response (Scacheri et al. 2004). The development of
siRNA as a molecular tool for understanding the role of genes has improved, with
recently designed siRNA having minimal off-target effects (Birmingham et al. 2006;
Jackson et al. 2006). There are also different methodologies for RNAi delivery into
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cells and the most commonly used approaches involve electroporation or cationic lipid
reagents (Fedorovetal. 2005).
In the Chapter 4, protease inhibitors were found to be substrates for SLCO1A2,
SLCOIB1 and SLCO1B3 in the X. Jaevis over-expression system. The aim ofthis
chapter wasto ascertain the importance of basal levels of SLCOsfor protease inhibitors
(PIs). However, due to time constraints it was only possible to conduct siRNA
optimisation experiments and attempt validation using estrone-3-sulphate (E3S). This
was conducted in Caco-2, HepG2, Huh7 and 293T humancelllines.
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6.2 Methods
6.2.1 Materials
Brain, lung, liver, lymph, heart, pancreas, colon, kidney, adrenal and thymustotal RNA
was purchased from Stratagene (Cheshire, UK). Caco-2, 293T, Huh7 and HepG2cell
lines were purchased from ECACC(Salisbury, UK). SLCO1A2, SLCO1B1, SLCO1B3
and SLCO3A1 ON-TARGETplus SMARTpool were purchased from Perbio Science
UK Ltd. (Northumberland, UK). Cell Line Nucleofector kit T and V were purchased
from Amaxa AG (Koeln, Germany). Lipofectamine 2000 was purchased from
Invitrogen (Paisley, UK). TaqMan Reverse Transcription Reagents and TaqMan Gene
Expression Assays were purchased from Applied Biosystems (Warrington, UK).
ABsolute QPCR mix was purchased from ThermoFisher Scientific (Loughborough,
UK).
6.2.2 Cell culture
239T, Huh7 and HepG2 cells were routinely cultured in DMEM supplemented with
10% FCS and incubated (37°C with 5% CQO). Caco-2 cells were cultured in DMEM
supplemented with 15% FCS and incubated using the same conditions as above. For
routine passaging, the cell lines were washed with HBSS (twice, 20mls) followed by
trypsin treatment (2mls, 10-20mins incubation at 37°C) and deactivation (3mls DMEM
with respective supplement). 239T were split 1:15, Caco-2 were split 1:3, Huh7 and
HepG2weresplit 1:6.
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6.2.3 mRNAextraction and reverse transcription
A panel of tissue mRNAconsisting of brain, lung, liver, lymph, heart, pancreas, colon,
kidney, adrenal and thymus were used to analyse tissue distribution of SLCO1A2,
SLCOIB1, SLCOIB3 and SLCO3A1. Tissue mRNA were reverse transcribed as
described in Chapter 3.2.4, whilst mRNA from cell lines were extracted by treatment
with TRI reagent and frozen (-20°C, overnight). After thawing, mRNA extraction and
cDNAsynthesis were conducted as described in Chapter 3.2.3 and 3.2.4, respectively.
6.2.4 Analysis of gene expression
cDNA wasquantified by Nanodrop (ThermoScientific) and normalised to 20ng/ul. The
PCR reactions were assembled at room temperature and included ABSOLUTE PCR
mastermix (12.51), respective primer and probe assay (1.25pl) and cDNA (40ng). Each
sample was performed in duplicate in Opticon 2 and Chromo 4 Real-Time PCR
machines (Biorad) to measure gene expression and the Opticon Monitor 3 software was
used to analyse the data.
The C(t) values were taken and the 5C(t) values were calculated (test C(t) values - B-
actin C(t) values). 56C(t) values were then calculated from 5C(t) values (test values
were normalised to cells only control, test 5C(t) - control 5C(t)) and the relative
expression was determined (2°). The mean ofthe duplicates were calculated and the
percentage knockdownlevels were calculated (test/control mean relative expression
100).
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6.2.5 siRNA delivery by Nucleofection intocell lines
293T, Huh7, HepG2 and Caco-2 cells were grown to confluence. The cells were
trypsinised, resuspended in DMEM with respective supplement and counted using the
NucloCounter. Amaxa Nucleofection kits and programmes were used as described in
the manufacturer’s protocols. Supplement R was added to Solution T and V prior to
resuspending the cells in the solutions (100p1). Nucleofector solution T was used for
Caco-2 and Huh7, whilst solution V was used for HepG2 and HEK293T. Programme
Q-001 was used for HEK293T, B-024 was used for Caco-2 and T-028 was used for
Huh7 and HepG2cells. For HEK293T, Huh7 and HepG2,610° cells were used and for
Caco-2 3x10° cells were used per transfection. For each cell line, SLCO1A2,
SLCOIB1, SLCO1B3 and SLCO3A1, ON-TARGETplus SMARTpool siRNA (final
concentration of 80nM) was used to knockdown gene expression. A cells-only control,
mocktransfection control, positive control and negative control (final concentration of
80nM) werealso included. Thepositive control was human GAPDH ON-TARGETplus
control pool siRNA and the negative control was human ON-TARGETplus Non-
Targeting Pool. Each transfection was transferred (2001) into 3 wells of a 48-wellplate
containing DMEM with respective supplement (750ul). Culture media was changed
daily and cells were treated with TRI reagent (Iml) at 24, 48 and 72 hours post
transfection.
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6.2.6 siRNAdelivery by Lipofectamine 2000 intocell lines
HepG2 and Caco-2 cells (5 x 10° cells, 4000p!) were grown in 24 well plates 24 hours
prior to transfection. SLCO1A2, SLCO1B3, SLCOIBI1 and SLCO3A1 ON-
TARGETplus SMARTpools (5-40pmol) were diluted with DMEM media supplemented
with 10% FCS (SOul, Smins, room temperature). Lipofectamine 2000 (0.5-1.5u1) was
mixed with DMEMsupplemented with 10% FCS (50ul, 10mins, room temperature) and
subsequently added to the diluted siRNA and incubated to form siRNA complexes
(20mins, room temperature). siRNA complexes (1001) were then added to pre-plated
cells. Media wasreplaced 24h post transfection and changed daily. Cells were collected
into TRI reagent (8001) 24h and 48hposttransfection.
6.2.7 Cellular accumulation of E3S in SLCO knockdowncells
The optimal seeding density of HepG2 in 6 well plates was investigated to determine
the seeding density for E3S uptake in SLCO knockdown HepG2cells.
Subsequently, HepG2cells were seeded (5x 10* - 5x10° cells/well) and grownin 6-well
plates (2.5ml DMEM supplemented with 10% FCS, incubated at 37°C with 5% COb,
48h). After incubation, HepG2cells were trypsinised (500ul, 37°C) until cells detached.
DMEMsupplemented with 10% FCS (500u1) was then added and the trypsinised cells
were placed into 1.5ml eppendorfs. The samples were centrifuged (2000rpm, 5mins),
the supernatant was removed andthe cells were resuspended in DMEM supplemented
with 10% FCS (5001). [3H] E3S (0.02uCi/ml, 500u1) was added to the cells and
incubated (37°C, 20mins). Following incubation, cells were centrifuged (13,000 x g,
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Imin) and supernatant (100ul) was added to scintillation vials. The remaining
supernatant was removed andice cold Hank’s balanced salt solution was used to wash
the cell pellets. The cell pellets were centrifuged (13,000 x g, Imin) and washed a
further 2 times. The cell pellets were solubilised in water (100u1) and transferred to
scintillation vials. Scintillation fluid (4ml) was added to all the samples and counted by
liquid scintillation spectroscopy. The cellular accumulation ratio (CAR) was calculated
as described in Chapter 2 (2.2.5) and the average cell volume of HepG2 cells was
assumed to be 1.2pl (Wehneret al. 2002).
HepG2cells were trypsinised, counted and cultured in 6-well plates (2.5x10° cells, 2ml,
overnight) prior to transfection. Lipofectamine 2000 was added to DMEMcontaining
10% FCS (7.5ul Lipofectamine 2000 per 250u1 media, Smins) and SLCO1B3 ON-
TARGETplus smartPOOL siRNA was added to DMEM containing 10% FCS and
upscaling was as per manufacturer’s protocols (Sul of SLCO1B3 siRNA at 20M per
250u1 media, S5mins). Lipofectamine 2000 in media was subsequently added to
SLCO1B3 siRNAin media (1:1) and incubated (20mins, room temperature). Media was
added to a separate stock of Lipofectamine 2000 with media (1:1, 20mins, room
temperature). Following the incubation period, media, Lipofectamine 2000 in media and
Lipofectamine 2000 with SLCO1B3 siRNA in media wasaddedto the pre-plated cells
(5001, 2.5ml total volume). At 48h and 72h posttransfection, cells were trypsinised
and used for uptake studies and treated with TRI reagent for subsequent mRNA
extraction, reverse transcription and gene expression studies.
Extraction and reverse transcription was performed as described in 6.2.3 and gene
expression was quantified as described in 6.2.4. Functional cell uptake studies were
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performed by adding [7H] E3S (0.02uCi/ml, 5001) to trypsinised cells resuspended in
DMEM media (500u1, 20mins, 37°C) and the subsequent methods for uptake were as
described above.
6.2.8 Statistical analysis
The samples were tested for normality using the Shapiro-Wilk test and at least one of
the data sets was not likely to be from a normal distribution; therefore, the Mann-
Whitney U-test was used totest for statistical differences between the conditions.
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6.3 Results
6.3.1 Expression of SLCOsin humantissues
The relative expression of SLCOIA2 mRNA was highest in the brain and with
detectable levels in the kidney, lung andliver (Fig. 1a). SLCO1B1 wasonly detected in
the liver (Fig. 1b) and SLCO1B3 wasdetected in the liver and the pancreas (Fig. Ic).
SLCO3A1 had ubiquitous expression amongstthe tissue samples tested (Fig. Id).
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The relative expressions of SLCOIA2, SLCOIB1, SLCOIB3 and SLCO3A1 were
assessed in Caco-2, Huh7, HepG2 and 293T cells and compared to their primary cell
counterparts (colon,liver and kidney).
SLCOI1B1 was not detected in colon or Caco-2, whereas SLCO1A2 was found to be
expressed in Caco-2 cells and not in colon mRNA. SLCO1B3 wasdetected in colon but
not in Caco-2 and relatively high expression of SLCO3A1 was detected in Caco-2 cells
comparedto colon (Fig. 3a).
In the liver, SLCOILA2, SLCOIB1, SLCOIB3 and SLCO3A1 were all detectable.
However, Huh7 and HepG2, whichare both hepatic cell lines, expressed different levels
of SLCOs. Huh7 cells did not express detectable levels of SLCO1B1 and relatively
lower levels of SLCO1B3 and SLCO3A1 compared to liver mRNA. SLCO1A2 was
highly expressed in Huh7 cells compared to liver (Fig. 3b). SLCO1A2 and SLCO3A1
were not detectable in HepG2 cells and there were relatively lower levels of SLCOIB1
and SLCO1B3 comparedto liver (Fig. 3c).
No SLCOIB1 or SLCO1B3 was detected in kidney mRNAorin 293Tcells. SLCO1A2
and SLCO3A1 were detected in kidney mRNAandlower levels of these transporters
were detected in 293T cells (Fig. 3d).
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6.3.2 Transfection of siRNA by Nucleofection
The TaqMan gene expression assay control, B-actin, was detectedin all the cell lines, in
every control (cells only) and in every test condition, and was comparablein each.
6.3.2.1 Caco-2 cells
Caco-2 cells had detectable knockdown of GAPDHafter 24h (decrease of 94.8%), but
this knockdown wasnotsustained at 48h and 72h post transfection (Fig. 4). SLCOIB1
and SLCO1B3 were not detected in the cell only control at 24h, 48h or 72h post
transfection and SLCO1A2 and SLCO3A1 had inconsistent detection in cell only
controls between the time points.
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Fig. 4 GAPDH knockdownusing Nucleofection with siRNA in Caco-2 cells (n=1)
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6.3.2.2 HepG2cells
HepG2 cells had detectable knockdown of GAPDHat 48h (decrease of 83.6%) and 72h
(decrease of 85.2%) post-transfection (Fig. 5). SLCO1B1 was detected in the cell only
control but no knockdown wasobserved at any of the time points. SLCOIB3 was
detected in cell only controls, but was not detectable in siRNA-treated cells at 24h and
72h. At 48h, SLCO1B3 had detectable knockdown (decrease of 87.3%). Detection of
SLCO1A2 and SLCO3A1 in the cell-only controls was inconsistent.
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6.3.2.3 Huh7cells
Huh7cells had detectable knockdown of GAPDHat 24h (86.8%) and 48h (95.8%) post-
transfection. At 72h, knockdownwasstill achieved (68.2%), but relatively more mRNA
was detected compared to 24h and 48h time points (Fig. 6). SLCO1B1 and SLCO1B3
mRNAwaspresent, but Nucleofection with respective siRNA did not decrease levels of
expression at any of the time points. SLCO1A2 had detectable knockdown at 24h
(55.9%) but detection in the cell-only control at 48h and 72h was inconsistent.
SLCO3A1 mRNAdetection was inconsistent.
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6.2.3.4 293Tcells
293T cells had detectable and sustained knockdown of GAPDHat 24h (94.2%), 48h
(97.5%) and 72h (97.4%, Fig. 7). No SLCO1B1 or SLCOIB3 wasdetected in 293T
cells at any of the time points. SLCO1A2 and SLCO3A1 mRNA wasdetected in all the
cell only controls. SLCO1A2 mRNA was detected, but no knockdown wasobserved at
any of the time points. Detectable knockdown of SLCO3A1 wasobserved at the 24h
time point (49.0%) and no detectable SLCO3A1 mRNA in SLCO3A1 siRNA-treated
cells.
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Fig. 7 GAPDH knockdownusing Nucleofection with siRNA in 293T cells (n=1)
To observe the functional effect of siRNA knockdown by Nucleofection, uptake
experiments using [*H] E3S would be required. The uptake experiments require a much
larger numberofcells and several electroporations to be able to yield enough cells to
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distinguish changes in CAR;therefore, further experiments using Nucleofection were
not pursued.
6.3.3 Transfection of siRNA by Lipofectamine 2000
6.3.3.1 Caco-2 cells
The highest level of knockdown of GAPDHachieved in Caco-2 cells after 24h was with
2.511 Lipofectamine 2000 and 40ul siRNA (76.3%). However, sustained knockdown of
GAPDHin Caco-2 cells treated with Lipofectamine 2000 and siRNA wasnot achieved
and conversely, many samples contained more GAPDH mRNAthan untreated cells
(Figure. 8a). SLCOIA2 knockdown at 24h was observed in a few ofthe treatment
conditions (Lipofectamine 2000 + siRNA, % knockdown: 1.5ul + Spl, 43.4%; 2ul +
Sul, 69.2%; 2u1 + 40ul, 60.0%), with the highest level of knockdown achieved with
20u1 siRNA and 1.5y1 Lipofectamine 2000 (82.8%, Fig. 8b). However, of these
samples, some had no detectable SLCO1A2 mRNA and others had no detectable
knockdown at 48h. SLCOIB1 was not detected in cells only or treatment at any
concentration of Lipofectamine 2000 and siRNAfor any of the time points. SLCO1B3
mRNAwasdetectedat all conditions at the 24h but not the 48h time point. Similar to
GAPDH and SLCO1A2, SLCO3A1 had detectable knockdown at several treatment
conditions (Lipofectamine 2000 + siRNA,2.51 + Spl, 85.7%; 2ul + 10pl, 57.8%; 2.5ul
+ 10ul, 71.6%; 1.5u1 + 20u1, 69.1%; 21 + 20ul, 58.8%; and1.Sul + 40pl, 59.1%, Fig.
8c), but at 48h, mRNA levels in many samples were higher than cells alone and a few
samples had no detectable mRNA.
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6.3.3.2 HepG2 cells
GAPDHwas knocked down in Lipofectamine and siRNA-treated HepG2 cells (1.5ul +
10ul, 52.1%; 0.5ul + 20ul, 41.6%; Il + 40u1, 50%) and in a few of these conditions,
this knockdown wassustainable at 48h post transfection (1.5ul + 10ul, 45%; 0.5p1 +
20ul, not detectable, 11 + 401, 82.0%; Fig. 9a). SLCO1A2 mRNA wasnotdetectable
in untreated or any treated samples. SLCO1B1 was detected (1ul + 20ul, 6.4%, Fig. 9b)
at 24h post-transfection and with the same Lipofectamine and siRNA concentrations,
further knockdown was observed at 48h (99.4%). At 24h post-transfection, many
SLCO1B3 samples contained more SLCOIB3 mRNA than cell-only controls, whilst
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some had no detectable mRNA. However, knockdown at 24h post transfection was
detected in one of the SLCO1B3 siRNA-treated samples (Lipofectamine 1.5u1 + siRNA
20ul, 52.4%) and with the same condition, this knockdown wassustained at 48h (1.51
+ 20ul, 99.6%; Fig. 9c). Two conditions were identified to have knockdown of
SLCO3A1 after 24h post transfection (0.5ul + 10pl, 15.3%; and 0.5ul + 20u1, 53.7%;
Fig. 9d) and at 48h, no SLCO3A1 mRNAwasdetected.
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Fig. 9 Knockdown of a) GAPDH,b) SLCO1B1, c) SLCO1B3 and d) SLCO3A1 using
Lipofectamine (x-axis, bottom row) with siRNA (x-axis, top row) in HepG2cells
(n=1).
The most reproducible results were with Lipofectamine 1.5ul + siRNA 20ul and hence
this condition wasused for analysis with [°H] E3S.
6.3.4 Optimisation of HepG2 seeding for PH] E3S uptake
HepG2cells had detectable (°H] E3Sin all seeding conditions with uptake increasing in
a cell number dependent manner. Adequate detection was observed starting from
1.5x10° cells (Fig. 10). Optimisation of siRNA knockdownwasbased upon 2.5x10° and
this cell density had adequate detection of PH] E3S.
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Fig. 10 Uptake of[°H] E3S in varying seeding densities of HepG2cells (n=1).
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6.3.5 Uptake of PH]-E3S in SLCO1B3 knockdown HepG?cells
At 48h post transfection, there was no difference in 7H] E3S accumulation between
HepG2cells only or cells incubated with Lipofectamine 2000 (7.5ul). There was a trend
towards an increase in radioactivity in cells incubated with Lipofectamine 2000 (7.5u1)
and SLCOIB3 siRNA (100ul) compared to cells-only control, but this was not
significant. At 72h post transfection, there was a trend towards a decrease in
radioactivity in cells incubated with Lipofectamine 2000 only and in cells incubated
with Lipofectamine 2000 with SLCO1B3 siRNA compared to cells-only control, but
this wasalso not significant (Fig. 11a).
At the mRNAlevel, there were no observable differences between the three conditions
at either 48h or 72h post transfection (Fig. 11b).
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Fig. 11a) Uptake of [*H]-E3S in SLCO1B3 knockdown HepG2?cells at 48h and 72h
post transfection andinitially seeded at 2.5x10° cells (n=3) and b) mRNAlevels of
SLCO1B3 in HepG2cells at 48h and 72h post transfection of siRNA andinitially
seededat 2.510cells (n=3).
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6.4 Discussion
HepG2, Huh7, Caco-2 and 293T cells are commonly used cell lines as models for
hepatic, intestinal and renal cells. RNAi is a widely used approach for knockdown of
variousgenes including those involved in drug transport and metabolism (Yu 2007).
Consistent with the literature, SLCO1B1 and SLCO1B3 were not expressed in Caco-2
cells (Hilgendorf ef al. 2007). SLCOIB1 and SLCO1B3 werealso reported not to be
detected in HepG2 (Cuier al. 2003), but expression of both transporters in HepG2 was
detectable in this study, which was consistent with the findings by Hilgendorfet al.
(2007). SLCO1B3 but not SLCOI1B1 was detected in Huh7 cells. This differs from
hepatocytes, which were found to contain high levels of SLCOIB1 and SLCO1B3
mRNA.Neither SLCO1B1 nor SLCO1B3 were detected; whereas, levels of SLCO1A2
and SLCO3A1 mRNAweredetected in 293Tcells, which was similar to their primary
cell counterparts. SLCO1A2 and SLCO3A1 were inconsistently detected in Caco-2,
HepG2cells and Huh7cells. This suggests that immortalized cell lines are, in general,
not good representatives of their primary cell counterparts for influx transporters.
However,cell lines are easier to culture and manipulate, and several studies have used
these cell lines to observe influx transport by transfecting plasmids with the influx
transporters of interest (Tamai et al. 2000; Junget al. 2001; Vavrickaet al. 2004).
Nucleofection (electroporation) and Lipofectamine (cationic lipid reagents) are common
methods of nucleic acid delivery. Different cells have been reported to respond to the
methodsof delivery with different efficiencies (Gresch ef al. 2004; Ghartey-Tagoeetal.
2006) and hence both methods havebeen tested. Lipofectamineallows easier scaling of
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experiments, as the ratio of the reagents (Lipofectamine, siRNA and numberofcells)
determinesthe efficiency of transfection (Hawley-Nelson er al. 2008). However, several
factors which determine the transfection efficiency of Lipofectamine, including the
dilution ratio, seeding density and Lipofectamine/siRNA incubation time, have been
described (Dalby et al. 2004). Amaxahas optimized nucleofection protocols for many
commonly used cell lines and is easy to operate, but does not scale up for larger
transfections and hence requires separate, smaller transfections. Interestingly, a study
comparing the effects of lipid based reagents and electroporation showed upregulation
of non-target genes by both methods,with relatively more non-target genes upregulated
usinglipid based reagents (Fedorovet al. 2005).
In the Nucleofection experiments, the GAPDH knockdownwasobservedin all of the
cell lines; however, with the test conditions, only SLCO3A1 knockdown was observed
in 293T cells. This may be due to the abundance of GAPDHinall the cell lines,
whereas the SLCO transporters may be expressed in much lower levels, making
knockdowndifficult to detect. Up-scaling uptake experiments require a larger number
of cells and would require several separate electroporations per sample; therefore,
SLCO3A1 knockdownin 293Tcells were not investigated further.
The Lipofectamine transfections in Caco-2 cells did not knockdown GAPDH,the
endogenouscontrol. This suggests that Caco-2 cells are difficult to transfect, which is
consistent with a study by Cryan ef al. (2003). In HepG2 cells, GAPDH and SLCO1B3
mRNAknockdown using Lipofectamine appeared to be consistent between the 24h and
48h post-transfection time points. E3S uptake in SLCO1B3 knockdown HepG2cells
(transfection condition, 2.54] SLCO1B3 siRNA + 1.5ul Lipofectamine) was measured
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to observe whether SLCO1B3 was knocked down. No significant difference was
observed between SLCOIB3 siRNA with Lipofectamine-treated cells and
Lipofectamine-treated cells only.
The inability to reproduce the knockdown in SLCO1B3 mRNAin the scaled up
transfections for E3S uptake, along with the inconsistent detection of other SLCOs
suggest that the SLCOsare not as abundant as GAPDH,increasing the difficulty in
detecting knockdown of mRNA.This suggests that the SLCOsin general are not highly
expressed in cell lines at basal level and supports observations by Hilgendorf ef al.
(2007) that cell lines do not truly reflect the levels of influx transporters compared to
their primary cell counterparts. However, the report also showed levels of efflux
transporters were a better representation of primary cell basal levels than influx
transporters. Levels of protein were not measured as currently there are no reliable and
commercially available antibodies for specific SLCO transporters.
Due to time constraints it was only possible to conduct optimisation experiments.
Whilst the results obtained are preliminary, there were several conclusions that could be
drawn. The detection of SLCO mRNA wasinconsistent amongst Caco-2 and Huh7
cells. Transfections with Nucleofection would not have yielded enough cells for
functional analysis and hence Lipofectamine 2000 was chosen for these experiments.
The knockdown of SLCOsin cell lines using Lipofectamine 2000 wasalso inconsistent
as the scaling-up of the Lipofectamine 2000 transfections did not reproduce the
observed effects of mRNA knockdownin the preliminary experiments and had no
observable effect on SLCO1B3 activity. RNAi is a useful technique to understand gene
function and has been usedto evaluate transporters, albeit efflux (Yu 2007). The use of
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primary cells, which have higher levels of influx transporters despite being harder to
transfect (Gresch et al. 2004; Tahvanainen et al. 2006), may be more appropriate for
analyzingthe role ofinflux transporters using RNAi.
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With continuing improvements to antiretroviral therapy, living with HIV has changed
from being a life threatening disease to a chronic illness. However, due to the high
mutation rate of HIV, viral resistance is a persistent problem and hence there is a
continual need for new therapeutic compounds in existing and new drug classes.
Recently licensed antiretrovirals such as raltegravir (Iwamotoef al. 2008) and darunavir
(Rittweger and Arasteh 2007) have improved pharmacokinetic andtoxicity profiles, but
viral resistance has already been reported for these compounds (Cooperet al. 2008;
Mitsuya et al. 2007). To limit the risks of viral resistance and to formulate effective
regimens, the mechanisms which govern their virologic and immunologic response in
addition to their pharmacokinetics need to be well characterised.
There are many factors which can impact on the efficacy and toxicity of antiretrovirals
and other xenobiotics. These factors include drug-drug interactions within the
antiretroviral regimen and/or concomitant drugs for other illnesses, age, weight,
transport and metabolism. Theinteractions between these factors are outlined in Fig. 1.
Research into each of the factors that contribute to the clinical outcomeofantiretroviral
therapy is progressing. The focus of this thesis was to examine the effect of drug
transport on cellular accumulation and observe the impact of polymorphisms in SLCO
transporters on lopinavir (LPV) pharmacokinetics.
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General Discussion
Since the discovery and characterisation of ABCB1, the study of transporters and their
influence on the pharmacokinetics of pharmacological compounds has been a major
focus. In antiretroviral therapy, many protease inhibitors (PIs) are substrates of ABCB1
and somearealso substrates for ABCC1 and ABCC2 (Huismanet al. 2002; Jannehet al.
2007). Darunavir (DRV), which is the most recently licensed PI, is also a substrate for
ABCBI (Chapter 2). There is increasing awareness that other transporters with different
tissue distributions and substrate specificities are important determinants ofvariability in
pharmacokinetics of endo- and xenobiotics.
The role of the SLCO transporters is currently being investigated, with various
xenobiotics being characterised for substrate specificity (Hirano et al. 2004; Lee et al.
2005). The specificity for antiretrovirals was investigated in Chapter 4 and many PIs
were demonstrated to be substrates of SLCO1A2, SLCOIBI1 and SLCO1B3, which
implicates these transporters in the distribution of PIs. SLCOIB1 and SLCOIB3are
hepatic influx transporters known to influence systemic exposure to many drugs.
SLCOIA2 is expressed in the brain (Lee et al. 2005) and hence may have role in
transporting substrates across the blood-brain barrier, where latent viral reservoirs reside
(Blankson 2006). There are other transporters in the SLCO subfamily and also within
the general SLC family, with different expression, distribution and substrate
specificities. Research into these transporters is sparse, althoughthis is increasing, which
will further our understandingoftheir roles for antiretrovirals and other xenobiotics.
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are not transported by
ABCBI (Dirson et al. 2006; Storch et al. 2007). Rilpivirine is an NNRTI in early
development, which has been shownto have properties different to other NNRTIs. This
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compound was shown not to be transported by ABCBI1 (Chapter 2), but was
demonstrated to be a substrate for SLCOIB1 and SLCO1B3 in the absence of human
serum albumin (HSA), whereas neither efavirenz nor nevirapine were shown to be
substrates for any of the SLCOtransporters (Chapter 4). The lack of substrate specificity
of SLCOIB1 and SLCO1B3forrilpivirine in the presence of HSA maybe due to the
high affinity protein binding, thereby lowering the amountofavailablerilpivirine.
Manyantiretrovirals have been characterised and exhibit high affinity for protein
binding. PIs bind primarily to a;-acid-glycoprotein and NNRTIs to HSA (Boffito ef al.
2003). The concentration of human serum albumin (HSA), the most abundant serum
protein, has an impact on the cellular concentration of efavirenz and rilpivirine in
Chapter 2, with rilpivirine exhibiting a high affinity for protein binding. This suggests
that HSA concentration may have a more important role in determining the
pharmacokinetics ofNNRTIsthancellular transport.
In this thesis, several in vitro models have been used to determine cellular transport. The
CEM and MDCKII models are well established models for assessing ABCB1 and
ABCCtransporters (Davey et al. 1996; Bakosef al. 1998). They are relatively easy to
manipulate and culture, but the limitations include unknowneffects of other transporters
within the model. For the CEM model, over-expression of ABCB1 in CEMyp,cells was
generated by drug selection so other tranporters in CEM cells may also be up- or down-
regulated and for the MDCKII model, there is inherent expression of canine transporters.
In this thesis, the X. laevis oocyte model was developed for analysis of influx
transporters as they contain few endogenoustransporters, but the model wasrelatively
variable and labour intensive (Sigel 1990). Whilst these models may not be a true
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representation of the im vivo environment, they serve as useful tools for observing the
mechanisms which govern cellular accumulation and offer an insight into individual
components of drug absorption and distribution. However, to understand the clinical
importance of transporters, metabolising enzymesandtheir regulators, their effects must
also be observed and characterised in the human population.
The study of pharmacogenomicsis increasing, with several large studies investigating
the effects of transport, metabolism and also regulators of transcription of genes on the
pharmacokinetics of antiretrovirals. Several functional polymorphisms have been
identified with varying strength of associations. Within the field of antiretrovirals, the
HLA-B*5701 SNP had the strongest association with hypersensitivity and has led to a
changein clinical practice in the use of abacavir (Mallal ef al. 2008). In Chapter 5, the
SLCOIBI 521 T>C genotype was associated with altered lopinavir (LPV) plasma
concentrations using the Liverpool TDM cohort, but other factors such as weight and co-
administered PIs were also associated. Moreover, there are a large number of
polymorphisms within each transporter, metabolism enzyme and the regulators of
transcription and each polymorphism has a varying degree of effect on their respective
genes; this increases the complexity of using genetic variation as a predictor of
pharmacokinetics. Due to the numberof possible genes which mayhaveaneffect on the
pharmacokinetics of antiretrovirals (and other xenobiotics), the use of
pharmacogenomics in a clinical setting requires multiloci genotyping and haplotype
analysesto predictclinical outcome.
There are two general approaches for identifying candidate polymorphisms for
pharmacogenomic analyses. The first is a whole genome approach, which requires
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analysing genetic databases for polymorphisms and testing these polymophisms for
associations with changes in pharmacokinetics of a given xenobiotic in a sample
population. The second involves identifying a mechanism which affects cellular
concentrations and validating these findings in a clinical scenario. The former method is
subject to an increased risk of false positives. These risks may be minimised by using
statistical corrections, but this may reduce the strength of the associations leading to a
risk of false negative, and hence large sample populations are required.
The strongest pharmacogenomic studies are prospective studies, which need to be
designed with clear strata and stringent sampling methods to identify associations. This
requires recruitment and follow-up of volunteers specific to the study and prospective
ethics committee approval. Whilst retrospective studies such as those that use TDM
cohorts may contain missing data or inaccurate samplingstrategies, they provide access
to a large resource ofreadily available genomic material (in the form of plasma or whole
blood) with matched pharmacokinetic and demographic data. Since samples are
anonymised, retrospective ethics approval can also be sought for these studies and the
advantage of using such cohortsis the time-effectiveness of obtaining samples as active
recruitment of volunteers is not required.
The findings in this thesis have contributed to the understanding of pharmacogenetic
variability of commonlyusedanti-retrovirals, firstly by identifying protease inhibitors as
substrates for SLCOs in the oocyte expression system and secondly by observing an
effect of SLCOIB1 521 T>C genotype on LPV plasmaconcentrations. Further studies to
determine the effects of SLCO SNPsin a larger pharmacogenetic study in combination
with novel transporter SNPs or with other mediators ofantitretroviral pharmacokinetics
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— such as metabolism enzymes — in human populations maylead to better understanding
of the overall pharmacogenetics of antiretrovirals. In depth pharmacogenetic studies may
lead to personalised medicine for HIV patients and improve the effectiveness of
regimensandclinical outcome.
To conclude, HIV therapy has improved since the introduction of the first anti-HIV
agent, zidovudine, with patients having treatment options, living longer and with
reduced adverse reactions to treatment. With new drugs in new classes and potentially
different modes of administration (e.g. rilpivirine given by intramuscular injection once
a month, Woodfall, 2008, for HIV patients is encouraging. However, there arestill many
challenges facing the goal of personalised medicine as there are many factors which
influence the efficacy of antiretrovirals. Research into analysing these factors (Fig. 1)
independently and their effects in concert are progressing. This thesis has contributed to
our understanding of pharmacokinetic variability and this in turn will ultimately translate
to improvement in patient outcome.
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